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  I 
Summary 
Malaria in humans is most often caused by either Plasmodium falciparum or P. vivax. Research efforts 
have mostly focused on P. falciparum, despite P. vivax being the most widespread Plasmodium species. 
This parasite species differs from P. falciparum in some key aspects like its ability to form dormant liver 
forms, an early appearance of gametocytes in the blood stream and its strict tropism to reticulocytes. 
Although P. vivax and P. falciparum invade different developmental stages of red blood cells, both express 
a highly abundant protein on the surface of their merozoites, the merozoite surface protein 1 (MSP-1). 
Initially expressed as a precursor protein, MSP-1 undergoes proteolytic processing and is cleaved into four 
processing fragments called p83, p30, p38 and p42. These fragments remain non-covalently associated 
and are attached to the surface of the merozoite via a GPI anchor at the C-terminal fragment p42. MSP-1 
is considered a promising vaccine candidate and P. falciparum MSP-1D is currently tested as a vaccine in 
a clinical trial. However, no similar vaccine was developed for P. vivax yet.  
The establishment of a protein production process for P. vivax MSP-1 (PvMSP-1) was an essential part 
of this study. Two different methods were developed, which both use individually expressed fusion 
proteins to assemble the full length MSP-1 protein. One fusion protein consists of the fragments p83 and 
p30, the other includes p38 and p42. In the first approach, the two halves are refolded together and 
purified by ion exchange chromatography and size exclusion chromatography. This protocol was also 
applied to produce P. berghei MSP-1 and test whether the assembly of a hybrid protein consisting of one 
P. falciparum half and one P. vivax half is possible. In the second approach contaminants are first 
removed from the individual fusion proteins by high resolution ion exchange chromatography before 
reconstitution of MSP-1. Both techniques result in a pure MSP-1 preparation, but the second approach 
results in a higher yield.  
The produced recombinant proteins were structurally characterised using a combination of 
bioinformatical, biophysical and biochemical methods. All recombinant proteins were cleaved by 
P. falciparum SUB1, indicating a high conservatism of the cleavage motifs. CD spectroscopy showed a 
mostly alpha-helical structure and only partial unfolding of the protein at high temperatures. Interestingly, 
this unfolding increased when MSP-1D was processed by SUB1 before performing thermal denaturation. 
This suggests an increased stability of the MSP-1 heterodimer compared to the complex consisting of four 
processing fragments. Prediction of the secondary structure revealed unstructured regions in all analysed 
MSP-1 proteins. The function of these regions remains unknown, but these sites could be responsible for 
interactions with other proteins. Cross-linking of MSP-1 paired with mass spectrometry uncovered a 
previously unknown interaction between the p83 and p42 processing fragment, leading to an updated 
model of MSP-1 with a globular instead of asymmetrical shape. 
This project provides two production processes for recombinant P. vivax MSP-1, which is now available 
for further immunological studies. The structural information acquired with this and other MSP-1 
proteins can be used as a base to further elucidate its function and three-dimensional structure.  
  II 
Zusammenfassung 
Malaria wird im Menschen meistens entweder von P. falciparum oder P. vivax verursacht. Die Forschung 
konzentrierte sich bisher hauptsächlich auf P. falciparum, obwohl P. vivax die am meisten verbreiteste 
Plasmodium Spezies ist. Dieser Parasit unterscheidet sich von P. falciparum in einigen Schlüsselaspekten, 
wie die Fähigkeit Dauerformen in der Leber zu bilden, dem frühen Erscheinen von Gametozyten in der 
Blutbahn und dem strengen Tropismus zu Retikulozyten. Obwohl P. falciparum und P. vivax in rote 
Blutzellen unterschiedlicher Entwicklungsstadien eindringen, exprimieren beide ein sehr häufiges Protein 
auf der Oberfläche ihrer Merozoiten, das „merozoite surface protein 1“ (MSP-1). MSP-1 wird als 
Vorläuferprotein exprimiert, welches proteolytisch prozessiert und in vier Fragmente namens p83, p30, 
p38 und p42 geschnitten wird. Diese Fragmente bleiben nicht-kovalent verbunden und sind mittels eines 
GPI Ankers am C-terminalen p42 Fragment mit der Oberfläche des Merozoiten assoziiert. MSP-1 wird 
als vielversprechender Impfstoffkandidat betrachtet und P. falciparum MSP-1D wird derzeit in einer 
klinischen Studie als Impfstoff getestet. Dennoch existierte bis jetzt keine entsprechende Präparation von 
P. vivax MSP-1.  
Die Entwicklung eines Verfahrens zu Herstellung von P. vivax MSP-1 war der Hauptbestandteil dieser 
Arbeit. Zwei verschiedene Methoden wurden entwickelt, die beide darauf beruhen zwei separat 
exprimierte Fusionsproteine zur Zusammensetzung des Gesamtproteins zu nutzen. Ein Fusionsprotein 
entspricht den Fragmenten 83 und 30, das andere beinhaltet p38 und p42. Im ersten Ansatz werden die 
beiden Hälften zusammen rückgefaltet und mittels Ionenaustauschchromatographie und 
Größenauschlusschromatographie aufgereinigt. Dieses Protokoll wurde auch zur Herstellung von 
P. berghei MSP-1 und für den Versuch ein Hybridprotein aus einer P. falciparum Hälfte und einer P. vivax 
Hälfte zusammenzusetzen genutzt. Bei der zweiten Variante werden Kontaminationen von den beiden 
Fusionsproteinen vor der Rückfaltung durch hochauflösende Ionenaustauschchromatographie 
abgetrennt. Beide Verfahren resultieren in sauberen MSP-1 Präparationen, mit der zweiten Methode wird 
allerdings eine höhere Ausbeute erreicht.  
Die produzierten rekombinanten Proteine wurden mit bioinformatischen, biophysikalischen und 
biochemischen Methoden strukturell charakterisiert. Alle rekombinanten Proteine wurden von 
P. falciparum SUB1 geschnitten, was eine hohe Konservierung der Schnittstellen suggeriert. CD 
Spektroskopie ergab eine größtenteils alpha-helikale Struktur und eine nur teilweise Entfaltung des 
Proteins bei hohen Temperaturen. Interessanterweise entfaltete sich MSP-1D stärker, wenn es vor der 
thermischen Denaturierung mit PfSUB1 prozessiert wurde. Diese Beobachtung deutet darauf hin, dass das 
MSP-1 Heterodimer eine größere Stabilität als der Komplex aus vier Prozessierungsfragmenten aufweist. 
Die Vorhersage der Sekundärstruktur offenbarte unstrukturierte Bereiche in allen analysierten MSP-1 
Proteinen. Die Funktion dieser Bereiche bleibt unbekannt, könnte aber in der Interaktion mit anderen 
Proteinen liegen. Cross-linking und massenspektrometrische Analysen enthüllten eine vorher unbekannte 
Interaktion zwischen den Prozessierungsfragmenten p83 und p42, was zu einem aktualisierten MSP-1 
Modell mit einer globulären anstelle einer asymmetrischen Form führt.  
Im Rahmen dieser Arbeit wurden zwei Herstellungsverfahren für rekombinantes P. vivax MSP-1 
entwickelt, welches nun für weitere immunologische Studien zur Verfügung steht. Die 
Strukturinformationen, die mit diesem und anderen MSP-1 Proteinen erarbeitet wurden, können als 
Grundlage zur weiteren Untersuchung der Funktion und dreidimensionalen Struktur dienen.   
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 1 
1. Introduction 
1.1. Malaria 
In the Western world, most people only think about malaria when planning a vacation in a foreign 
country. However, nearly half of the world’s population is at risk of infection with this vector-borne 
disease. Current estimations state that there were 216 million cases of malaria and 445,000 deaths caused 
by the disease in 2016, making malaria one of the most common and most severe infectious diseases 
worldwide. Pregnant women, non-immune travellers and children under the age of 5 years are particularly 
susceptible to malaria with 70% of deaths occurring in this age group. The vast majority of infections 
occurred in Africa (90%) followed by South East Asia (7%) and the Eastern Mediterranean region 
(2%)(Figure 1) (World Health Organization, 2017). 
 
Figure 1. Word Map highlighting countries and territories with indigenous malaria cases. Malaria infections most 
often occur on the African continent, followed by South America and South East Asia (red). Countries shown in blue had 
no reported malaria cases for the past 3 years. Tajikistan (yellow) had no cases in 2016. Green marks countries that were 
certified malaria free since 2000 and includes Krygystan and Sri Lanka, which received malaria free status in 2006. 
Source: (World Health Organization, 2017) 
Malaria cases were first documented in the Early Greek period by Hippocrates, who described a disease 
characterised by intermittent fever, which could be classified into febris tertian (every third day) and 
frebris quartana (every fourth day) (Cox, 2002). But malaria has affected human populations even before 
that since ancient DNA for Plasmodium falciparum, a parasite causing malaria in humans, was identified 
in mummy tissues from ~4,000 years ago (Nerlich et al., 2008). The name malaria, meaning “bad air” in 
medieval Italian, was invented by the Romans in the middle ages, based on the belief that the illness was 
caused by toxic fumes arising from swamps. It was only in 1880 that Charles Alphonse Laveran 
discovered Plasmodium parasites in the blood of an infected soldier (Bruce-Chwatt, 1981). Six years later, 
Camillo Golgi reported that the parasite replicates asexually in red blood cells and that lysis of these cells 
and the release of the parasites caused the fever in infected patients (Golgi, 1886). The link between 
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Plasmodium parasites and mosquitoes was not discovered until 1989, when Ronald Ross found the 
parasite in the stomach of an Anopheles mosquito (Ross, 1898). Proof that female Anopheles mosquitoes 
could transmit malaria was published two years later by Amico Bignami and Giovanni Grassi (Grassi, 
1900).  
Today, more than 150 Plasmodium species have been discovered, but only five have been shown to be 
pathogenic to humans: Plasmodium malariae, P. ovale, P. vivax, P. falciparum and P. knowlesi (Singh 
and Daneshvar, 2013). Almost all malaria infections (99%) in sub-Saharan Africa are caused by 
Plasmodium falciparum, while P. vivax is more prevalent in the Americas (64%), South East Asia (30%) 
and in the Eastern Mediterranean regions (40%) (World Health Organization, 2017).  
Encouraged by the availability of insecticides, such as DDT, and antimalarial medications, the World 
Health Organisation (WHO) initiated the malaria eradication program in 1955 with the aim to eliminate 
malaria worldwide. Measures to fight the disease included indoor residual spraying, insecticide-treated 
mosquito nets, drainage of breeding sites and treatment of infections with chloroquine. Despite these 
efforts, permanent success could only be achieved in Europe and North America, leading to the 
abandonment of the program in 1969. Failure of the campaign resulted from the emergence of parasite 
resistance to antimalarial medicines and mosquito resistance to insecticides, poor infrastructure, political 
and cultural problems and lack of consistent funding.  
Resistance of P. falciparum to antimalarial drugs still poses a serious problem. The artemisinin-based 
combination therapy (ACT) is the most powerful treatment to date, but parasites resistant to artemisinin 
have been found in five countries in South East Asia (World Health Organization, 2017). However, the 
WHO recently updated the information on artemisinin resistance to clarify that “resistant” parasites only 
display a partial resistance as the resistance mechanisms developed by the parasite affect only the ring 
stage and lead to a delayed clearance of parasites in patients after ACT treatment. The development of 
new antimalarial drugs can be beneficial, but an effective vaccine would be the most powerful tool in 
malaria control. Malaria research has made significant progress by establishing a culture system for 
P. falciparum (Trager and Jensen, 1976) and sequencing the genomes of P. falciparum (Gardner et al., 
2002), P. vivax (Carlton, Adams, et al., 2008), P. knowlesi (Pain et al., 2008) and the mosquito Anopheles 
gambiae (Holt et al., 2002). Nevertheless, the most advanced vaccine candidate RTS,S/AS01 
(GlaxoSmithKline Biologicals), a circumsporozoite protein (CSP)-based subunit vaccine, was only 
partially effective against severe malaria in clinical phase III trials (RTS, 2015). This result was particularly 
discouraging as the efficacy in the high risk group of children under the age of five was below 30%. 
Hence, alternative vaccine candidates need to be examined to achieve better protection against malaria. 
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1.2. Life cycle of Plasmodium  
The Plasmodium parasite is an eukaryotic unicellular microorganism belonging to the phylum 
Apicomplexa. This obligate intracellular parasite can infect a wide range of vertebrate hosts, including 
birds, reptiles, non-human primates and humans. Its complex life cycle includes switching from an 
invertebrate to a vertebrate host, replicating asexually and sexually, passing through several stages in 
different cell types and tissues, and subsequently requires adaption to changing environmental conditions 
like temperature, pH and the host’s metabolism. (Figure 2). 
 
Figure 2. Life cycle of Plasmodium vivax. When an infected Anopheles mosquito transmits sporozoites to the human 
host, the parasites actively move through the skin until they penetrate a blood vessel and are getting carried by the 
bloodstream to the liver. During the first few days the sporozoite replicates asexually in hepatocytes and forms 
merozoite-filled merosomes. Disintegration of these structures releases merozoites, which in turn invade red blood cells. 
P. vivax parasites have a strict preference for reticulocytes, while P. falciparum invades erythrocytes. The erythrocytic 
stage can be separated into a ring, trophozoite and schizont stage. The end result is a schizont containing up to 32 
daughter merozoites, which are released upon reticulocyte rupture and invade new reticulocytes. Due to a 
developmental switch from asexual to sexual proliferation in the red blood cell, immature gametocytes are formed that 
can be taken up by a mosquito during a blood meal. In the mosquito midgut, male and female gametocytes differentiate 
into microgametes and macrogametes, respectively. The microgametes fertilise macrogametes to form a zygote, which 
develops into a motile ookinete that passes through the midgut epithelium and settles as an oocyst in the outer gut 
lining. Within that oocyst, sporozoites are created by asexual replication and ultimately migrate to the salivary glands to 
restart the life cycle. Additionally, P. vivax has the ability to form dormant liver forms, so-called hypnozoites, which can 
begin another cycle of parasite development within the human host even after all parasites were cleared from the blood 
circulation. Source: (Mueller et al., 2009). 
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Infection in humans is initiated by a bite of an infected female Anopheles mosquito. Approximately 
15-123 sporozoites are injected during a blood meal and deposited into the skin of the vertebrate host 
(Rosenberg et al., 1990; Medica and Sinnis, 2005). The sporozoites actively migrate through the skin, but 
only around 35% of them reach a blood vessel that passively transports them through the body and into 
the liver (Douglas et al., 2015). The remaining sporozoites stay in the skin or end up in lymph vessels 
(Graewe et al., 2012). Once in the liver, sporozoites invade hepatocytes by invagination of the host cell 
plasma membrane, which forms a parasitophorous vacuole (PV) and creates a physical barrier between 
the parasite and the host (Lingelbach and Joiner, 1998). In 5-15 days, the parasite develops into a 
multinucleated schizont by asexual replication. One of these schizonts can contain up to 30,000 
merozoites, meaning that one sporozoite reaching the liver and completing its development is enough to 
initiate a malaria infection. Individual vesicles filled with merozoites are created by repeated invaginations 
of the host plasma membrane. These vesicles, called merosomes, bud of the host cell and are released into 
the blood stream (Sturm et al., 2006). Rupture of these merosomes in the lung capillaries and the release 
of infectious merozoites ends the clinically silent phase and starts the erythrocytic stage (Baer et al., 2007). 
P. vivax also generates dormant liver forms, known as hypnozoites, which can trigger a new round of 
parasite development within the human host independently of new transmissions (Mueller et al., 2009).  
Once in the bloodstream, merozoites invade red blood cells. P. vivax parasites have a strict tropism for 
reticulocytes, whereas P. falciparum invades erythrocytes. Infected red blood cells can be identified by a 
typical ring-like structured parasite within the cell. This ring stage is followed by a trophozoite and 
schizont stage during which the parasite replicates asexually to form more merozoites. The exact duration 
of this intraerythrocytic development varies among the Plasmodium species. P. knowlesi is the fastest and 
completes one cycle in 24 hours while it takes between 42-48 hours for P. falciparum, 48 hours for 
P. vivax and P. ovale, and 72 hours for P. malariae (Singh et al., 2004; Greenwood et al., 2005; Tuteja, 
2007). The end of each cycle is marked by the rupture of red blood cells and the release of 16-32 
merozoites into the bloodstream where they quickly invade and exploit the next red blood cell. The clinical 
symptoms of malaria are exclusively caused by this asexual blood stage.  
 
In addition to asexual proliferation, some parasites differentiate into gametocytes, the sexual parasite 
stages. These gametocytes enter the blood flow and can be taken up by an Anopheles mosquito during a 
blood meal. In the mosquito midgut, external signals such as the shift in pH and temperature and the 
presence of xanthurenic acid triggers the parasite’s development (Billker et al., 1998). The nucleus of male 
gametocytes divides into 4-8 nuclei and forms microgametes, which undergo exflagellation. These 
microgametes fertilise mature female gametocytes (macrogametes). The resulting zygote develops into a 
motile ookinete that traverses the midgut wall and transforms into a spherical oocyst between the midgut 
epithelium and the basal lamina (Sinden and Billingsley, 2001). Asexual multiplication within the oocyst 
forms sporozoites, which break through the oocyst wall and enter the haemolymph before migrating to 
the salivary glands. Once these sporozoites have reached the salivary glands, they can be transmitted to 
the next vertebrate host by a mosquito bite and begin the cycle anew.  
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1.3. Invasion of red blood cells 
The asexual blood stage relies on the parasite’s ability to penetrate red blood cells. These host cells offer 
both a rich nutrient source and a niche where the parasite is hidden from the immune system. Plasmodium 
merozoites are the invasive form of the blood stage. Their elongated and polarised form with characteristic 
organelles at the apical end directs the movement direction of the parasite (Figure 3). Merozoites are the 
smallest parasite stage in the life cycle of Plasmodium and can be between 1.5-2.5 µm long and 1.0-2.0 µm 
wide. These differences in size are species-specific. For example, P. vivax merozoites were observed to be 
larger than P. falciparum ones. The outer surface of merozoites is covered in numerous merozoite surface 
proteins, often leading to the description of a fuzzy coat. The apical organelles, such as micronemes and 
rhoptries, are characteristic for Apicomplexan organisms and contain parasite proteins that are involved 
in the invasion mechanism (Cowman and Crabb, 2006). Dense granules and exonemes are additional 
reservoirs of such proteins, like the subtilisin-like protease-1 (PfSUB1) (Yeoh et al., 2007). In addition to 
the apical organelles, the merozoites also possess typical organelles found in eukaryotes, like a nucleus, 
mitochondrium, endoplasmic reticulum, Golgi, microtubules and ribosomes. The apicoplast is a 
non-hotosynthetic plastid that is crucial for the parasite’s survival. However, the exact function is still not 
completely elucidated.  
 
 
       
Figure 3. Invasion of red blood cells by merozoites. (A) Morphology of a merozoite. The structure is pear-shaped and 
its surface is heavily covered in proteins creating a fibrillar coat. Apart from the typical eukaryotic organelles, 
Apicomplexan parasites have specialised organelles such as rhoptries and micronemes and dense granules, as well as 
exonemes that contain parasite proteins involved in the invasion process. The polar ring at the apical end functions as 
a microtubule organising centre. (B) Invasion of red blood cells by merozoites includes three distinct steps. First, the 
merozoite attaches reversibly to a potential new host cell. Surface proteins on the merozoite allow the identification of 
permissive red blood cells. Next, the merozoite reorientates itself and the apical end binds to the red blood cell 
membrane. This binding is irreversible and a tight junction is formed which actively pushes the parasite into the host cell 
during the final step. The fuzzy surface protein coat is shed during the parasite’s entry into the red blood cell. After 
invasion, the parasite is surrounded by the parasitophorous vacuole, which was created by invagination of the host cell 
membrane. Source: (Cowman and Crabb, 2006). 
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The invasion process can be seen as the parasite’s Achilles’ heel. Plasmodium is intracellular for most of 
its life cycle with the merozoites being the only extracellular form in the blood stage. Hence, the time 
between egress and invasion of another red blood cell, poses a brief chance for the immune system to 
attack. If the invasion process were to be disrupted by therapeutic measures or immune mechanisms 
induced by vaccination, the symptom-causing asexual multiplication of Plasmodium could come to a 
standstill. The invasion of red blood cells by merozoites was first studied using P. knowlesi  (Dvorak et 
al., 1975) and previously made observations were later confirmed with P. falciparum (Gilson and Crabb, 
2009). Generally, the invasion event can be divided into three phases. (i) Initial reversible attachment of 
the merozoite to the red blood cell membrane. In this phase, the merozoite must distinguish between host 
cells suitable for invasion and other cell types. These initial contacts were shown to cause heaving 
perturbations of the red blood cell membrane, giving these interactions a dynamic appearance (Gilson 
and Crabb, 2009). Specific recognition of permissive host cells is thought to be mediated by GPI-anchored 
surface proteins and their associated partners (Sanders et al., 2005; Cowman and Crabb, 2006). (ii) The 
next step is reorientation of the merozoite and irreversible attachment of the apical pole to the red blood 
cell. Micronemes and rhoptries discharge proteins involved in tight junction formation, such as 
reticulocyte-binding protein homologues and erythrocyte binding antigens (Rayner et al., 2001; Taylor, 
Grainger and Holder, 2002; Duraisingh et al., 2003; Gilberger et al., 2003). (iii) Finally, the parasite 
enters the red blood cell by invagination of the cell membrane, creating the parasitophorous vacuole. The 
extracellular protein coat is shed during this step as the tight junction moves from the apical to the 
posterior end using its actin-myosin motor, propelling the merozoite into the host cell (Keeley and Soldati, 
2004; Cowman and Crabb, 2006).  
Usually, merozoites recognize a new target cell within one minute after their release from a schizont and 
parasite entry is completed 30 seconds after initial contact (Gilson and Crabb, 2009). However, studies 
on the invasive half-life of merozoites showed that an immediate invasion is not required for the parasite’s 
survival. The in vitro determined invasive half-life was 8 minutes at 37°C. 20% of merozoites were still 
able to invade erythrocytes after 10 minutes of incubation without red blood cells. At room temperature, 
this observed invasive half-life even increased to 20 minutes (Boyle, Wilson and Beeson, 2013). 
Interestingly, incubation at 40°C reduced the invasive capacity of merozoites, indicating that fever is 
indeed an effective response by the immune system (Boyle, Wilson, et al., 2010). Loss of invasive potential 
could be due to spontaneous cleavage or shedding of surface proteins (Langreth, Nguyen-Dinh and 
Trager, 1978; Johnson et al., 1981; Blackman et al., 1991), premature release of proteins from rhoptries 
and micronemes (Johnson et al., 1980) or loss of metabolic activity.  
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1.4. Plasmodium vivax 
Most fatal malaria cases are caused by Plasmodium falciparum, but another Plasmodium species called 
P. vivax is actually more widespread and is responsible for more than 50% of malaria cases in non-African 
regions. South America and South East Asia are reporting the majority (66%) of P. vivax infections, but 
the parasite was also observed in some African and Eastern Mediterranean regions (Figure 4, (World 
Health Organization, 2017)). Current estimations state that 2.6 billion people are at risk of an infection 
with P. vivax and 80-300 million clinical cases per year are caused by this parasite (Arévalo-Herrera, 
Chitnis and Herrera, 2010).  
 
Figure 4. Distribution of P. vivax worldwide. Plasmodium vivax is the most widespread Plasmodium species infecting 
humans. South America and South East Asia carry the majority of the P. vivax burden, but some African regions also 
report P. vivax infections. The data on this map represents cases reported in 2010. The colour code ranges from light 
blue for low endemicity to red for high endemicity. Source: The Malaria Atlas Project. 
Although both P. falciparum and P. vivax can infect humans, there are some key differences between the 
two. P. vivax shows a strict tropism for CD71+ reticulocytes and does not invade mature erythrocytes 
(Russell et al., 2011; Malleret et al., 2014). This restriction also poses a numerical limit as reticulocytes 
usually only represent ~ 2.5% of all circulating red blood cells. Because of this restriction, the parasitemia 
observed during P. vivax infections is generally lower compared to P. falciparum infections. Sequestration 
is another pathological process that occurs both in P. falciparum and P. vivax, but the observed 
cytoadhesion levels of P. vivax were 10-fold lower in in vitro assays and the in vivo numbers might be 
even lower (Carvalho et al., 2010). This finding implies that sequestration is a rather insignificant factor 
in P. vivax infections. 
Another major characteristic of P. vivax is the ability to differentiate into hypnozoites (Figure 5). These 
dormant liver forms are undetectable by blood tests and can remain in the liver for months or even years 
before causing a relapse of the disease. This additional P. vivax reservoir within the human host can 
re-establish the erythrocytic stage of the parasite’s life cycle without a second transmission of sporozoites.  
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Figure 5. Microscopic image of a hypnozoite. The hypnozoite (green dot on the right) is shown next to a liver schizont. 
This dormant form can remain in the liver for years before causing a relapse and is undetectable by commonly used 
blood tests. Source: (Vogel, 2013) 
Prevention of these relapses can be achieved by radical cure treatment, which consists of co-administration 
of the antimalarial drugs chloroquine or artemisinin, targeting blood stages, and a hypnozoite-eliminating 
drug like primaquine. This compound is metabolised in the liver by an enzyme called cytochrome 
CYP2D6, suggesting that the actual hypnozoite killing agent is a metabolite (Baird and Hoffman, 2004). 
Hence, treating patients without a functional CYP2D6 metabolism could result in treatment failure 
(Bennett et al., 2013). Also, people suffering from glucose-6-phosphate dehydrogenase (G6PD) deficiency 
cannot benefit from primaquine medication as this substance causes fatal haemolysis in these patients. 
Poor compliance is another factor that hinders successful treatment as primaquine needs to be taken for 
14 days. Tafenoquine is an alternative compound that is currently under investigation for its potential use 
as a single-dose radical cure treatment alongside with chloroquine or artemisinin-based combination 
therapy. However, tafenoquine belongs to the same chemical family as primaquine and is equally 
contraindicated for treatment of G6PD-deficient patients and pregnant or lactating women (Watson et 
al., 2018). 
 
The life cycle of P. vivax seems to put a stronger emphasis on generating gametocytes than P. falciparum, 
as P. vivax gametocytes can already be detected in the blood of infected patients before they experience 
any symptoms. This quick occurrence of sexual stages, which can be taken up by mosquitoes to further 
transmit the disease and the fact that up to 71 mosquito species can carry P. vivax parasites might 
contribute to this parasite’s wide distribution (Vogel, 2013).  
 
Individuals who are permanently exposed to P. vivax develop milder clinical manifestations or even 
asymptomatic infections. This naturally acquired immunity progressively builds up during the first two 
decades of life (Doolan, Dobaño and Baird, 2009) but protection against P.  vivax could also be achieved 
by immunising human volunteers with attenuated sporozoites (Clyde, 1975). Due to the apparently milder 
symptoms, P. vivax was used as malariotherapy between 1917 and 1940, which means patients suffering 
from certain diseases like neurosyphilis were infected with P.  vivax to induce high fevers that were meant 
to combat the primary disease. In 1927, Julius Wagner-Jauregg received the Nobel prize for inventing this 
technique. However, this treatment has since been abandoned because it killed 15% of the treated patients  
(White, 2011). Today, P. vivax should no longer be considered harmless as reports of severe disease and 
even deaths accumulate (Baird, 2007; Anstey et al., 2009; Mueller et al., 2009; Lacerda et al., 2012). 
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The central dogma of P. vivax infection used to be that the parasite relies on an interaction of the P. vivax 
Duffy binding protein and the Duffy antigen receptor for chemokines (DARC) on reticulocytes  (Horuk 
et al., 1993). Reduced levels of the Duffy antigen were associated with resistance to P. vivax infection 
(Zimmerman et al., 1999). This resistance could have been the driving factor for the single nucleotide 
polymorphism in the DARC promoter, which results in the complete absence of the Duffy receptor in the 
homozygous state (Tournamille et al., 1995). Following this theory, P. vivax may have been highly 
prevalent in west and central Africa and the parasite itself enforced the fixation of the Duffy negative 
allele in the human population (Carter and Mendis, 2002). However, there is a growing number of 
reported P. vivax infections in Duffy-negative individuals, suggesting that either an unidentified 
alternative pathway exists or that the parasite is currently in the process to evolve such a mechanism 
(Rosenberg, 2007; Ménard et al., 2010; Zimmerman et al., 2013; Russo et al., 2017). It has been suggested 
that Duffy-positive individuals might function as a reservoir for P. vivax parasites in Duffy-negative 
regions, creating an environment in which parasites that are able to invade reticulocytes without the need 
for this antigen could be selected for (Ménard et al., 2010). 
 
As the Duffy antigen is shown to be less important than initially believed, another receptor-ligand 
interaction was demonstrated to be responsible for parasite’s strict tropism for reticulocytes. The 
interaction between the P. vivax reticulocyte-binding protein 2b (PvRBP2b) and the transferrin receptor-1 
(TfR1) also known as CD71, is thought to allow the exclusive selection of young reticulocytes. TfR1 is 
an iron transporter, which is found on the surface of reticulocytes but not on mature erythrocytes. A 
cryo-electron microscopy structure of the ternary complex of PvRBP2b bound to human TfR1 and 
transferrin was recently published by (Gruszczyk, Huang, et al., 2018). The same study showed that 
PvRBP2b residues involved in complex formation are conserved, implying PvRBP2b as a new P. vivax-
specific drug target.  
This selectivity does not only concentrate P. vivax invasion on immature CD71+ reticulocytes, it also 
localises the parasite burden out of the peripheral blood as these host cells are generally restricted to the 
bone marrow (Malleret et al., 2014). This extravascular invasion is most likely another contributing factor 
to lower parasitemia in the peripheral blood. TfR1-deficient erythroid cells were shown to be refractory 
to P. vivax invasion and anti-PvRBP2b monoclonal antibodies can block invasion in field isolates 
(Gruszczyk, Kanjee, et al., 2018).  
 
Once the P. vivax parasite has invaded a CD71+ reticulocyte, the host cell undergoes rapid remodelling 
and transforms from a rigid immature reticulocyte to a deformable CD71- cell within 6 hours 
post-invasion. These remodelled cells have lost all reticular matter and several surface markers  (Malleret 
et al., 2014). The increase in deformability is particularly interesting as P. falciparum infected erythrocytes 
become more rigid, whereas P. vivax infection has the opposite effect on the host cell. Experiments using 
laminar shear flow and microfluid conditions suggested that the increased deformability represents an 
adaption to avoid splenic clearance of parasitised blood cells (Suwanarusk et al., 2004; Handayani et al., 
2009). In contrast to erythrocytes, reticulocytes still own the translation machinery to express surface 
Introduction 
 10 
proteins, such as human leukocyte antigen-1 (HLA-1), which presents antigens to CD8+ T cells to activate 
them. Recent studies suggest that P. vivax depletes the reticulocyte cell membrane of cholesterol and 
thereby increases the infected reticulocyte’s susceptibility to granulysin, a substance released by cytotoxic 
CD8+ T cells that forms pores in the membrane and delivers granzyme B, triggering apoptosis in the 
infected cell (Junqueira et al., 2018). These findings suggest that CD8+ T cells could contribute 
significantly to P. vivax parasite clearance and that T cell-mediated immunity should not be neglected 
during vaccine development targeting P. vivax infections. 
 
All things considered, these recent developments strongly indicate that P. vivax cannot be neglected in 
malaria research any longer and the focus on drug discovery and vaccine development should not be 
restricted to P. falciparum alone anymore. 
 
1.5. Clinical manifestation and immunity  
The first symptoms of a malaria infection can be observed between 7 and 18 days after a mosquito bite, 
depending on the Plasmodium species. These symptoms are usually unspecific in the beginning and include 
tiredness, diarrhea, nausea, sweating, chills and dizziness. During the progression of the infection, patients 
experience more severe effects such as anaemia, respiratory distress, hypoglycaemia and in the worst cases 
also multi-organ failure and cerebral malaria (World Health Organization, 2017). These clinical signs of 
malaria are caused solely by the asexual erythrocytic replication of the Plasmodium parasite. Once the 
parasite has successfully invaded blood cells, three different mechanisms contribute to the disease pattern.  
(i) Rupture of infected erythrocytes leads to anaemia and impairs oxygen transport, consequently resulting 
in respiratory distress. (ii) Parasite metabolites, like hemozoin, and parasite antigens that are shed when 
the merozoites invade the next cell can stimulate the immune system to produce pro-inflammatory 
cytokines (Shio et al., 2010). These cytokines include tumour necrosis factor alpha (TNF-a), interleukin-1 
(IL-1) and interferon-g (Clark, 1987), which increase body temperature and lead to the typical fever 
associated with the rupture of red blood cells. Interestingly, many merozoite surface antigens are anchored 
to the parasite membrane by a glycosylphosphatidylinositol (GPI) moiety that has been shown to induce 
TNF and IL-1 production in macrophages (Ramasamy, 1998). (iii) Infected erythrocytes are modified by 
the parasite and express parasite surface antigens, like the Plasmodium falciparum erythrocyte membrane 
protein 1 (PfEMP1), which confer binding to the endothelium of blood vessels and inner organs such as 
brain, liver, lung and kidneys. This process called sequestration can result in low parasite numbers in the 
peripheral blood and allows the parasite to evade clearance in the spleen (Howard and Gilladoga, 1989). 
Rosetting, the agglutination of infected and uninfected red blood cells can further increase these effects. 
Together, sequestration and rosetting can block the blood flow, cause oxygen deprivation, inflammation 
in the capillaries and in the worst case result in multi-organ failure. The most deadly course of the disease 
is termed cerebral malaria and is characterized by sequestration to the microvasculature of the brain. 
Initial symptoms of impaired vision, coordination and movement problems quickly progress to coma and 
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death after a short period of time. But even if a patient survives cerebral malaria, the neurological 
consequential damage will impact the quality of life permanently. 
Malaria in pregnant women is also a significant complication. Plasmodium is mostly replicating in the 
placenta, which seems to be an immunologically naïve site (English and Newton, 2002). Sequestration in 
the placental capillaries can have a series of negative effects on the mother and baby, ranging from 
miscarriage, premature delivery, low birth weight, severe anaemia and increased mortality of the newborn 
and the mother (Tuteja, 2007).  
However, the human body is not entirely defenceless against malaria infections. People living in malaria 
endemic areas can develop semi-immunity after multiple infections. This semi-immunity protects against 
severe consequences of recurrent malaria infections, but semi-immune individuals still function as a 
reservoir for the parasite (Ramasamy, 1998). Genetic polymorphisms can be advantageous in terms of 
malaria as well. Hemoglobinopathies, altered erythrocyte membrane proteins (such as Duffy negativity), 
altered red blood cell enzymes (G6PD) and modifications of immunity related genes (TNF-a) can confer 
resistance to Plasmodium infections or the accompanying symptoms (Williams, 2006). 
 
1.6. Vaccine development  
The total number of malaria cases has dropped worldwide but emerging resistances against insecticides 
and antimalarial drugs put this achievement at risk (World Health Organization, 2017). Hence, a safe 
and efficient vaccine remains a requirement for malaria eradication worldwide. The target groups for 
vaccine development include those who suffer most from the disease, namely infants, children and 
pregnant women, but also migrants who move to malaria-endemic regions, travelers and military 
personnel (Hollingdale and Sedegah, 2017). The US military has defined a need for at least 80% efficacy 
for a malaria vaccine and including not only P. falciparum but also P. vivax infections (Teneza-Mora, 
Lumsden and Villasante, 2015).  
 
Anti-sporozoite vaccines aim to inhibit the invasion of hepatocytes by sporozoites and to reduce the initial 
parasite load. The most advanced vaccine candidate to date is RTS,S/AS01, which is a subunit vaccine 
consisting of part of the repeat region and the remaining C-terminus of the pre-erythrocytic 
circumsporozoite protein (CSP) of P. falciparum sporozoites fused to a viral envelope protein of the 
hepatitis B virus (Crompton, Pierce and Miller, 2010). However, the results of a phase III clinical trial 
were sobering as RTS,S/AS01 showed no efficacy over a 7 year period in African children (Olotu et al., 
2016). Another anti-sporozoite vaccine candidate is based on the thrombospondin-related adhesive 
protein (TRAP), but a phase II clinical study in adults revealed no efficacy against P. falciparum malaria 
(Mensah et al., 2016).  
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Whole parasite vaccines are thought to mediate immunity by inducing cytotoxic T cell responses against 
liver stages. The used sporozoites are manipulated so that they cannot complete their development and 
can be safely administered to malaria-naïve individuals. There are three different modes of developmental 
arrest. Radiation attenuated sporozoites (RAS) were exposed to g-radiation to induce multiple random 
double-strand breaks in their DNA, leading to an early arrest in liver stage development (Hoffman et al., 
2002). While sterile immunity was achieved by intravenous injection in humans, a high dose was required 
(Lyke et al., 2017). Interestingly, using P. vivax irradiated sporozoites for vaccination was also able to 
induce sterile protection in study participants (Arévalo-Herrera et al., 2016), suggesting that this 
technique is reproducible for other Plasmodium species. 
Another approach uses gene deletion to create genetically attenuated parasites (GAP), which arrest at a 
defined developmental stage in the liver(Mueller et al., 2005). Immunisation experiments in mice showed 
an improved protection in comparison to radiation attenuated sporozoites (Butler et al., 2011). 
Alternatively, wildtype sporozoites can be injected under simultaneous chemoprophylaxis using 
chloroquine  azithromycin or primaquine to arrest the parasite’s development at a defined stage (Putrianti 
et al., 2009; Friesen et al., 2010; Mordmüller et al., 2017). This method was able to induce sterile 
protection in humans when sporozoites were delivered by mosquito bite (Roestenberg et al., 2009, 2011) 
or by intravenous injection of cryopreserved P. falciparum sporozoites (Mordmüller et al., 2017).  
As promising as these results might seem, a whole parasite vaccine faces three problems. (i) The laborious 
production and purification needs to be improved by establishing an in vitro culture system to produce 
sporozoites of sufficient quantity and quality. (ii) Intravenous injection is not an accepted mode of vaccine 
administration, but intramuscular or subcutaneous injections require about 23 times more sporozoites 
(Gómez-Pérez et al., 2015). (iii) Parasites need to be stored in liquid nitrogen or dry ice, which is a 
logistical challenge in remote African regions, hence this kind of vaccine is probably not applicable in the 
area where it is most needed. 
 
Transmission blocking vaccines follow the altruistic principle and will not be able to protect the individual 
but aim to reduce transmission within a population by inducing antibodies against the sexual stages of 
Plasmodium (Wu et al., 2015) . These antibodies are taken up by the mosquito during a blood meal and 
inhibit parasite development in the mosquito midgut. This vaccine type alone will most likely not be 
sufficient to eliminate malaria and should be combined with other vaccines targeting erythrocytic or 
pre-erythrocytic stages. 
 
Blood stage vaccines are intended to reduce parasitemia or prevent clinical disease by targeting infected 
red blood cells and merozoites. Most vaccine candidates rely on the humoral immune response, but an 
optimal vaccine should also be able to elicit T cell-mediated immunity to induce multistage protection. 
These antigens are commonly produced as a recombinant protein and formulated with a suitable adjuvant 
or inserted into a viral vector for optimal immunogenicity. One vaccine candidate found on infected 
erythrocytes is PfEMP1. This parasitic protein enables infected red blood cells to bind to endothelial cells 
and is a key mediator in cytoadherence and sequestration of P. falciparum parasites. However, vaccine 
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development based on PfEMP1 is difficult as this protein is encoded by 60 var genes and consequently is 
extremely diverse. Other blood stage vaccine candidates focus on merozoite proteins, such as the apical 
membrane antigen 1 (AMA-1), erythrocyte-binding antigen 175 (EBA-175), serine repeat antigen 5 
(SERA-5) or glutamate-rich protein (GLURP). For years, AMA-1 has been an attractive target due to its 
involvement in erythrocyte invasion, but despite a promising immunogenicity profile, it showed no 
efficacy in a phase IIb study (Ouattara et al., 2010) and even after reformulation with another adjuvant, 
higher antibody titres were unable to confer protection against sporozoite challenge (Duncan et al., 2011). 
Antibodies against EBA-175, another protein on the merozoite surface that interacts with glycophorin A 
on the red blood cell, caused only modest growth inhibition in in vitro assays and immunisation with 
GLURP, a protein of unknown function, resulted in no protective efficacy in a phase IIb study (Sirima et 
al., 2016). SERA-5 has been proposed to function as a protease in merozoite egress (Beeson et al., 2016) 
and could reduce the incidence rate of high parasitemia in volunteers in a phase Ib study (Palacpac et al., 
2013). The most abundant protein on merozoites, the merozoite surface protein 1 (MSP-1) is a well-
studied vaccine candidate that will be discussed in more detail in 1.7.  
 
Despite all the progress being made in recent years, a malaria vaccine that is cost-effective, targets different 
stages of the Plasmodium life cycle and is able to confer long-lived protection against more than one 
Plasmodium species is still missing.  
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1.7. The Merozoite surface protein 1  
Merozoites are the invasive form of Plasmodium blood stages, hence they require surface proteins that 
facilitate the identification and interaction with new host cells before and during invasion. The surface of 
merozoites is often compared to a fuzzy layer, with one protein in particular accounting for the majority 
of these surface proteins, leading to the name merozoite surface protein 1 (MSP-1)(Figure 6). MSP-1 was 
detected in all Plasmodium species so far and albeit it being considered a blood stage antigen, MSP-1 was 
also detected in late trophozoites and schizonts developing in hepatocytes (Szarfman et al., 1988; Haussig, 
Matuschewski and Kooij, 2011). 
 
 
Figure 6. MSP-1 is the most abundant protein on the surface of merozoites. Right: Photograph of a Plasmodium 
blood culture stained with Giemsa with mixed stages including a just ruptured schizont and free merozoites. Middle: A 
merozoite in the process of penetrating a new host cell. M: merozoite, E: erythrocyte, V: vacuole. Source: (Miller et al., 
1979). Right: Model of the non-covalently associated MSP-1 complex on the surface of a merozoite.  
The primary sequence of P. falciparum MSP-1 can be divided into 17 blocks of low, moderate and high 
conservation among different isolates (Tanabe et al., 2007). Despite this variability, all P. falciparum 
msp-1 sequences can be classified into one of two allelic isoforms, either the MAD20 or K1 allelic variants, 
which are field isolates from Papa New Guinea and Thailand, respectively. Cross-species comparisons 
also revealed areas within the msp-1 sequence that are highly conserved among species (Figure 7). Ten 
blocks with >48% sequence identity among P. falciparum, P. vivax and P. yoelii were identified, plus 
three blocks of >50% sequence identity when only P. falciparum and P. vivax were considered.  
 
 
Figure 7. Interspecies conserved and conserved blocks within the MSP-1 sequence. 10 interspecies conserved 
blocks with a sequence identity of >48% were identified in P. vivax, P. falciparum and P. yoelii MSP-1. The conserved 
blocks share a sequence identity of >50%, referring only to P. vivax and P. falciparum sequences. Source: (del Portillo 
et al., 1991).  
Introduction 
 15 
1.7.1. Proteolytic maturation of MSP-1 
In all Plasmodium species, MSP-1 is encoded by a gene of approximately 5,000 bp on chromosome 9 and 
is initially expressed as a precursor of 185-200 kDa. A hydrophobic N-terminal signal sequence of 19 
amino acids is cleaved from the protein after translocation into the endoplasmic reticulum. The full length 
protein is not glycosylated except for the addition of a glycosylphosphatidylinositol moiety at the 
C-terminus (Berhe et al., 2000). However, the precursor protein is proteolytically processed by a protease 
called subtilisin-like protease 1 (SUB1), which is localised in exonemes and secreted into the PV prior to 
egress (Blackman et al., 1998). As a result, MSP-1 is cleaved into the four fragments p83, p30, p38 and 
p42, which are named according to their approximate molecular weight. These fragments remain 
non-covalently associated to each other and the merozoite surface. Cleavage by SUB1 is not restricted to 
MSP-1 as several other targets were identified via a bioinformatic screen, including the serine-rich antigens 
SERA 4, 5, 6, MSP-6, MSP-7 and the rhoptry associated protein 1 (RAP-1) (Yeoh et al., 2007; de Monerri 
et al., 2011). The cleavage of P. falciparum MSP-1 into four processing fragments occurs in a distinct but 
variant-specific order. In the MAD20 variant cleavage starts at the 30/38 site, followed by 83/30 and 
finally the 38/42 site, whereas processing of the K1 variant simply begins at the N-terminus with the 83/30 
site and follows the order of cleavage sites as they occur in the primary sequence up to the C-terminus 
(Child et al., 2010). SUB1 processing was shown to induce structural changes in the conformation of its 
substrates and thus changes their binding properties, which prepares the merozoites for invasion and 
egress (Kauth et al., 2006; Koussis et al., 2009). This proteolytic processing seems to be of vital importance 
for the function of MSP-1 as several alternative cleavage sites for PfSUB1 have been identified (Cooper 
and Bujard, 1992). The cleavage motif of SUB1 always contains an aliphatic residue at the P4 position, a 
small uncharged amino acid at P2, a polar residue at P1 and an acidic residue at one or more of the P1’-P5’ 
positions (de Monerri et al., 2011; Withers-Martinez et al., 2012) (Figure 8). 
  
 
 
Figure 8. Cleavage sites of PfSUB1. (A) The subtilisin-like protease 1 recognises its cleavage sites by an aliphatic 
residue at P4, an uncharged amino acid at P2 followed by a polar residue at P1. The P1’ to P5’ positions contain one or 
more acidic residue. Source: (de Monerri et al., 2011) (B) Scheme of the primary sequence of MSP-1D, corresponding 
to the MAD20 isolate as previously published by (Kauth et al., 2006). Cleavage sites for PfSUB1 and PfSUB2 are 
indicated with downward arrows. Conserved, dimorphic and oligomorphic regions are shown in white, grey and black, 
respectively. SP: signal peptide, GPI: glycosylphosphatidylinositol signal sequence. 
 
A B 
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MSP-1 undergoes a second proteolytic processing step just before or during invasion. Another 
subtilisin-like protease called SUB2 is discharged from micronemes onto the merozoite surface and cleaves 
the C-terminal p42 subunit into two fragments called p33 and p19 (Harris et al., 2005). While p19 
remains tethered to the merozoite membrane via the GPI anchor, the remaining MSP-1 subunits are shed 
from the surface of the merozoite during its entry into the host cell (Blackman et al., 1991; Blackman and 
Holder, 1992) (Figure 9). 
 
 
Figure 9. Processing of MSP-1 by SUB1 and SUB2 takes place at specific stages of the parasite’s life cycle. 
Initially, MSP-1 is expressed as a precursor protein that is connected to the merozoite membrane via a GPI anchor. 
Before egress from the host cell, SUB1 is released from exonemes and cleaves the precursor protein into the four 
fragments p83, p30, p38 and p42. A second proteolytic processing occurs during invasion into a new host cell. SUB2, 
a protease released from micronemes cleaves p42 into p33 and p19. The C-terminal p19 portion is internalised into the 
red blood cell with the merozoite while the remaining MSP-1 subunits are shed from the merozoite surface.  
1.7.2. Function of MSP-1 in invasion and egress 
MSP-1 is one of the most studied Plasmodium proteins. However, its precise function is still under 
investigation while several studies indicate its involvement in both invasion and egress. That MSP-1 plays 
a crucial role in the parasite’s development became apparent when attempts to genetically knockout the 
msp-1 gene failed. Only the EGF-like domains of the C-terminal part could be functionally replaced by 
the same sequence from another P. falciparum isolate (Drew et al., 2004) or by the homologue sequence 
from the rodent parasite P. chabaudi (O’Donnell et al., 2000).  
Current studies suggest that MSP-1 could function as an anchoring platform for other parasite proteins 
during initial attachment to the red blood cell (Lin et al., 2016). Previous experiments using recombinant 
MSP-1, MSP-6 and MSP-7 proteins showed that these three proteins form a complex after being processed 
by SUB1 (Kauth et al., 2006). Other reported interaction partners are band 3, an anion transporter in the 
erythrocyte membrane that interacted with the p42 and p19 portion of MSP-1, heparin-like 
proteoglycans, glycophorin A, spectrin and recently also MSPDBL-1 and MSPDBL-2 (Herrera et al., 
1993; Goel et al., 2003; Boyle, Richards, et al., 2010; Baldwin et al., 2015). The latter are members of 
the MSP-3 family and harbour Duffy-binding like domains, which are thought to mediate the interaction 
with red blood cells (Lin et al., 2014). However, the exact receptor on red blood cells used for this 
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interaction is unidentified. MSPDBL-1, MSPDBL-2, MSP-3, MSP-6 and MSP-7 were all shown to bind 
to MSP-1 independently of each other, allowing the formation of different MSP-1 dependent complexes 
with presumably overlapping functions. Interestingly, only MSP-1 complexes containing MSP-6, 
MSPDBL-1 and MSPDBL-2 were able to attach to human erythrocytes (Lin et al., 2016). The same study 
pointed out that p83 seems to play a key role in the assembly of these complexes as their formation could 
be prevented by antibodies directed against that subunit. This antibody-mediated inhibition also reduced 
parasite growth in vitro. Another experiment using monoclonal antibodies directed against the EGF-like 
domains of the p19 MSP-1 fragment showed that invasion of merozoites could be inhibited if the 
secondary processing of MSP-1 was blocked (Blackman et al., 1990, 1994).  
At the same time, evidence is accumulating that MSP-1 is not only crucial for invasion but also for egress. 
When genetic knockouts of msp-1 failed, conditional mutagenesis experiments were used as an alternative 
approach to study whether the parasite could develop normally in absence of MSP-1. The lack of MSP-1 
caused an abnormal development in the liver stage, where merozoite formation was noticeably disturbed 
and the infected hepatocytes showed internal budding and misshaped daughter cells (Combe et al., 2009). 
Additionally, MSP-1 must not only be present, it also has to be processed by SUB1 to fulfil its function as 
inhibition of SUB1 discharge or the expression of MSP-1 mutants that are refractory to SUB1 processing 
causes a severe egress defect (Yeoh et al., 2007; Das et al., 2015). In contrast to MSP-1’s role as an 
anchoring platform during invasion, MSP-1 itself is thought to be interacting with the cytoskeleton of the 
host cell before egress. Proteolytic processing by SUB1 enables MSP-1 to bind to heparin and spectrin. 
Following the rupture of the parasitophorous vacuole membrane, intracellular merozoites can bind to 
spectrin in the plasma membrane of the host cell. This interaction could cause internal shear forces that 
disrupt the structural integrity of the cytoskeleton and finally, lead to the rupture of the red blood cell 
membrane and release of merozoites (Das et al., 2015). 
 
1.7.3. MSP-1 structure 
Structural information can often complement data from functional assays to elucidate the properties of a 
protein and its potential as a drug target or vaccine candidate. So far, little is known about the 
three-dimensional structure of MSP-1. Due to its size and high flexibility of the N-terminal part, all 
attempts to obtain a crystal structure have failed so far. Only the structure of the C-terminal p19 fragment 
could be solved by NMR spectroscopy for P. falciparum and P. vivax (Morgan et al., 1999; Babon et al., 
2007), and by x-ray analysis for P. falciparum, P. cynomolgi and P. knowlesi (Chitarra et al., 1999; 
Garman et al., 2003; Pizarro et al., 2003). All these studies reveal two EGF-like domains which contain 
three disulphide bonds each, indicating structural and functional conservation of the p19 fragment among 
Plasmodium species. The entire p19 fragment is compact and flat, and both EGF-domains are folded back 
on one another in a side-by-side arrangement. Attempts to generate individual point mutations in this 
MSP-1 subunit proved to be difficult and but the EGF-like domains could be functionally replaced with 
the corresponding domains from P. chabaudi MSP-1 and P. berghei MSP-8 (O’Donnell et al., 2000; Drew 
et al., 2004). 
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Figure 10. Structure of p19 and model of the MSP-1 complex with MSP-6, MSP-7, MSPDBL-1 and MSPDBL-2. (A) 
Structure of the P. knowlesi p19 fragment solved by x-ray crystallography. The EGF-domains (D1, D2) are arranged side 
by side. Beta-strands are shown as ribbons and numbered in each domain. Disulphide bonds are indicated in yellow. 
Source: (Garman et al., 2003). (B) Model of MSP-1 in its PfSUB-processed form and known interaction partners. MSP-6 
forms a tetramer after processing and binds to the p38 fragment. MSP-7 also requires processing by SUB1 to be able 
to bind to p83, p30 and p38 (Kauth et al., 2006). MSPDBL-1 and MSPDBL-2 form an oligomer and interact with p83, 
p38 and p42, but not with p30 (Lin et al., 2016).  
Intramolecular interactions were analysed using recombinant MSP-1 processing fragments that were 
incubated together followed by affinity chromatography using an affinity resin that binds to only one of 
the MSP-1 fragments. In these experiments, p30 was shown to interact with p83, p38 and p42. The 
C-terminal p42 and p38 proteins also interacted with each other, whereas p83 had no second interaction 
partner within MSP-1 (Kauth et al., 2003). Interactions with other proteins such as MSP-6 and MSP-7 
were demonstrated as well, but only the processed form of MSP-6, namely MSP-636, could bind to MSP-1. 
MSP-636 tetramerises and binds solely to p38, while MSP-7 interacts with p38, p30, and p83 (Kauth et 
al., 2006). MSPDBL-1 and MSPDBL-2 have also been identified as interaction partners of MSP-1 and 
were shown to bind to p42, p38 and p83 (Lin et al., 2014). Another study focused on the C-terminal half 
of P. falciparum MSP-1 only by using a fusion protein comprising p38 and p42 to identify interaction 
partners. MSP-3, MSP-6, MSP-7 and MSP-9 were all found to interact with this fusion protein, but not 
with the p19 fragment, suggesting that only sequences upstream of the p19 C-terminal region are involved 
in molecular interactions with other MSP proteins (Paul et al., 2018).  
 
1.7.4. MSP-1 as a vaccine 
MSP-1 is a promising vaccine candidate because of its abundance on the merozoite surface and crucial 
role in the parasite’s life cycle. Several epidemiological studies in malaria endemic regions demonstrated 
a positive correlation between naturally acquired antibodies directed against different parts of 
P. falciparum and P. vivax MSP-1 and acquired clinical immunity. For instance, antibodies against the 
N-terminal p83 fragment of P. falciparum MSP-1 were associated with protection against malaria in 
adolescents in Mali (Tolle et al., 1993), while antibodies targeting the C-terminal p42 and p19 fragments 
were correlated with clinical immunity in children in West Africa and Papa New Guinea (al-Yaman et al., 
A B 
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1996; Egan et al., 1996). Interestingly, antibodies against the oligomorphic block 2 (Figure 11) strongly 
correlated with protection against P. falciparum malaria in children in Gambia and Ghana (Conway et 
al., 2000; Cavanagh et al., 2004), suggesting that both the conserved and the oligomorphic regions 
contribute to significant immune reactions.  
An immune response based on MSP-1 vaccination could attack the Plasmodium parasite using a variety 
of mechanisms. The main contributor to an effective immune response is thought to be the humoral 
immune response. Antibodies directed against either the C-terminal p19, N-terminal p83 fragment or the 
full length MSP-1 protein were able to directly inhibit the growth of blood stages in vitro (Blackman et 
al., 1990; Woehlbier et al., 2006). Additionally, MSP-1 induced antibodies can interact with complement 
factors as shown for anti-p19 antibodies in vitro (Boyle et al., 2015). Recruitment of other immune cells, 
such as neutrophils and monocytes, pose other mechanisms to eliminate the parasite in the host. The p19 
fragment was also shown to activate polymorphonuclear neutrophils and trigger the release of reactive 
oxygen species in a reaction called antibody-dependent respiratory burst (Joos et al., 2010). Another 
indirect growth inhibition mechanism relying on the recruitment of monocytes was demonstrated with 
antibodies against the N-terminal block 2 of P. falciparum MSP-1 (Galamo et al., 2009).  
But the blood stage is not the only part of the parasite’s life cycle that can be targeted by an MSP-1 induced 
immune response. Vaccination of mice with p42 using viral vectors AdHu5 and MVA induced CD4+ and 
CD8+ T cells and resulted in an enhanced survival rate and reduced parasite burden presumably due to 
increased IFN-g levels (Draper et al., 2009). Several CD8+ T cell epitopes were identified within the MSP-
1 sequence, suggesting that MSP-1 has the potential to induce cellular immune responses in humans and 
could lead to multistage protection (Carralot et al., 2008). Such a stage-overlapping immunity is of 
particular importance for P. vivax infections, as an effective immune response in the liver could eliminate 
hypnozoites and hence, reduce or eliminate the risk of recurring relapses.  
In malaria research, immunisation experiments regularly use mice and monkeys as animal models to 
validate the efficacy of a vaccine candidate or antimalarial drug. Such experiments were performed using 
both native MSP-1 isolated from parasite cultures and recombinant protein fragments. Purified MSP-1 
from P. yoelii parasite cultures (Holder and Freeman, 1981) and recombinant p19 and p42 produced in 
E. coli (Daly and Long, 1995; Tian et al., 1997) or S. cerevisiae (Hirunpetcharat et al., 1997) induced 
protection against P. yoelii infection in mice. Similar experiments using native P. falciparum MSP-1 or 
recombinant MSP-1 fragments showed that whereas the complete protein could induce protection against 
lethal infections in Saimiri and Aotus monkeys (Perrin et al., 1984; Herrera et al., 1990; Etlinger et al., 
1991; Cavanagh et al., 2014), the recombinant fragments only caused partial protection (Herrera et al., 
1990; Etlinger et al., 1991; Cavanagh et al., 2014). Immunisation trials using only the C-terminal p42 
fragment in adenoviral vectors or as a recombinant protein combined with adjuvant were unsuccessful in 
inducing significant protection in humans (Ogutu et al., 2009; Sheehy et al., 2012). However, other studies 
have pointed out the importance of the dimorphic and oligomorphic regions within the MSP-1 sequence. 
A longitudinal study in Mali revealed that antibodies detected in the population were predominantly 
directed against dimorphic regions (Früh et al., 1991) and as mentioned previously, antibodies directed 
against the block 2 sequence in P. falciparum were able to activate other immune cells (Galamo et al., 
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2009). These findings suggest that instead of focusing on specific parts of MSP-1, the full length protein 
should be used as a vaccine.  
 
Many vaccination experiments focused on MSP-1 fragments instead of the full length protein as obtaining 
it as a recombinant protein in sufficient quantity and quality is technically challenging due to the high AT 
content (~80%) of the Plasmodium falciparum sequence, but also because of the sheer size of the 
molecule. Optimising the codon usage to human codon frequency reduced the AT content to 55% and 
allowed the synthesis of two MSP-1 proteins, namely MSP-1D and MSP-1F based on the MAD20 and K1 
isolates (Pan et al., 1999) (Figure 11). The MSP-1D variant is identical to the MAD20 isolate, except for 
block 2 and 4, which were replaced with the K1 sequence. Block 2 has also been replaced by the sequence 
of the MAD20 isolate in the MSP-1F protein, which largely resembles the K1 isolate.  
A vaccine formulation composed of MSP-1D and the IDRI-GLA-SE adjuvant was developed in the 
research group of Prof. Hermann Bujard and has recently been tested in a phase Ia clinical trial at the 
University Clinic Heidelberg. 
 
 
Figure 11. Synthetic genes of MSP-1D and MSP-1F and their correlation to field isolates MAD20 and K1. The 
codon optimised sequence of MSP-1D is mostly based on the MAD20 isolate from Papa New Guinea. The dimorphic 
block 2 and 4 were replaced with the sequence from the K1 isolate. In reverse, the MSP-1F protein is based on the K1 
isolate from Thailand and only has block 2 replaced with the MAD20 variant. Arrows indicate processing sites for SUB1 
and SUB2 leading to fragments p83, p30, p38, p42  after SUB1 processing and p33 and p19 resulting from p42 cleavage 
by SUB2. The numbering of the sequence blocks is based on (Tanabe et al., 1987). White: conserved region, black: 
MAD20 sequence, grey: K1 sequence. 
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1.8. Aim of this thesis 
A recombinant protein vaccine based on P. falciparum MSP-1 has recently been tested in a phase I clinical 
trial. However, a similar formulation for P. vivax is missing, despite rising numbers of infections and the 
parasite’s proven ability to cause severe disease in humans (Baird, 2007; Anstey et al., 2009; Mueller et 
al., 2009; Lacerda et al., 2012). The core part of this project was the establishment of a protein production 
procedure for recombinant P. vivax MSP-1 (PvMSP-1) that can be used for structural and immunological 
analysis.  
This protein production process should meet the following criteria: (i) The structural conformation of 
PvMSP-1 has to be identical or at least as close as possible to the native confirmation to ensure the 
inclusion of structural epitopes. (ii) The process itself has to be robust and result in a high yield at low 
costs. Most countries affected by P. vivax malaria are newly industrialised countries and although this 
project is the very preliminary stage of vaccine development, cost-efficiency should be considered. (iii) 
Upscaling of the protocol to pharmaceutical manufacturing facilities following GMP guidelines has to be 
possible. 
 
Structural information about MSP-1 is still limited and no crystal structure of the full length protein is 
available. An efficient recombinant protein production protocol can help overcoming limitations due to 
low quantity or quality of a protein and facilitate in depth structural analysis. In this study, structural 
information was gathered by CD spectroscopy of P. vivax MSP-1 and other recombinant MSP-1 proteins 
to control proper folding of the protein. In vitro processing using P. falciparum SUB1 was used to check 
for conserved cleavage sites among MSP-1 proteins from different Plasmodium species. Interactions 
within MSP-1 were identified by combining cross-linking techniques with mass spectrometry, leading to 
an updated model of MSP-1 and the arrangement of its processing subunits. 
 
Immunological experiments proved to be difficult due to the lack of a long-term P. vivax cell culture or 
animal model. In recent years, other laboratories in proximity to P. vivax endemic areas managed to 
establish short-term cultures or have collected blood samples from different cohorts to be used in P. vivax 
research. During the course of this study, preparations were made to collaborate with other research 
facilities to analyse the immunological potential of PvMSP-1. Recombinant proteins corresponding to 
individual PvMSP-1 processing fragments were purified and can be used to analyse fragment-specific 
immune responses. However, cohort studies and in vitro experiments have their limitations compared to 
animal models. As neither P. falciparum nor P. vivax MSP-1 can be analysed in non-humanised mouse 
models, P. berghei MSP-1 was produced in the same manner as P. vivax MSP-1. This protein based on 
the rodent parasite P. berghei ANKA is ready to be used in immunisation studies to analyse the potential 
protective effect of MSP-1 against cerebral malaria. 
 
 
Materials & Methods 
 22 
2. Materials & Methods 
2.1. Materials 
2.1.1. Laboratory equipment 
ABI 7500 Real-Time PCR System Life technologies, CA, USA 
Analytical ultracentrifuge Beckman Coulter, CA, USA 
Autoclave 5075 ELV Systec, Wettenberg 
BioPhotometer Eppendorf, Hamburg 
BioTek Cytation Hybrid multi-mode reader BioTek Instruments, Bad Friedrichshall 
CD spectrometer J-715 Jasco,  Pfungstadt 
Centrifuges 
Heraeus Megafuge 16 
Heraeus Pico 17 
Heraeus Megafuge 1.0R 
 
Thermo Fisher Scientific, MA, USA 
Thermo Fisher Scientific, MA, USA 
Heraeus Instruments, Hanau 
Chromatography system, ÄKTA Purifier 100 GE Healthcare, Little Chalfont, UK 
Dialysis clips WeLoc, Smålandsstenar, Sweden 
Digital timer Carl Roth, Karlsruhe 
Electrophoresis Power Supply EV243 Sigma-Aldrich, MO, USA 
ELISA reader Multiskan FC Thermo Fisher Scientific, MA, USA 
Freezers 
   -20°C 
   -80°C 
 
Liebherr International GmbH, Biberrach an der Riß  
Thermo Fisher Scientific, MA, USA 
Fridges Liebherr International GmbH, Biberrach an der Riß  
Bosch, Stuttgart 
Gel Electrophoresis System EasyPhor Biozym, Hessisch Oldendorf 
GeneTouch Thermal Cycler Biozym, Hessisch Oldendorf 
Heating block VWR International GmbH, Darmstadt 
Ice machine Ziegra Eismaschinen, Isernhagen 
Incubator shaker, Innova 4000/4300 New Brunswick Scientific Co. Inc., Enfield, CT, USA 
Incubators Heraeus Instruments, Hanau 
Magnetic stirrer C-MAG HS7 IKA, Staufen 
Microwave oven Zanussi, Nuremberg 
Nalgene™ Polysulfone Filter Holder Thermo Fisher Scientific, MA, USA 
pH meter InoLab® pH7110 WTW, Weilheim 
Pipetting aid Pipetus® Hirschmann Laborgeräte, Eberstadt 
Precision balances  Kern EG 2200-2NM, Balingen 
Protein Electrophoresis system Mighty Small II  Hoefer, Inc., Holliston, MA, USA 
Roll mixer RS-TR05 Phoenix Instruments, Garbsen 
Single channel pipettes HTL Discovery comfort Kinesis GmbH, Langenfeld 
Sonicator Sonopuls HD 2070 Bandelin electronics, Berlin 
Standard Analog Shaker VWR International GmbH, Darmstadt 
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Vortex VWR International GmbH, Darmstadt 
Water bath Precitherm PFV Labora, Mannheim 
Water purifcation system Purelab Plus ELGA Labwater, Celle 
Wet blot system XCell SureLockTM Thermo Fisher Scientific, MA, USA 
 
2.1.2. Consumables 
Amicon Ultra Centrifugal filters Merck Milipore, Darmstadt 
Cell strainer Thermo Fisher Scientific, MA, USA 
Cuvettes Sarstedt AG & Co., Nümbrecht 
Falcons (15 mL, 50 mL) Greiner Bio-One, Frickenhausen 
Gloves Ansell, Yarra City, Australia 
Immobilon-P PVDF Membrane (0,45 μm) Millipore, Corp. Billerica, MA, USA 
Immobilon-P Transfer Membrane, PVDF Merck Milipore, Darmstadt 
Microcentrifuge tubes 
- 1.5 mL  
- 2 mL 
- 5 mL 
 
Sarstedt AG & Co., Nümbrecht 
Sarstedt AG & Co., Nümbrecht 
Eppendorf, Hamburg 
Parafilm M® Bemis Flexible Packaging, WI, USA 
PCR tubes Sarstedt AG & Co., Nümbrecht 
PD10 Desalting columns GE Healthcare, Little Chalfont, UK 
Pipette tips Diamond (10 µL, 200 µL, 1000 µL)  Gilson International, Bad Camberg 
Plastic pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml) Greiner Bio-One, Frickenhausen 
Polystyrene columns Thermo Fisher Scientific, MA, USA 
Spectra/Por Dialysis Membrane  Spectrum Laboratiries Inc., CA, USA 
Sterile filters, Rotilabo® (0.2μm; 0.45μm) Carl Roth, Karlsruhe 
Whatman Paper GE Healthcare, Little Chalfont, UK 
 
2.1.3. Chemicals and reagents 
2-Mercaptoethanol Sigma-Aldrich, MO, USA 
4-Nitrophenyl phosphate disodium salt hexahydrate tablets Sigma-Aldrich, MO, USA 
Agar Bacteriology grade AppliChem, Darmstadt 
Ammonium persulfate Grüssing, Filsum 
BCIP tablets Sigma-Aldrich, MO, USA 
Bissulfosuccinimidyl suberate Thermo Fisher Scientific, MA, USA 
Brilliant Blue G250 Carl Roth, Karlsruhe 
Calcium chloride dihydrate AppliChem, Darmstadt 
cOmplete Tablets mini EDTA-free EASYpack Roche, Basel, Switzerland 
Diethanolamine Carl Roth, Karlsruhe 
Dipotassium phosphate  Grüssing, Filsum 
Disodium hydrogen phosphate AppliChem, Darmstadt 
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Disuccinimidyl sulfoxide Thermo Fisher Scientific, MA, USA 
DTT Carl Roth, Kalrsruhe 
E64 Sigma-Aldrich, MO, USA 
EDTA 0.1 mol/L J.T.Baker, PA, USA 
EDTA disodium salt dihydate AppliChem, Darmstadt 
Ethanol Zentralbereich Neuenheimer Feld, Heidelberg 
Ethidiumbromide Carl Roth, Karlsruhe 
Glutathione oxidised Carl Roth, Karlsruhe 
Glycerol VWR Chemicals 
Glycine Sigma-Aldrich, MO, USA 
Guanidine hydrochloride Sigma-Aldrich, MO, USA 
Hydrochloric acid Honeywell Fluka, NJ, USA 
Imidazole Merck & Co., Inc, NJ, USA 
IPTG Carl Roth, Karlsruhe 
L-Arginine Carl Roth, Karlsruhe 
L-Glutathione reduced Carl Roth, Karlsruhe 
LB broth Sigma-Aldrich, MO, USA 
Leupeptin Sigma-Aldrich, MO, USA 
Lysozyme Carl Roth, Karlsruhe 
Magnesium chloride Merck, Darmstadt 
Midori Green Biozym, Hessisch Oldendorf 
Ni-NTA agarose Superflow Qiagen, Hilden 
Pefabloc Sigma-Aldrich, MO, USA 
Potassium acetate Sigma-Aldrich, MO, USA 
Potassium chloride AppliChem, Darmstadt 
Potassium dihydrogen phosphate Carl Roth, Karlsruhe 
Powdered milk Carl Roth, Karlsruhe 
Protein Assay Dye Reagent Concentrate  Bio-Rad, CA, USA 
Rotiphorese Gel 30 (30% acrylamide) Carl Roth, Karlsruhe 
SDS Ultra pure Carl Roth, Karlsruhe 
Sodium bicarbonate Sigma-Aldrich, MO, USA 
Sodium carbonate Sigma-Aldrich, MO, USA 
Sodium chloride Sigma-Aldrich, MO, USA 
Sodium dihydrogen phosphate Grüssing, Filsum 
Sodium hydroxide Honeywell Fluka, NJ, USA 
TCA Sigma-Aldrich, MO, USA 
TEMED Carl Roth, Karlsruhe 
Tris Carl Roth, Karlsruhe 
Tween 20 Carl Roth, Karlsruhe 
UltraPureTM Agarose Thermo Fisher Scientific, MA, USA 
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2.1.4. Buffers, media and solutions 
2.1.4.1. Antibiotic stock solutions 
Ampicillin 50 mg/mL in ddH2O 
Kanamycin 25 mg/mL in ddH2O 
Chloramphenicol 34 mg/mL in Ethanol 
 
2.1.4.2. Molecular biology 
TAE buffer (50x) 2 M Tris 
50 mM EDTA, pH 8.0 
1 M acetic acid 
ad 1L with ddH2O 
 
2.1.4.3. Culture and transformation of E. coli  
Transformation buffer 70 mM CaCl2 
35 mM MgCl2 
LB medium 10 g/L tryptone  
5 g/L yeast extract 
5 g/L NaCl 
2.1.4.4. Microbiological methods 
Lysis buffer 20 U/mL DNAseI 
10 µg/mL lysozyme 
1 protease inhibitor tablet (Roche) 
in PBS, pH 7.4 
Solubilisation buffer 6 M guanidine hydrochloride 
2 mM EDTA 
50 mM NaH2PO4 
50 mM DTT 
pH 8.0 
Freezing solution 20% PBS 
80% glycerol 
Solution A 50 mM CaCl 
10 mM potassium acetate, pH 6.2 
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Solution B 50 mM CaCl 
20% glycerol 
10 mM potassium acetate, pH 6.2 
2.1.4.5. Biochemical methods 
Blocking buffer TBST + 1% skim milk powder 
Coomassie staining solution 250 mL ethanol 
50 mL acetic acid 
200 mL ddH2O 
1.25 g coomassie blue 
 
D.1 For Pv83: 
18.9 mM Na2HPO4 
1.1 mM NaH2PO4 
20 mM NaCl 
pH 8.5 
 
For PvMSP-1: 
18.9 mM Na2HPO4 
1.1 mM NaH2PO4 
50 mM NaCl 
pH 8.0 
D.2 18.9 mM Na2HPO4 
1.1 mM NaH2PO4 
300 mM NaCl 
pH 8.0 
D.3 18.9 mM Na2HPO4 
1.1 mM NaH2PO4 
1 M NaCl 
pH 8.0 
Destaining solution 100 mL acetic acid 
200 mL ethanol 96% 
ad 1 L H2O 
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ELISA coating buffer 34 mM Na2CO3 
16 mM NaHCO3 
pH 10.6 
ELISA substrate buffer 99 mM Diethanolamine 
1 mM MgCl2 
pH 9.5 
Lower Tris 1.5 M Tris 
0.4% SDS 
pH 8.8 
Mono Q buffer A 8 M Urea 
20 mM Tris 
4 mM DTT 
pH 8.0 
Mono Q buffer B 8 M Urea 
20 mM Tris 
500 mM NaCl 
4 mM DTT 
pH 8.0 
Mono S buffer A 8 M Urea 
20 mM NaPO4 
4 mM DTT 
pH 6.5 
Mono S buffer B 8 M Urea 
20 mM NaPO4 
500 mM NaCl 
4 mM DTT 
pH 6.5 
Ni-NTA elution buffer 50 mM NaH2PO4 
300 mM NaCl 
250 mM imidazole 
pH 8.0 
Ni-NTA wash buffer 50 mM NaH2PO4 
300 mM NaCl 
20 mM imidazole 
pH 8.0 
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Phosphate buffer 10 mM NaH2PO4 
pH 7 
Quenching buffer (crosslinking) 1 M Tris-HCl 
pH 7.5 
 
Renaturation buffer For Pv42 and PbMSP-1: 
500 mM arginine 
50 mM NaH2PO4 
1 mM EDTA 
10 mM reduced glutathione 
1 mM oxidised glutathione 
pH 8 
 
For Pv83: 
500 mM arginine 
50 mM NaH2PO4 
1 mM EDTA 
5 mM DTT 
pH 8.5 
 
For PvMSP-1: 
1 M arginine 
100 mM Tris 
1 mM EDTA 
10 mM reduced glutathione 
1 mM oxidised glutathione 
pH 8.5 
 
SDS gel (10%) For one separating gel: 
1.85 mL 30% acrylamide 
1.25 mL lower Tris buffer 
2.1 mL H2O 
10 µL TEMED 
50 µL 10% APS   
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For one stacking gel: 
330 µL 30% acrylamide 
625 µL upper Tris buffer 
1.55 mL H2O 
5 µL TEMED 
25 µL 10% APS 
SDS-PAGE running buffer (10x) 10 g SDS 
30,3 g Tris 
144,1 g glycine 
SDS-PAGE sample buffer (4x) 8% SDS 
50% upper Tris buffer 
40% glycine 
0.08% bromphenol blue 
100 mM DTT 
SUB1 buffer 50 mM Tris-HCl 
15 mM CaCl 
pH 7.6 
TBST 150 mM NaCl 
10 mM Tris 
0.05% Tween 20 
pH 8.0  
Transfer buffer 25 mM Tris 
192 mM glycine 
0.01% SDS 
20% EtOH 
Upper Tris 0.5 M Tris 
0.4% SDS 
pH 6.8 
2.1.5. Commercial kits  
High Molecular Weight Calibration Kit GE Healthcare, Little Chafont, UK  
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 
NucleoSpin Plasmid Macherey-Nagel 
Protein Kit (Biuret Method) Merck 
Zero Blunt® TOPO PCR Cloning Kit Thermo Fisher Scientific, MA, USA  
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2.1.6. Enzymes 
BamHI-HF New England Biolabs, MA, USA 
BglII New England Biolabs, MA, USA 
ClaI New England Biolabs, MA, USA 
DNAse I Sigma-Aldrich, MO, USA 
Phusion® High-Fidelity DNA polymerase New England Biolabs, MA, USA 
PstI New England Biolabs, MA, USA 
PvuI-HF New England Biolabs, MA, USA 
SacI-HF New England Biolabs, MA, USA 
SphI-HF New England Biolabs, MA, USA 
T4 ligase New England Biolabs, MA, USA 
 
2.1.7. Markers 
2 log DNA ladder New England Biolabs, MA, USA 
Color Plus Protein Marker New England Biolabs, MA, USA 
Protein ladder 10-250 kDa New England Biolabs, MA, USA 
Unstained protein standard Broad range 10-200 kDa New England Biolabs, MA, USA 
  
2.1.8. Antibiotics 
All antibiotics were prepared as a 1,000x stock solution, sterile filtered and stored at -20°C. 
 
Table 1. Overview of used antibiotics. 
 stock concentration  manufacturer 
Ampicillin 50 mg/mL  Carl Roth, Karlsruhe 
Chloramphenicol 34 mg/mL Carl Roth, Karlsruhe 
Kanamycin 25 mg/mL Carl Roth, Karlsruhe 
 
2.1.9. Antibodies 
Table 2. Antibodies used for Western Blots or ELISA. 
antibody  manufacturer 
Anti-Human IgG-alkaline phosphatase Sigma-Aldrich, MO, USA 
Anti-Mouse IgG-alkaline phosphatase Sigma-Aldrich, MO, USA 
Anti-Penta-His monoclonal antibody Thermo Fisher Scientific, MA, USA 
Anti-Rabbit IgG-alkaline phosphatase Sigma-Aldrich, MO, USA 
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2.1.10. Prepacked chromatography columns for ÄktaTM systems 
Table 3. List of prepacked chromatography columns 
model name manufacturer 
HiLoadTM 26/600 SuperdexTM 200 prep grade GE Healthcare, Little Chalfont, UK 
HiPrep 26/10 Desalting GE Healtchare, Little Chalfont, UK 
Mono Q 10/10 GE Healthcare, Little Chalfont, UK 
Mono S 10/10 GE Healthcare, Little Chalfont, UK 
SuperdexTM 200 Increase 10/300 GL  GE Healthcare, Little Chalfont, UK 
 
2.1.11. Software & Online Tools 
Software  
Adobe Illustrator Adobe Systems Software, Dublin, Republic of Ireland 
Adobe Photoshop Adobe Systems Software, Dublin, Republic of Ireland 
Ape Version 2.0.47 M. Wayne Davis  
Enzyme X 3 Mekentosj, Dordrecht, Netherlands 
Microsoft Excel Microsoft Corporation, Redmond, WA, USA 
Microsoft Word Microsoft Corporation, Redmond, WA, USA 
Prism 6 GraphPad Software Inc., CA, USA 
Serial Cloner Version 2.6.1 Franck Perez, SerialBasics 
Snapgene Viewer GSL Biotech LLC, IL, USA 
 
Online Tools  
Clustal Omega Embl-Ebi, Cambridgeshire, UK 
ExPASy Bioinformatics Resource Portal Swiss Institute of Bioinformatics, Switzerland 
GeneArtTM Synthesis Thermo Fisher Scientific, MA, USA 
Graphical Codon Usage Analyser Dr. Thomas Schödl, University of Regensburg, Germany 
JPred4 University of Dundee, Dundee, UK 
mFold web server The RNA Institute, State University of New York at Albany 
NCBI BLAST National Center for Biotechnology Information, MD, USA 
NEB Tm Calculator New England Biolabs, MA, USA 
NEBioCalculator New England Biolabs, MA, USA 
PoPS Dr. Sarah Boyd, Monash University, Melbourne, Australia 
WatCut University of Waterloo, Canada 
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2.1.12. E.coli strains 
Table 4. E. coli strains used for cloning and protein expression. 
Strain Genotype Source 
Dh5alphaZ1 Δ(lac)U169, end A1, gyrA46, hsdR17(rK-mK+), 
phi80,Δ(lacZ)M15, recA1,relA1, supE44, thi-1, laciq, tetR,SPr 
Dr. Rolf Lutz, ZMBH 
W3110Z1 ATCC Nr. 27325, laciq, tetR, SPr Dr. Rolf Lutz, ZMBH 
 
2.1.13. Amino acid sequences of MSP-1 
Table 5. Uniprot entries for used MSP-1 amino acid sequences. 
Plasmodium strain Uniprot entry 
Berghei ANKA A0A077XCK6 
Falciparum 3D7 Q8I0U8 
Falciparum FCB-1 P04933 
Knowlesi A7BG19 
Vivax Belem Q8I1M7 
Vivax Salvador I A5K724 
 
2.1.14. Primers 
Table 6. Oligonucleotides used in this study. 
Oligonucleotide Sequences 5’ to 3’ TM (°C) 
pMA-Pv42seq CAGTGAGCGGAAGGC 53.2 
Pv30Claup CCATCGATAGCGAGACAGGCACCACC 59.3 
Pv30Pstdown TTCTGCAGTTAGTTGCCGCCCACTCTTCTG 59.0 
Pv3842BamHup CGGGATCCATGAGCGAGGAAAAGCCC 52.1 
Pv38Claup CCATCGATAGCGAGGAAAAGCCCGAG 57.8 
Pv38Pstdown TTCTGCAGTTACTCGCCGGTGGTCACTTGATC 60.3 
Pv42Claup CCATCGATGCCGAGAGCGAGGCCCCTGAAATTC 65.5 
Pv42Pstdown TTCTGCAGTCAGCTGGAGCTGC 51.5 
Pv8330BamHup CGGGATCCATGGAAACCGAGAGCTACAAGCAG 55.7 
Pv8330Cladown CCATCGATTTAGTTGCCGCCCACTCTTCTG 59.0 
Pv83Claup CCATCGATGAAACCGAGAGCTACAAGCAG 55.7 
Pv83Pstdown AACTGCAGTTAGGCGCCTCTCAGAGAC 55.3 
Pv83Seq1 GCGACCTGATCATTGCCG 56.7 
Pv83Seq2 GACATTCGGCGACCTC 53.0 
T1Avr CCTAGGTCTAGGGCGGCGGATTTGTCC 65.7 
Pb8330ClaXaup CCATCGATATCGAAGGTCGTGAAACCATCGAGGTGTACAACGACATCATC 60.5 
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Pb8330Pstdown TTCTGCAGTTAGGACTCGGCTCTGGTGGTG 60.7 
Pb3842BamHup CGGGATCCATGGAGGAAGATATCCCCGCC 54.7 
Pb3842Cladown CCATCGATTTAGCTGCTGGAGGAGCAGAACAC 60.6 
pZE23 N-terminal GATTCAATTGTGAGCGG 50.0 
pZE23 C-terminal CTCAGGAGAGCGTTCACCGAC 59.7 
Pb8330Seq1 GCACCACCGGAACA 46.7 
Pb8330Seq2 CAGAACATCCTGGT 46.1 
PfPv8330 CGGGATCCATGGTGACTCACGAATCGTATCAAGAATTGGTGAAGAAGCTCGAA
GCTTTAGAGGACGCCGTATTGGGCTACGAGCTGTTCCACAAGAAGAA 
60.6 
 
2.1.15. Expression plasmids 
Table 7. Overview of expression plasmids for MSP-1 halves and processing fragments. 
vector resistance marker 
pZE13-HXPv30 Amp 
pZE13-HXPv38 Amp 
pZE13-HxPv42 Amp 
pZE13-HxPv83 Amp 
pZE13-HxPv83/30 Amp 
pZE13-XaPb83/30 Amp 
pZE23-Pb38/42 Kan 
pZE23-PfPv83/30 Kan 
pZE23-Pv38/42 Kan 
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2.2. Methods 
2.2.1. Molecular biological methods 
2.2.1.1. Obtaining the synthetic genes 
All expression plasmids of PvMSP-1 and its processing subunits were cloned using a synthetic gene of PvMSP-1. The 
sequence of this gene was based on the MSP-1 nucleotide sequence found in the Salvador I P. vivax strain (GeneID: 
PVX_099980, PlasmoDB.org). The nucleotide sequence was optimised for two reasons: i) The DNA of Plasmodium 
is usually very AT-rich, which can cause problems during cloning. ii) Optimising the sequence for humans allows the 
usage of the synthetic gene in adenoviruses for vaccination challenges. 
The nucleotide sequence was optimised according to human codon usage via the GeneArt Synthesis online tool. The 
three restriction sites used for cloning (BamHI, ClaI, PstI) were excluded from this procedure to avoid these restriction 
sites in the synthetic gene. For cloning purposes, a start codon (ATG) was added at the 5’ end of the sequence and a 
stop codon plus ClaI restriction site at the 3’ end.  
The synthetic gene was split into three fragments to lower the costs of gene synthesis. For this purpose, the nucleotide 
sequence was scanned for possible silent mutations using the WatCut online tool by the University of Waterloo, 
Canada. The usage of normal restriction sites would have caused a frameshift or insertion of additional amino acids 
into the sequence, while silent mutations do not alter the amino acid sequence. A BglII restriction site was added to 
split the gene into fragment one and two, a SphI restriction site was included to allow ligation of fragment two and 
three. The fragments were later ligated using these restriction sites and PvuI, which cuts once within the GeneArt 
vector, to obtain the full synthetic gene.  
 
Expression plasmids for PbMSP-1 were created following the same principle. The coding sequence of P. berghei 
ANKA MSP-1 (GeneID: PBANKA_0831000, PlasmoDB.org) was optimised according to codon frequency in mice to 
enable insertion into adenoviral vectors for immunisation purposes. The restriction sites used for cloning into pZE 
expression plasmids were excluded from this optimisation. Instead of ordering the synthetic gene in three fragments, 
the entire coding sequence was ordered as one gene and the nucleotide sequence coding for each of the MSP-1 halves 
was amplified via PCR before ligation into the expression plasmids. 
2.2.1.2. Isolation of plasmid DNA from E. coli  
Gene fragments and expression plasmids were amplified in the E. coli strain Dh5alphaZ1 and purified by alkaline 
lysis using the NucleoSpin Plasmid Kit (Macherey-Nagel). Three mL overnight culture were pelleted (11,000 g, 1 min) 
and resuspended in buffer A1 (250 µL). The addition of a buffer containing sodium hydroxide (buffer A2, 250 µL) 
alkalised the mixture and broke the hydrogen bonds between the complementary DNA strands of both genomic and 
plasmid DNA. When a neutralisation buffer was added (buffer A3, 300 µL), the plasmid DNA refolds, while the 
genomic DNA remained unfolded. In the following steps, the refolded plasmid DNA was purified via its interaction 
with a silica membrane. First, the lysate was spun at 11,000 g for 10 minutes to separate cell debris from the solution 
containing the DNA. The supernatant was loaded onto a NucleoSpin Plasmid column (11,000 g, 1 min), which was 
then washed with buffer A4 (600 µL, 11,000 g, 1 min). The silica membrane was dried by another centrifugation step 
(11,000 g, 2 min). Elution was achieved by adding the elution buffer (50 µL) to the column, incubating for 1 minute 
at room temperature and centrifugation (9,000 g, 2 min) after placing the column in a new microcentrifuge tube.  
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2.2.1.3. Agarose gel electrophoresis of DNA 
DNA electrophoresis was frequently used to check purified plasmid DNA and PCR products during the cloning 
procedure. The agarose gels used in this study contained 1% agarose in TAE buffer. Ethidium bromide was added 
directly to the gel before polymerisation to visualise the DNA (3 µL in 50 mL agarose). Gels were run at 80-120 V 
and analysed under UV light. 
2.2.1.4. Purification of DNA from agarose gels 
Restriction digested plasmids and PCR products were separated on a 1% agarose gel running at 80 V. The desired 
bands were cut from the gel and used for purification with the NucleoSpin® Gel and PCR Cleanup Kit. Usually, 1 mL 
of NTI buffer was added to the gel samples before they were heated at 50 °C. When all agarose was melted, the 
solution was transferred into the column and centrifuged at 11,000 g for 30 s.  The silica membrane was washed with 
700 µL NT3 buffer (11,000 g, 30 s), followed by a drying step (11,000 g, 1 min) to remove all buffers completely. 
For the elution, 15-30 µL of elution buffer were pipetted on the silica membrane and incubated for 1 min before 
centrifugation (11,000 g, 1 min).  
2.2.1.5. Determination of nucleic acid concentration  
There are several different techniques to measure DNA concentration. In this study, two methods to determine the 
concentration of DNA were used. At the beginning of the experiments, the DNA concentration was determined by 
running a specific volume of the sample on a 1% agarose gel and comparing it to the 2-log DNA ladder bands or by 
direct measurement with UV/Vis absorbance. The manual of the DNA ladder states the amount of DNA in nanogram 
per band, allowing direct comparison of the bands to estimate the concentration. Later on, the DNA concentration 
was measured using the BioTek Cytation Hybrid multi-mode reader and the Take3 Micro-volume plate. This setup 
allows the measurement of the nucleic acid concentration via UV/Vis absorbance using only 2.5 µL of sample. 
2.2.1.6. Primer Design 
The construction of expression vectors for all individual recombinant proteins required specific primers for each 
plasmid. These primers were designed to contain a homologous region, which binds to the template DNA, a restriction 
site for cloning and a start or stop codon if such a codon was not included in the amplified region of the template. 
The length of the homologous region varied between 20-30 nucleotides and was adjusted to include cytosine or 
guanine at the end to ensure a strong binding to the template. The length was also adjusted depending on the GC 
content and melting temperature of the primer. If the PCR product was intended to be inserted into pZE23 expression 
plasmids, a BamHI restriction site was included in the forward primer and a ClaI restriction site in the reverse primer. 
Ligation into the pZE13 expression plasmids required a ClaI cleavage site in the forward primer and a PstI restriction 
site in the reverse primer. The aimed GC content was 40-60% and the melting temperature was designed to be 
approximately 60°C. The primers were ordered at Thermo Fisher as custom oligos. 
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2.2.1.7. Polymerase chain reaction (PCR) 
The polymerase chain reaction is a standard technique to amplify specific nucleotide sequences for cloning and control 
purposes. The coding sequences for the two halves of MSP-1 and its processing fragments were amplified using 
primers that contained the start and stop codon for protein expression and restriction sites for insertion into pZE13 
or pZE23 expression plasmids. The less error-prone Phusion polymerase was used to lower the risk of amino acid 
substitutions or truncations of the recombinant protein. The exact setup and thermocycling conditions for a 
preparative PCR are given in Table 8and Table 9. All primers were originally prepared as a 100 µM stock and diluted 
1:10 before being used in a PCR.  
 
Table 8. Components of a preparative PCR. 
Component Volume Final concentration 
5x Phusion HF buffer 10 µL 1x 
10 mM dNTPs 1 µL 200 µM 
10 µM forward primer 2.5 µL 0.5 µM 
10 µM reverse primer  2.5 µL 0.5 µM 
Template DNA 1 µL < 250 ng 
Phusion DNA polymerase 0.5 µL  
Water Ad 50 µL  
 
Table 9. PCR protocol using Phusion polymerase. 
Step Temperature Time 
Initial denaturation 98°C 30 s 
30 cycles 98°C 
Tm 
72°C 
5 s 
30 s 
15-30 s per kb 
Final extension 72°C 10 min 
 
The melting temperature used in the PCR was calculated for each primer pair using the Tm calculator provided on 
the website of New England Biolabs. This calculation takes the used polymerase, buffer and primer length and 
concentration into consideration. All used melting temperatures for each primer set are listed in Table 10. 
 
Table 10. Overview of used primer sets and the respective temperature used during PCR. 
Forward primer Reverse primer Calculated melting temperature 
Pb8330ClaXaup Pb8330Cladown 68°C 
Pb3842BamHup Pb3842Cladown 63°C 
Pv8330BamHup Pv8330Cladown 59°C 
Pv3842BamHup Pv3842Cladown 59°C 
Pv38Claup Pv38Pstdown 67°C 
Pv30Claup Pv30Pstdown 59°C
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Pv42Claup Pv42Pstdown 55°C 
Pv83Claup Pv83Pstdown 60°C 
PfPv8330 Pv8330Cladown 68°C 
 
2.2.1.8. Subcloning in TOPO vector 
Some PCR products were subcloned into the commercially available TOPO vector to amplify the PCR product in 
E. coli before moving on to restriction digestion and ligation into the intended expression plasmid. The PCR product 
was mixed with the salt solution included in the Zero Blunt® TOPO PCR Cloning Kit and water before the vector, 
which is fused to the TOPO isomerase, was added (see Table 11). The mixture was incubated at room temperature 
for 5-30 minutes before transformation into the E. coli strain Dh5alphaZ1.  
 
Table 11. Setup for inserting a PCR product into the TOPO vector. 
Reagent Volume 
PCR product 2 µL 
Salt solution 1 µL 
Water Ad 5 µL  
pCRTMII-Blunt-TOPO 1 µL 
Final volume 6 µL 
 
2.2.1.9. DNA restriction 
DNA restriction is a standard technique to insert a coding nucleotide sequence at a specific site in an expression 
plasmid or to check vectors for correct insertion. In this study two types of expression plasmids were used. The pZE13 
plasmid contains an upstream ClaI restriction site immediately downstream of the His-tag, and a PstI cleavage site 
downstream of the insert. For the expression of full-length MSP-1, the pZE23 vectors were usually used, which 
contain a BamHI restriction site at the N-terminal end of the insert and a ClaI cleavage site at the C-terminal end. 
The ligation of these expression plasmids with a PCR product required a double digest, using two enzymes cleaving 
the DNA sequences with sticky ends. If the cleaved DNA was to be used in further cloning steps, a preparative 
digestion was performed. If the DNA restriction was done as a control for correct insertion, a smaller volume of the 
reaction mixture was prepared. See Table 12 for details. 
Table 12. Restriction digest for cloning and control purposes. 
Reagent Standard protocol Preparative digestion 
Cutsmart buffer  1 µL 5 µL 
Restriction enzyme 0.3 µL each 1 µL each 
DNA 100 – 200 ng ~ 1 µg or all of the PCR product 
Water ad 10 µL ad 50 µL 
 
The mixture was incubated at 37 °C for one hour (standard protocol) or 2 hours (preparative digestion). The resulting 
digested DNA was run on a 1% agarose gel for analysis or subsequent purification steps. 
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2.2.1.10. Ligation 
Ligation of restriction digested plasmids and inserts was performed using T4 DNA ligase. The specific volumes of 
DNA were calculated using the NEBioCalculator based on the length of the nucleotide sequence (see formula below). 
Usually, a ratio of 3:1 and 1:1 was used unless otherwise stated. The ligation reaction was performed at 16°C 
overnight. 
 
Table 13. Components of a ligation reaction. 
Component Volume/amount 
10x T4 Ligase buffer 2 µL  
Expression plasmid 50 ng 
Insert Calculated with NEBioCalculator 
T4 DNA ligase 1 µL 
Water ad 20 µL 
 
Formula for calculating ligation mixture:  𝑚𝑎𝑠𝑠	𝑖𝑛𝑠𝑒𝑟𝑡	(𝑔) = 	𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑖𝑛𝑠𝑒𝑟𝑡𝑣𝑒𝑐𝑡𝑜𝑟 	𝑚𝑜𝑙𝑎𝑟	𝑟𝑎𝑡𝑖𝑜	 × 	𝑚𝑎𝑠𝑠	𝑜𝑓	𝑣𝑒𝑐𝑡𝑜𝑟	(𝑔)	× 	𝑟𝑎𝑡𝑖𝑜	𝑜𝑓	𝑖𝑛𝑠𝑒𝑟𝑡	𝑡𝑜	𝑣𝑒𝑐𝑡𝑜𝑟	𝑙𝑒𝑛𝑔𝑡ℎ𝑠 
 
2.2.1.11. Sequencing 
To confirm the correctness of expression plasmids, all cloned vectors were sent to GATC Biotech for sequencing using 
the SUPREMERun protocol. If possible, primers offered by the GATC Biotech company were used, otherwise custom 
primers were sent with the DNA samples. The sample requirements were 30-100 ng/µL for the DNA to be sequenced 
and 10 pmol/µL for the primers. Both DNA and oligonucleotides were sent in a total volume of 20 µL.  
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2.2.2. Microbiological methods 
2.2.2.1. Preparation of chemically competent cells 
Bacterial strains used for cloning and protein expression are usually made either chemically or electrocompentent to 
increase the uptake of foreign DNA. The cells used in this study were washed in two different CaCl2 containing 
buffers to render them chemically competent. First, an overnight culture of the strain was grown in 5 mL LB medium 
with the appropriate antibiotic at 37°C. The next day, 500 mL LB medium with antibiotic were inoculated with 2 mL 
of overnight culture and grown to an OD600 of 0.3-0.4. The culture was cooled on ice for 15 min, centrifuged at 
4,000 rpm for 7 min at 4°C and resuspended in 250 mL cold solution A. After another incubation step on ice for 
30 min, the cell suspension was centrifuged again and resuspended in 25 mL of cold solution B. The bacteria 
suspension was distributed into aliquots of 300-500 µL and immediately frozen. The chemically competent cells were 
stored at -80°C. 
2.2.2.2. Transformation of chemically competent cells 
Cloning of DNA and production of recombinant proteins in E. coli exploits the ability of bacteria to take up foreign 
DNA, called transformation. The E. coli strains used in this study were treated with CaCl2 to enhance their 
competence in DNA uptake. Constructs were amplified using the Dh5alphaZ1 strain, while the W3110Z1 strain was 
used for protein expression.  
Transformation of both strains was performed using the same protocol: 1-5 µL of purified plasmid DNA or ligated 
DNA were pipetted to 100 µL of chemically competent E. coli bacteria and 100 µL of transformation buffer. The 
mixture was incubated on ice for 30 minutes, followed by a heat shock at 42°C in a water bath. After another 
incubation step of 15 minutes on ice, 1 mL of LB medium was added and the bacteria were grown at 37°C, 220 rpm 
for 1 hour. The cells were pelleted at 6,000 g for 3 minutes. Most of the supernatant was removed, leaving 200-300 µL 
in the tube, in which the cell pellet was resuspended. The bacteria were plated on LB agar plates containing the 
appropriate antibiotic.  
2.2.2.3. Preparation of glycerol stocks for cryopreservation 
Once an E. coli strain was successfully transformed with the desired expression plasmid, frozen stocks were created 
as a backup and for the inoculation of overnight pre-cultures. 1 mL of LB medium containing the appropriate 
antibiotic was inoculated with 30 µL overnight culture. The culture was grown at 37°C for 2-3 hours. 675 µL of this 
culture was mixed with 375 µL freezing solution and stored at -80°C.  
2.2.2.4. Testexpression 
A small scale expression test was performed to identify W3110Z1 clones expressing the recombinant protein. An 
overnight culture of 5 mL with the appropriate antibiotic (kanamycin in case of pZE23, ampicillin in case of pZE13 
expression plasmids) was prepared. Next day, 3 mL LB medium with antibiotic were inoculated with 60 µL of 
overnight culture. Once the culture has reached an OD600 of 0.4-0.5 the culture was split into two tubes. One was 
induced with 1 mM IPTG, the other was grown without the addition of IPTG. Both cultures were incubated for 
further 3 hours at 37°C before centrifuging 200 µL of each culture at 6,000 g for 5 minutes at room temperature. 
The pellet was resuspended in 40 µL of SDS sample buffer with DTT. Analysis of protein expression was done via 
SDS-PAGE comparing the noninduced and the induced sample.  
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2.2.2.5. Expression of recombinant proteins 
500 mL LB medium were autoclaved in a 2 L Erlenmeyer flask the day before protein expression was performed. 
Either ampicillin or kanamycin were added to the medium directly before use (see Table 7 for resistance markers of 
used plasmids). The medium was inoculated with 10 mL of an overnight pre-culture of the E.coli strain W3110Z1 
(see Table 4) containing the expression plasmid of the protein of interest. The culture was grown to an OD600 of 0.4-
0.5 at 37°C, 220 rpm. Protein expression was induced by addition of 1 mM IPTG after a sample of the noninduced 
culture was taken. The induced culture was incubated for further 3 hours at 37°C, 220 rpm. A sample of the induced 
culture was taken at the end of the incubation step to compare the noninduced and induced culture via SDS-PAGE. 
The bacterial cells were harvested at 4,000 rpm, 4°C for 25 minutes. The bacterial pellet was transferred into a 50 mL 
falcon and was frozen at -80°C until cell rupture was performed. 
2.2.2.6. Cell rupture 
Some recombinant proteins are expressed in soluble form, others accumulate in aggregates of insoluble proteins, 
known as inclusion bodies. Therefore, the first step of every protein purification protocol is to separate the soluble 
from the insoluble fraction. The bacterial pellets were thawed on ice. 2 mL of lysis buffer per gram of cell pellet were 
used to resuspend the pellet. The suspension was transferred into a beaker and stirred at 4°C for 20 minutes. This 
mixture was poured into a small centrifuge tube and sonicated 6 times on ice for 30 seconds at 50% power. The 
soluble and insoluble parts were separated by centrifugation at 12,000 rpm, 4 °C for 20 minutes. The pellet was 
resuspended a second time with the same amount of lysis buffer, followed by sonication and centrifugation. The 
remaining pellet was resuspended using solubilisation buffer to solubilise inclusion bodies. The suspension was 
sonicated as described before, then stirred for 2 hours at room temperature before centrifugation. The supernatants 
of each step were transferred into a 15 mL Falcon and stored at -80°C or at 4°C until further usage. Additionally, a 
sample for SDS-PAGE was collected after every centrifugation step.  
 
2.2.3. Biochemical methods 
2.2.3.1. Pulse renaturation 
Recombinant proteins of high molecular weight often accumulate in inclusion bodies and have to be refolded to gain 
a functional protein. One method to refold insoluble proteins is the pulse-renaturation technique (Rudolph and Lilie, 
1996). Briefly, solubilised inclusion bodies are quickly diluted by adding them directly to renaturation buffer. This 
step was repeated 8 times every hour. Correctly folded proteins are removed from the reaction and cannot aggregate 
anymore. The aimed final concentration was approximately 1 mg/mL for optimal yield without protein precipitation. 
Refolded proteins were dialysed against the buffer used during following protein enrichment steps. The formula below 
was used to calculate the exact volume of protein added per pulse.  
 𝑣𝑜𝑙𝑢𝑚𝑒	𝑜𝑓	𝑒𝑎𝑐ℎ	𝑝𝑢𝑙𝑠𝑒 =	 0.125	𝑚𝑔/𝑚𝐿		𝑥		𝑣𝑜𝑙𝑢𝑚𝑒	𝑜𝑓	𝑟𝑒𝑛𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛	𝑏𝑢𝑓𝑓𝑒𝑟𝑝𝑟𝑜𝑡𝑒𝑖𝑛	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  
 
The inclusion bodies had to be dialysed against solubilisation buffer without DTT for optimal renaturation and the 
renaturation buffer had to be adjusted for every protein as well, depending on the presence of disulphide bonds in 
the refolded protein and its isoelectric point. The pH value of the renaturation buffer should be at least one pH value 
above the isoelectric point of the protein. Arginine is always included in the buffer, varying from 0.5–1 M and acts 
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as a mild denaturing agent. Cysteines in the protein cause the formation of interchain disulphide bonds, which reduce 
solubility in the absence of reducing agents. The addition of reduced and oxidised glutathione paired with a mildly 
alkaline milieu (pH 8-8.5) allows a thiol-disulphide exchange, which leads to the reduction of these interchain 
disulphide bonds and the formation of correct and energetically favourable disulphide bonds. If there are no cysteines 
in the protein, a redox system does not have to be included in the renaturation buffer. 
 
The renaturation of PvMSP-1 and PbMSP-1 required an estimation of the protein concentration of the two halves. 
The solubilised inclusion bodies of both halves were run on a SDS gel at 3-4 dilutions (1:25, 1:50, 1:100, 1:200) to 
determine the ratio of 83/30 to 38/42. The exact protein concentrations were measured via Biuret assay.  
2.2.3.2. Purification of His-tagged proteins 
Recombinant proteins that are fused to an isolation tag can be purified by affinity chromatography. The MSP-1 
processing fragments were all expressed with an N-terminal 6xHis-tag, which generally allows enrichment using 
Ni-NTA. All steps of this protocol were performed at cool temperatures to limit protein degradation. 1 mL of 50% 
Ni-NTA slurry was used for 4 mL lysate or refolded protein. The appropriate amount of Ni-NTA was equilibrated 
with lysis buffer and 10 mM imidazole. The mixture was gently inverted and centrifuged at 1200 rpm for 3 minutes 
to remove the buffer. Imidazole was added to the lysate to a final concentration of 10 mM to prevent binding of 
contaminants to the Ni-NTA. The mixture was gently shaken on a rotary shaker for 60 minutes at 4°C. Unbound 
proteins were removed by a centrifugation step at 1,200 rpm for 3 minutes at 4°C. A washing step with wash buffer 
(same volume as volume of used lysate) containing 20 mM imidazole was used to remove loosely bound proteins. 
The mixture was rotated for 5-10 minutes before centrifugation. This washing step was repeated once but instead of 
centrifuging the sample, it was poured into an empty column with a frit at the bottom. The Ni-NTA is retained in 
the column, while the buffer flows through. The proteins were eluted in two steps. First, 4 mL of elution buffer 
containing 50 mM imidazole was added, followed by a stronger elution with 250 mM imidazole. The eluted proteins 
were stored at 4°C or -80°C.  
If the Ni-NTA was intended to be reused for the same protein, it was washed with 30 CVs 0.5 M sodium hydroxide 
and 10 CVs 30% ethanol directly after the purification procedure and stored in the fridge. 
2.2.3.3. Ion-exchange chromatography using Q-Sepharose  
The first purification step after refolding recombinant MSP-1 from its two halves is Ion-exchange chromatography, 
using Q-Sepharose as an anion exchanger. Therefore, the renatured protein was dialysed against buffer D.1 to remove 
arginine from the renaturation buffer and charge the protein negatively. The negative charge is a result of the buffer’s 
pH being at least one unit above the isoelectric point of the protein, causing deprotonation of the protein.  
The volume of the Q-sepharose matrix was adjusted to the measured protein concentration in the load. 1 mL of 
Q-sepharose has a binding capacity of 10 mg. The matrix was initially washed with ddH2O, equilibrated with buffer 
D.1 and then activated with 5 CV of buffer D.3 (1 M NaCl). All buffers used for the ÄKTA system were filtered and 
degassed. The column was equilibrated with buffer D.1 again before loading the protein. Loading of the protein was 
performed using a 150 mL loop and a flow rate of 0.8 mL/min. The protein was eluted directly with 75 mM, 100 mM 
and 150 mM NaCl by mixing buffer D.1 and D.2 appropriately. Remaining proteins were eluted from the column 
with buffer D.3. After each purification, the column was cleaned with H2O. If another protein was purified next, the 
column was regenerated with 1 M NaOH for 1 hour before rinsing the column with H2O again. All ÄKTA columns 
were stored in 20% ethanol.  
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2.2.3.4. Size-exclusion chromatography using a Superdex 200 column 
Size-exclusion chromatography (SEC) was used as an additional purification step after ion-exchange 
chromatography. With this technique, individual proteins can be separated based on their hydrodynamic radius. 
Briefly, large molecules will pass the matrix faster than smaller ones and therefore elute earlier. All size-exclusion 
chromatographies were performed in filtered, degassed PBS with a constant flow rate of 1.4 mL/min. The protein 
sample was loaded using a 6 mL sample loop, which was directly filled using a 10 mL syringe. Samples were collected 
when the UV rises on the spectrum. The eluted protein samples were analysed via SDS-PAGE before concentrating 
the desired fractions using Amicon Ultra centrifugal filters. 
2.2.3.5. Purification of inclusion bodies using Mono S/Mono Q 
The production workflow of recombinant Plasmodium vivax MSP-1 was optimised using Mono S and Mono Q 
columns to increase the final yield. In this case, the inclusion bodies were solubilised in 8 M Urea and purified further 
before the MSP-1 heterodimer was assembled.   
The buffer of the solubilised inclusion bodies was exchanged for the Mono Q buffer A or Mono S buffer A for 
PfPv83/30 and Pv38/42, respectively. Approximately 20 mL solubilised inclusion bodies were loaded onto the 
respective column. For PfPv83/30 the Mono Q 10/10 column was used and the Mono S 10/10 column for Pv38/42. 
A gradient elution was performed with Mono Q buffer B or Mono S buffer B, with both containing 500 mM NaCl. 
The purified inclusion bodies of both halves did not require further purification and were used for direct buffer 
exchange into the refolding buffer to reconstitute the MSP-1 heterodimer. 
2.2.3.6. Desalting using prepacked columns 
Desalting of a protein solutions can be necessary when salts, amino acids or additives in the buffer are interfering 
with the next step in protein purification or with a specific assay. Small volumes up to 2.5 mL were desalted using 
commercial PD10 columns, whereas two HiPrep 26/10 columns were connected in series to perform a buffer exchange 
with larger volumes. Both column types are filled with a porous sepharose resin, which allows separation of proteins 
with a larger hydrodynamic radius from those with a smaller one, identical to a size exclusion chromatography but 
with lower resolution. As a result, the proteins are passing through the column faster than any salt or additive in the 
buffer. In this project, this principle was frequently used to remove arginine from lyophilised protein samples or after 
the refolding step.  
Before desalting, the columns were equilibrated with the desired buffer. In case of the PD10 columns, at least 25 mL 
of buffer has to be used to remove any UV-absorbing stabilisers, which are included in the storage solution. Next, 
the protein solution was loaded onto the column, followed by 3.5 mL of buffer to elute the protein in fractions à 
500 µL. The collected fractions were measured at 280 nm using the BioTek reader to determine samples containing 
the highest protein concentrations. The HiPrep26/10 column was used with the ÄKTA system, allowing a more 
precise collection of eluted protein according to the UV spectrum.  
2.2.3.7. Analytic size-exclusion chromatography 
Analytic size-exclusion chromatography was used to analyse the homogeneity of the sample and to determine the 
hydrodynamic radius, which was used in combination with the sedimentation coefficient to calculate the molecular 
weight of the recombinant protein. As proteins vary in size and shape, analytical size-exclusion chromatography 
should not be used to directly determine the molecular weight.  
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The column volume of the used Superdex 200 Increase 10/300 GL column was 24 mL. The dead volume of 8 mL 
was identified using blue dextran. The High Molecular Weight Calibration Kit (see Table 14) was used to gain a 
spectrum matching elution volumes to specific known hydrodynamic radiuses. A flow rate of 0.6 mL/min was used 
for the calibration kit and the analyte. PBS was used as a standard buffer for these experiments. The hydrodynamic 
radius of MSP-1 was determined by matching the elution volume to those of the marker proteins in the calibration 
kit. 
 
Table 14. Proteins included in the High Molecular Weight Calibration Kit and their elution volume using the 
Superdex 200 Increase 10/300 GL. 
Protein Molecular weight Stoke’s radius Elution volume 
Thyroglobulin 669 kDa 85.0  8.8 mL 
Ferritin 440 kDa 61.0 10.1 mL 
Aldolase 158 kDa 48.1 12.4 mL 
Conalbumin 75 kDa NA 13.8 mL 
Ovalbumin 44 kDa 30.5  14.9 mL 
 
2.2.3.8. Protein quantification using Bradford Assay 
The Bradford assay is a commonly used colorimetric test to quantify protein in solution. This method is based on the 
binding of Coomassie brilliant blue G-250 to protein, which causes an absorbance shift in acidic conditions. The 
unbound red dye is stabilised by binding to protein and turns blue. This increase in absorbance is highest at 595 nm 
and is proportional to the protein concentration. High concentrations of commonly used detergents, such as SDS or 
guanidine hydrochloride interfere with this reaction. Thus, if proteins in guanidine hydrochloride buffer have to be 
measured, the Biuret assay is a more accurate alternative. The Bradford assay is linear over a range of 0 µg/mL to 
2 mg/mL. Higher concentrated samples have to be diluted for precise measurements.  
The standard protocol for such a measurement is to dilute the Bradford reagent 1:5 in water. For each protein, four 
different concentrations are prepared containing either 2.5 µL, 5 µL, 10 µL or 20 µL of the original sample in Milli-Q 
water to a total volume of 20 µL. 1 mL of the diluted dye is added to each of these dilutions and incubated for 
20 minutes. The OD595 is measured using a photometer and the diluted dye as blank. The exact protein concentrations 
are calculated using a standard curve created with BSA dilutions. The standard curve used for this assay resulted in 
the following equation for direct determination of protein concentrations: 
 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	 B𝑚𝑔𝑚𝐿C =	 𝑂𝐷FGF0.0583𝑠𝑎𝑚𝑝𝑙𝑒	𝑣𝑜𝑙𝑢𝑚𝑒 	× 	𝑜𝑝𝑡𝑖𝑜𝑛𝑎𝑙	𝑝𝑟𝑒𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
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2.2.3.9. Protein quantification using Biuret Assay 
The Biuret assay is a method of protein quantification, which is commonly used when the protein solution contains 
substances that cause incorrect results in the Bradford assay. This chemical test is based on the formation of 
violet-coloured complexes in the presence of peptide bonds in an alkaline solution. 10, 25 and 50 µL of the protein 
solution were mixed with 1 mL of H2O and precipitated with 0.5 mL 50% TCA, followed by a 10 min centrifugation 
step at 10,000 g. The precipitate is resolved in 2 mL Biuret reagent, which contains NaOH, hydrated copper(II) 
sulphate and potassium sodium tartrate. The nitrogen atoms of the peptide bonds react with the cupric ions from the 
Biuret reagent in alkaline conditions and form a chelate complex, which cause the violet colour of the solution. The 
colour intensity is concentration-dependent and was measured at 546 nm. 
The protein concentration was calculated for each individual measurement using the following equation. For further 
experiments, the average of the three obtained values was considered as the correct protein concentration. 
 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	 B𝑚𝑔𝑚𝐿C = 𝑂𝐷FJK × 	19	 × 2𝑠𝑎𝑚𝑝𝑙𝑒	𝑣𝑜𝑙𝑢𝑚𝑒	 × 5	 
2.2.3.10. Dialysis 
Dialysis was used to transfer a protein into a different buffer to remove a reducing agent, such as DTT. The protein 
solution was transferred into a dialysis membrane with a molecular weight cut-off (MWCO) lower than the molecular 
weight of the protein. The MWCO represents the molecular weight of the protein that is 90% retained in the 
membrane. In case of PvMSP-1 and its subunits, a dialysis membrane with a MWCO of 12-14 kDa was used. The 
dialysis membrane was filled with the protein solution, closed with dialysis clips and placed into new buffer for at 
least 4 hours or overnight. The remaining concentration of the substance that is to be removed can be calculated by 
multiplying the initial concentration with the sample volume, divided by the volume of dialysis buffer.  
 
A faster way to exchange the buffer is dialysis via centrifugation using Amicon Ultra Centrifugal filters. Usually a 
MWCO of 30,000 Da was used. Centrifugation was performed at 4°C, with a maximum speed of 4,000 g when using 
a swinging bucket rotor or 5,000 g when using a fixed angle rotor. The samples were immediately removed from the 
centrifugal filters after centrifugation for optimal protein recovery.  
2.2.3.11. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was frequently used to analyse protein samples during and after protein expression. In general, self-poured 
10% gels were used unless otherwise stated. Samples were prepared using the SDS-PAGE sample buffer (4x) with or 
without DTT and boiled for 10 minutes at 80°C. Usually, 7 µL of protein ladder and 10 µL of protein sample were 
loaded into the pockets of the gel. Initially, the gel was run at 120 V, then at 200 V when the samples had reached 
the separating gel. After the run, the gels were stained with Coomassie for at least 25 minutes, followed by shaking 
in destaining solution.  
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2.2.3.12. Western Blot analysis 
Protein samples were separated on a 10% SDS gel before transferring the proteins onto a PVDF membrane via wet 
transfer (125 mA, 2 hours). The membrane was blocked with 3% milk powder in TBST for 1 hour at room 
temperature. Both the primary and secondary antibody were diluted in TBST with 3% milk powder. Usually, an 
anti-His antibody was used at a dilution of 1:2,000. Secondary antibodies are often more sensitive and can be used 
at a higher dilution of 1:20,000. Incubation with the primary antibody was done overnight in the cold room. Next, 
the membrane was washed three times with TBST for 10 minutes on a shaker. The membrane was incubated with 
the secondary antibody for 1 hour at room temperature. The used secondary antibody was conjugated with alkaline 
phosphatase to allow development of the Western Blot without a machine after adding BCIP as a substrate. One BCIP 
tablet was dissolved in 10 mL H2O to obtain a substrate solution. After washing the membrane as described 
previously, the substrate was added to the membrane. The reaction was observed and stopped before the bands were 
overexposed or at the latest after 30 minutes by washing the membrane with water. 
2.2.3.13. Enzyme-linked immunosorbent assay (ELISA) 
Recombinant proteins were diluted in coating buffer at a final concentration of 100 nM. A 96 well plate was coated 
using 100 µL of the diluted protein, covered with parafilm and incubated at 4°C overnight. The plate was washed 
twice with 200 µL TBST per well before adding 200 µL of blocking buffer. After incubation for 1 hour at room 
temperature, the plate was washed again with 200 µL TBST per well. 100 µL of blocking buffer were added into the 
wells. The sera from Brazilian volunteers were diluted in blocking buffer (1:100 if the plate was coated with PvMSP-1, 
Pv83 or Pv42 and 1:25 if the plate was coated with Pv30 or Pv38). 100 µL of the prediluted sera were added to the 
wells and mixed with the previously added blocking buffer. All sera were measured in duplicates. The sera were 
incubated for 2 hours at room temperature before washing the plate 4 times with TBST. The secondary antibody, 
anti-human IgG coupled to alkaline phosphatase, was diluted 1:30,000 in blocking buffer and 100 µL were added to 
each well followed by incubation for 1 hour at room temperature. The plate was washed twice with TBST and twice 
with substrate buffer. 4-Nitrophenyl phosphate disodium salt hexahydrate tablets were used a substrate. One tablet 
was dissolved in 20 mL of substrate buffer. 100 µL of substrate solution were added to each well and incubated for 
another hour at room temperature in the dark. The reaction was stopped by addition of 0.2 M NaOH (100 µL/well) 
before measuring the absorption at 405 nm.  
2.2.3.14. PfSUB1 cleavage assay 
The following procedure is based on a publication by (Koussis et al., 2009) and was used to verify whether MSP-1 
proteins from other Plasmodium strains can be processed by the subtilisin-like protease 1 (SUB1) from P. falciparum 
in a similar fashion than PfMSP-1.  
The protein to be analysed was dialysed into SUB1 buffer to create optimal conditions for the protease. The used 
enzyme PfSUB1 was kindly provided by Michael J. Blackman. After dialysis, the sample was centrifuged to remove 
any precipitates. The protein concentration was measured and adjusted to 0.25 mg/mL with SUB1 buffer. The total 
volume required for the assay was 350 µL. The protease inhibitors listed in Table 15 were added to make sure that 
the protein will not be cleaved by any other enzymes than PfSUB1. 
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Table 15. Protease inhibitors used in the PfSUB1 cleavage assay. 
Inhibitor concentration function 
E64 10 µM irreversible cysteine protease inhibitor 
Leupeptin 10 µg/mL cysteine and serine protease inhibitor 
Pefabloc 100 µg/mL irreversible serine protease inhibitor 
  
1.5 units of PfSUB1 were added per 100 µL of sample volume. The mixture was divided into 6 aliquots of 50 µL 
each. All samples were incubated at 16 °C, but varying incubation times were applied. Two controls were incubated 
overnight, one without PfSUB1 and one without protease inhibitors. The remaining six samples were incubated for 
0 min, 30 min, 1 hour, 3 hours, 6 hours and overnight. After each time point, the samples were centrifuged for 2 min 
at 10,000 g. The supernatant was transferred into a new Eppendorf tube before stopping the reaction by boiling for 
10 min at 95 °C in 1x SDS sample buffer and 4.5 µL DTT. As a final step, all samples were analysed via SDS-PAGE. 
2.2.3.15. Analytical ultracentrifugation 
A sedimentation velocity run can be used to determine the Svedberg coefficient (s) and homogeneity of a sample. The 
Svedberg constant can then be used in combination with the hydrodynamic radius determined by size exclusion 
chromatography to calculate the molecular weight. 
The protein solution was centrifuged at 14,000 rpm for 10 min to remove most of the aggregates. The sample cell 
was filled with 500 µL PBS (left side) and 450 µL MSP-1 (right side). Multiple scans were performed at 42,000 rpm, 
20°C. The absorbance was measured at 280 nm. 
2.2.3.16. Circular Dichroism (CD) spectroscopy 
Circular dichroism is the difference in absorbance of left- and right-handed circularly polarised light by an optically 
active molecule. 19 out of 20 amino acids are chirally active and as a consequence, all proteins are as well and can 
therefore be studied using this technique. The method used in this study involves thermal degradation, meaning CD 
spectra were recorded at different temperatures (10-85 °C) to study the structure and unfolding temperature of 
MSP-1. 
The analyte was dialysed in 10 mM phosphate buffer, pH 7, to remove any light-absorbing substances, like salts from 
PBS or arginine phosphate, which had been added during the lyophilisation process in case of MSP-1D. The 
spectrometer was flooded with nitrogen 15 min before the measurement. The quartz cuvette was rinsed with H2O, 
then with phosphate buffer. 150 µL of protein solution were filled into the cuvette and the spectrum was recorded 
from 190- 250 nm. A temperature/wavelength scan was performed to follow the unfolding of the protein at 10°C, 
20°C, 30°C, 37°C, 40°C, 42°C, 50 °C, 60°C, 70°C and 85°C. After the measurement, the cuvette was cleaned using 
10% SDS and concentrated nitric acid.  
Individual CD spectra at each temperature were created with Prism. The melting temperature was determined by 
fitting the data using Prism.  
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2.2.3.17. Cross-linking 
Cross-linking combined with mass spectrometry analysis was used to identify interactions within MSP-1. Initial 
experiments were performed using the bissulfosuccinimidyl suberate (BS3) cross-linker, whereas follow-up 
experiments used disuccinimidyl sulfoxide (DSSO) to facilitate data analysis. The optimal cross-linker concentration 
was titrated using MSP-1D, which contains 211 lysine residues. Due to the high arginine content in the lyophilised 
preparation, 150 µg MSP-1D was first dissolved in 150 µL Milli-Q water, followed by a buffer exchange into PBS to 
remove arginine before adding the cross-linker. Stock solutions of each cross-linker were freshly prepared according 
to the manufacturer’s instructions. The suitable amount of cross-linker was determined by analysing cross-linked 
MSP-1D via SDS-PAGE. In the end, a 2.5-fold molar excess of BS3 and a 20-fold molar excess of DSSO were used to 
cross-link MSP-1 proteins. When MSP-1 preparations were already in PBS, a buffer exchange was not necessary for 
the cross-linking reaction. MSP-1 was incubated with BS3 for 30 minutes and with DSSO for 60 minutes at room 
temperature before stopping the reaction with quenching buffer. The trypsin digest and mass spectrometry analysis 
was performed by the mass spectrometry core facilities in the ZMBH and DKFZ.  
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3. Results 
3.1. Design of synthetic MSP-1 gene 
The prerequisite for structural and immunological analysis of P. vivax MSP-1 was obtaining sufficient 
amounts of protein. Direct extraction from the Plasmodium parasite was not an option, as the process 
itself only resulted in low yields using P. falciparum, but even more so as P. vivax is difficult to culture 
long-term (Thomson-Luque et al., 2017). Alternatively, recombinant protein production techniques can 
be used to acquire the needed material. In case of Plasmodium MSP-1, E. coli was chosen as a suitable 
expression system as native MSP-1 is not glycosylated (Berhe et al., 2000), which would otherwise have 
required a mammalian expression system. Protein expression in E. coli usually offers a high protein yield 
combined with low costs and is less labour-intensive than other expression systems.  
 
P. vivax research so far focused mostly on the Salvador I strain, resulting in its genome being sequenced 
(Carlton, Adams, et al., 2008) and the establishment of functional assays using this strain, such as a 
sporozoite challenge in Aotus monkeys for testing antimalarial vaccines (Jordán-Villegas et al., 2005). 
The MSP-1 sequence of the Salvador I strain was also chosen for the development of a protein production 
process in this project (see Uniprot entry A5K724). The sequence identity with the second most common 
strain P. vivax Belem is 84% (NCBI protein blast, (Altschul et al., 1997)) which leads to the assumption 
that a recombinant protein based on the Salvador I sequence might resemble the Belem variant very 
closely. 
 
The AT-rich nucleotide sequences found in Plasmodium have often caused severe difficulties for cloning 
techniques (Gardner et al., 2002). To overcome this and also enable the use of P. vivax msp-1 in 
adenoviral vectors as a vaccine, the msp-1 gene was codon optimised for humans before ordering it as a 
synthetic gene. While the AT-content in Plasmodium vivax msp-1 is considerably lower than in 
P. falciparum, the AT content could still be reduced from 57% to 46%. A further modification of the 
native msp-1 gene was the removal of the N-terminal signal peptide and the C-terminal 
glycosylphosphatidylinositol (GPI) anchor signal sequence as both were not required for the planned 
analysis. 
 
Since the production process for the P. falciparum protein was already established, the approach for the 
P. vivax variant was based on the corresponding patent by Prof. Hermann Bujard (Bujard et al., 2011) 
and uses the pZE expression plasmids previously developed by (Lutz and Bujard, 1997). It is important 
to note that this approach uses known processing sites to split the MSP-1 protein into two halves, which 
are expressed separately and refolded together at a later step to reconstitute the full length protein. The 
base for this method is the processing of MSP-1 by SUB1 and the corresponding cleavage sites can be seen 
in Figure 12. While sequences matching the SUB1 cleavage motif can be found in all MSP-1 variants, the 
exact positions are sometimes shifted, resulting in processing fragments of varying length. However, in 
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this thesis, the nomenclature of the P. falciparum processing fragments is used for all MSP-1 subunits and 
the Plasmodium species is indicated (e.g. Pv83 for the P. vivax 83 fragment) to simplify the comparison 
of structural and immunological data. 
 
 
Figure 12. Alignment of PfSUB1 cleavage sites within the MSP-1 sequence from various Plasmodium strains. 
Predictions were made using the PfSUB1 model and the PoPs online tool. Cleavage sites resulting in four processing 
fragments were found in all analysed sequences (highlighted in yellow). However, the exact positions of these cleavage 
sites are shifted by up to ~230 amino acids (e.g. p38/42 cleavage sites), resulting in processing fragments of varying 
length. All protein sequences were originally retrieved from the Uniprot database. 
 
3.2. Construction of pZE expression plasmids 
3.2.1. Cloning of expression plasmids for His-tagged PvMSP-1 subunits 
The focus of this project is on the structural analysis of the full length protein. Nevertheless, some 
experiments ask for recombinant proteins representing only a specific MSP-1 processing fragment. The 
protein sequence of P. vivax MSP-1 was analysed using the P. falciparum SUB1 model (de Monerri et al., 
2011) and the Prediction of Protease specificity (PoPs) online tool (Boyd et al., 2005).The nucleotide 
sequences corresponding to predicted processing fragments were amplified by PCR using primers 
containing ClaI and PstI restriction sites. All obtained PCR products were subcloned into TOPO vectors 
for easier amplification and digestion with restriction enzymes before ligation with the pZE13 expression 
plasmid backbone. These plasmids contain an ampicillin resistance marker, an N-terminal 6xHis-tag to 
facilitate protein purification and use the IPTG inducible PA1lacO-1 promoter (Lutz and Bujard, 1997) 
(Figure 13).  
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Figure 13. Map of a pZE13 plasmid used for expression of P. vivax MSP-1 processing fragments. The shown map 
represents the plasmid used for the P. vivax 83 processing fragment and comprises an N-terminal 6xHis-tag and an 
ampicillin resistance marker. The insert was ligated with the plasmid backbone following a classical cloning strategy 
using the restriction enzymes ClaI and PstI. PA1lacO-1: LacR-regulated promoter (Lutz and Bujard, 1997).  
 
3.2.2. Expression plasmids for full length PvMSP-1 
Obtaining the full length P. vivax MSP-1 protein was of paramount importance for this study. This 
protein was not only to be used for acquiring structural data, but could also be used as an antimalarial 
vaccine targeting the so-far neglected P. vivax parasite. A requirement for this was the production of a 
recombinant protein without any purification tags, such as a His-tag, as demanded by regulatory agencies. 
This process is based on the previously patented protein production protocol (Bujard et al., 2011) and 
includes splitting the MSP-1 protein sequence into an N-terminal and C-terminal half according to the 
predicted cleavage site between the Pv30 and Pv38 fragment. The resulting sequences are named Pv83/30 
and Pv38/42. Both were amplified via PCR using primers with BamHI and ClaI restriction sites to 
facilitate insertion into pZE23 expression plasmids. The pZE23 plasmids differ from their pZE13 
counterparts by including a kanamycin resistance marker instead of the ampicillin one and the lack of a 
purification tag (Figure 14).  
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Figure 14. Map of a pZE23 expression plasmid used for expression of the two halves of the MSP-1 heterodimer. 
The plasmid carries a kanamycin resistance cassette and can be used for expression of recombinant proteins without a 
purification tag. The gene of interest is inserted using the restriction sites BamHI and ClaI. Shown here is the expression 
plasmid for Pv38/42. The expression plasmid for Pv83/30 is identical except for the coding sequence (blue) which is 
replaced accordingly.  
The pZE23 expression plasmid achieved high expression levels of Pv38/42, but Pv83/30 showed similar 
difficulties as previously observed with P. falciparum 83/30 in our laboratory. In case of P. falciparum 
83/30, these issues were overcome by targeted mutation of the N-terminal nucleotide sequence to remove 
hairpin structures obstructing ribosomal binding. Analysis of the Pv83/30 mRNA structure revealed some 
hairpin formation which could be overcome by addition of an N-terminal tag or replacement with an 
already optimised nucleotide sequence. The first 22 amino acids of P. falciparum and P. vivax MSP-1 
have a sequence identity of 65% (Figure 15), leading to the assumption that a replacement would not 
alter the P. vivax protein in a severe manner. Consequently, the pZE23-PfPv83/30 plasmid was generated 
by replacement of 66 nucleotides at the N-terminal end.   
 
 
Figure 15. Alignment of the N-terminal amino acid sequence of the 83/30 half of P. falciparum and P. vivax. The 
depicted sequences correspond to the first 22 amino acids of MSP-1 in both Plasmodium species. The signal peptide 
found in the wildtype protein has been excluded. The direct alignment only reveals 6 direct matches, but the overall 
sequence identity was determined as 65% by protein blast.  
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3.2.3. Design of P. berghei msp-1 expression plasmids 
The goal of this project was to obtain precise structural information of MSP-1. In addition to the P. vivax 
variant, MSP-1 from other parasite species such as P. knowlesi and P. falciparum were available for 
analysis. However, including a Plasmodium species that solely infects rodents but is well studied could 
improve our understanding of consistent features within MSP-1. For this purpose, a protein production 
protocol was developed for P. berghei ANKA MSP-1 (PbMSP-1) based on the previously mentioned 
method. Here, the full length protein was considered sufficient and expression of PbMSP-1 processing 
fragments was omitted.  
P. berghei MSP-1 was analysed with the PoPs tool (Figure 12) and  coding sequences corresponding to 
the N-terminal Pb83/30 and C-terminal Pb38/42 halves were cloned into pZE23 expression plasmids as 
described in 3.2.2. As a future use of PbMSP-1 in vaccination experiments using mice was not excluded, 
the synthetic gene was codon optimised for mice to allow usage in adenoviral vectors. This optimisation 
also decreased the AT content of the original nucleotide sequence from 75% to 45%.  
Initially, the coding sequences of the PbMSP-1 halves were cloned into pZE23 expression plasmids as 
described for the P. vivax protein in 3.2.2. Whereas good expression levels were observed for Pb38/42, 
the pZE23-Pb83/30 expression plasmid showed similar issues as previously noticed for P. vivax and 
P. falciparum 83/30. As the P. berghei MSP-1 was never intended to be used as a human vaccine, the 
addition of an N-terminal His-tag was chosen as the easiest solution to overcome these expression 
difficulties. Therefore, a pZE13 expression plasmid was used for Pb83/30 instead and a factor Xa cleavage 
site was added via PCR to allow His-tag removal if required (Figure 16). 
 
 
Figure 16. Plasmid map of pZE13-HXPb83/30. As expression of the N-terminal half of P. berghei MSP-1 without a 
purification tag was difficult but still desirable, a pZE13 plasmid was designed which includes a removable His-tag. The 
plasmid’s backbone is identical to previously shown pZE13 plasmids, except for the addition of a factor Xa cleavage 
site between the His-tag and the protein sequence.  
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3.3. Expression of recombinant P. vivax and P. berghei MSP-1  
All previously described pZE plasmids were cloned using the E. coli strain Dh5alphaZ1, but as this strain 
has a low growth rate, the faster growing W3110Z1 strain was more suitable for large scale production 
of recombinant MSP-1. All constructs and halves of MSP-1 were expressed separately in standard LB 
medium at 37°C. Expression of His-tagged processing fragments using pZE13 plasmids was successfully 
induced after addition of IPTG (Figure 17) followed by further incubation at 37°C for 3 hours.  
 
Figure 17. IPTG-inducible expression of P. vivax processing fragments using pZE13 plasmids. All four processing 
fragments were successfully produced after addition of IPTG. First lane: before IPTG addition, second lane: after IPTG 
addition. The calculated molecular weights are 83 kDa (Pv83), 31 kDa (Pv30), 41 kDa (Pv38) and 44 kDa (Pv42). P. vivax 
MSP-1 has a high proline content, which influences the running behaviour on SDS gels. This is especially noticeable 
with the Pv30 protein, which runs close to the 60 kDa marker instead of the 30 kDa one.  
Obtaining full length MSP-1 revealed to be more difficult than the processing fragments. The 83/30 
proteins from P. vivax and P. berghei could not be expressed using the standard pZE23 plasmid (data not 
shown). While both could be produced after addition of an N-terminal His-tag, this approach was not 
ideal as proteins with an isolation tag cannot be used as a vaccine for humans. Fortunately, replacement 
of the first 22 amino acids as described in 3.2.2 was sufficient to achieve protein expression in W3110Z1 
under standard conditions (Figure 18). 
 
The PvMSP-1 processing fragments Pv30, Pv38 and the PfPv83/30 half migrate on an SDS gel as if they 
have a higher molecular weight. This is probably due to the very high proline content of P. vivax MSP-1. 
As prolines cause kinks and structural rigidity, the electrophoretic mobility of proteins with a high proline 
content is decreased (Hames, 1998). This altered migration behaviour is most noticeable for Pv30, a 
protein consisting of 287 amino acids out of which 23 are prolines (8%). The full length P. vivax MSP-1 
is made of 1,751 amino acids, including 73 prolines (4.2%). 
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Figure 18. The two halves of PvMSP-1 were expressed in W3110Z1 after addition of IPTG. Expression of the 
N-terminal half was achieved by replacing the first 22 amino acids with the already optimised nucleotide sequence for 
P. falciparum 83/30, resulting in the PfPv83/30 protein. Pv38/42 shows good expression without modification of the 
original nucleotide sequence. The expected molecular weights are 110 kDa (PfPv83/30) and 82 kDa (Pv38/42). 
P. berghei msp-1 showed a similar protein expression behaviour as observed for its P. vivax and 
P. falciparum counterparts. The Pb38/42 half can be produced without an isolation tag or any 
modification using a pZE23 expression plasmid. However, the Pb83/30 half showed no expression using 
the same plasmid backbone. Inserting the coding sequence into a pZE13 plasmid enabled production of 
Pb83/30 with an N-terminal His-tag. Nevertheless, in comparison to the noninduced sample, the induced 
one contains additional bands at approximately 140 kDa, 120 kDa and 90 kDa. This leads to the 
conclusion that although Pb83/30 can be expressed, it is prone to degradation or premature termination 
of translation, which severely limits the obtainable yield.  
 
 
Figure 19. Recombinant protein expression of the two halves of P. berghei MSP-1. Pb83/30 was expressed with 
an N-terminal 6xHis-tag and a factor Xa cleavage site using a pZE13 expression plasmid. The C-terminal half Pb38/42 
was produced using a pZE23 expression plasmid with no additional tags. Molecular weights were predicted as 118 kDa 
for Pb83/30 and 79 kDa for Pb38/42. The induced sample of the Pb38/42 culture contains one strong band. But Pb83/30 
seems to be prone to degradation as the induced sample contains additional bands at ~140 kDa, 120 kDa and 90 kDa 
compared to the noninduced sample. 
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3.4. Purification of P. vivax MSP-1 
The primary goal of this project was to elucidate the structure of MSP-1 using recombinant proteins. Since 
our research group’s focus has been on vaccine development, a secondary goal of this project was to 
develop a production protocol for P. vivax MSP-1, which not only supplies enough material for 
biophysical and biochemical experiments, but can also be applied for large scale production meeting Good 
manufacturing practice (GMP) standards.  
The initial approach for P. vivax MSP-1 purification was based on the patented purification protocol for 
P. falciparum MSP-1 (Bujard et al., 2011). Due to the fact that these two proteins don’t share the same 
amino acid sequence, they also behave slightly differently during protein purification. Therefore, 
adjustments were made to certain buffer compositions to improve the final yield of P. vivax MSP-1. 
Technical progress since the development of the patented procedure also allowed the replacement of a 
few cost- and labour-intensive steps with faster or more efficient alternatives.  
 
High expression levels of heterologous proteins in E. coli often lead to accumulation of insoluble proteins 
in form of inclusion bodies (Singh et al., 2015). These cytoplasmic aggregates can be easily separated from 
soluble proteins but need to be refolded in vitro to obtain recombinant proteins similar or ideally identical 
to the native form. The PvMSP-1 processing fragments Pv30 and Pv38 were expressed as soluble proteins 
whereas Pv83, Pv42 and the two halves of the full length protein were insoluble. What is usually an 
obstacle in protein production was utilised to reconstitute the complete MSP-1 heterodimer using two 
denatured halves and refolding them together. The scheme in Figure 20 shows the basic steps of the 
PvMSP-1 production protocol, which are explained in more detail in the following chapters. Briefly, the 
full length protein is refolded and purified using a combination of ion exchange and size exclusion 
chromatography. 
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Figure 20. Scheme of recombinant MSP-1 production including reconstitution of the heterodimer and protein 
enrichment using ion exchange and size exclusion chromatography. The two halves of MSP-1 are expressed 
separately and inclusion bodies are solubilised in buffer containing guanidine hydrochloride and DTT. The heterodimer 
is renatured in refolding buffer containing arginine and a glutathione redox system. Refolded MSP-1 is purified by ion-
exchange chromatography using Q-sepharose after arginine has been removed by dialysis. Remaining contaminants or 
degradation products are separated from MSP-1 during size exclusion chromatography (SEC). The protein solution can 
be concentrated between purification procedures and/or after the final chromatography step. 
After protein expression, bacterial cells were lysed by sonication using pre-cooled PBS-based lysis buffer 
containing lysozyme, DNase and protease inhibitors. Lysozyme breaks down bacterial cell walls in 
addition to the mechanical sonication and DNase is used to degrade nucleic acids to improve the viscosity 
of the lysate and prevent interference with chromatography steps. Handling of bacterial lysates was 
performed at low temperatures and in presence of protease inhibitors to decrease protein degradation by 
endogenous proteases from E. coli. Soluble and insoluble proteins were separated by centrifugation before 
a second round of sonication was performed. Finally, inclusion bodies were solubilised in 6 M guanidine 
hydrochloride buffer with dithiothreitol (DTT), pH 8. Usage of the chaotropic agent guanidine 
hydrochloride in high concentrations results in the complete denaturation of proteins, while DTT reduces 
disulphide bonds. The goal of this step is to unfold the insoluble proteins entirely as a base for renaturation 
without any folding intermediates found in inclusion bodies. A control of this cell rupture and preparation 
of solubilised inclusion bodies can be seen in Figure 21 for the two halves of P. vivax MSP-1. Both proteins 
are insoluble and can only be seen in the inclusion bodies samples.  
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Figure 21. Both halves of P. vivax MSP-1 accumulate in inclusion bodies. Bacterial cells were lysed twice by 
sonication to separate soluble from insoluble proteins. In the last step, insoluble proteins that had aggregated in inclusion 
bodies were solubilised. The inclusion bodies samples sometimes show an altered running behaviour on SDS gels due 
to the high content of guanidine hydrochloride. Samples were analysed in dilutions of 1:10 and 1:20 or 1:20 and 1:50. 
The molecular weights are 110 kDa (PfPv83/30) and 82 kDa (Pv38/42). SN: supernatant containing soluble proteins, IB: 
inclusion bodies.  
Renaturation of recombinant MSP-1 follows the so-called “pulse renaturation” principle (Rudolph and 
Lilie, 1996). Here, denatured proteins are rapidly diluted in a buffer containing arginine and reduced and 
oxidised glutathione to reduce precipitation of folding intermediates. Arginine is a commonly used 
additive in renaturation procedures as it prevents aggregation of proteins. Glutathione functions as a 
redox system, which improves the formation of disulphide bonds during the refolding process. MSP-1 
contains 6 disulphide bonds at the C-terminal end, so using a redox system was crucial for renaturing the 
full length protein.  
The solubilised inclusion bodies were dialysed against 6 M guanidine hydrochloride, 2 mM EDTA, 
50 mM NaPO4, pH 3 to remove DTT as this reducing agent would disturb the refolding process. The low 
pH prevents formation of intra- and intermolecular disulphide bonds before the denatured proteins are 
added to refolding buffer. The exact composition of the refolding buffer was adjusted for each 
recombinant protein. P. vivax MSP-1 required 1 M arginine, 100 mM Tris, 1 mM EDTA, 10 mM reduced 
glutathione, 1 mM oxidised glutathione and a pH of 8.5 for optimal refolding. As MSP-1 is reconstituted 
from two separate proteins during the renaturation step, the protein concentration of the two halves was 
determined beforehand by Biuret assay and SDS-PAGE to make sure both halves are added in equal 
amounts. The name “pulse renaturation” refers to the way the solubilised inclusion bodies are added to 
the renaturation buffer. In contrast to refolding by dialysis, a low amount of denatured proteins is added 
to a 100-fold higher volume of renaturation buffer every hour. In case of MSP-1, a maximum protein 
concentration of 0.12 mg/mL per step was used. After 10 steps, a concentration of 1.2 mg/mL was reached 
and the mixture was incubated for 12-16 hours at 4°C before precipitated protein was removed by 
centrifugation. 
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3.4.1. PvMSP-1 enrichment using ion-exchange and size exclusion chromatography 
The previously refolded P. vivax MSP-1 was purified using a combination of the most commonly used 
purification methods for tagless proteins, ion exchange and size exclusion chromatography. The principle 
of ion exchange chromatography is that ionisable groups bind to a stationary phase and can be eluted by 
displacement with mobile ions of higher affinity. Thus, the success of this purification technique relies on 
the pH of the used buffer as the net charge of a protein is influenced by the pH value. A pH too close to 
the isoelectric point of a protein results in no net charge and only weak binding to the matrix. Apart from 
choosing the wrong pH for ion exchange chromatography, the presence of arginine can also hinder 
binding to the column. Accordingly, P. vivax MSP-1 was dialysed against buffer D.1 (18.9 mM Na2HPO4, 
1.1 mM NaH2PO4, 50 mM NaCl, pH 8) to remove arginine and to change the net charge of the protein. 
The isoelectric point of P. vivax MSP-1 is 6.6, so it should be negatively charged in a buffer of pH 8 and 
be able to bind to an anion exchanger. Q-sepharose is a strong anion exchanger consisting of cross-linked 
6% agarose beads, with quaternary ammonium (Q) strong anion exchange groups. The matrix was 
packed into a column suitable for the ÄKTA system and activated with buffer D.3, which contains 
1 M NaCl before equilibrating it with buffer D.1. PvMSP-1 was loaded onto the column with a 150 mL 
sample loop and a flow rate of 0.5 mL/min. Initially, a gradient elution was performed to find the optimal 
settings for washing and elution. This method uses the ÄKTA system to gradually mix buffer D.1 and 
buffer D.2, which contains 300 mM NaCl, to slowly increase the salt concentration. But as PvMSP-1 
already eluted at 75 mM NaCl, a washing step was omitted and a stepwise elution protocol was 
established using 75, 100 and 150 mM NaCl. Fractions were collected as soon as the UV spectrum rose 
significantly and samples were analysed on SDS gel. Buffer D.3 was used as a final washing step to remove 
all remaining proteins from the column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 59 
 
  
Figure 22. P. vivax MSP-1 purification using Q-sepharose. A) The OD280 and conductivity spectrum was recorded 
during the purification. The numbers above individual peaks correspond to the samples in the SDS gel. B) SDS gel of all 
collected fractions to identify fractions containing PvMSP-1. Refolded PvMSP-1 in D.1 buffer containing 50 mM NaCl 
bound to the anion exchanger. However, it was already eluting at 75 mM NaCl (sample 1), suggesting only weak binding. 
Removal of excess halves, which had not refolded to form the full length MSP-1 was achieved in two steps. First, excess 
Pv8330 did not bind to the column and can be seen in the flow through sample. Second, Pv3842 bound strongly to the 
column and eluted at higher concentrations than the reconstituted heterodimer. The two halves can be seen as two 
separate bands on SDS gels. The Pv8330 half runs at ~140 kDa and the Pv3842 half at ~90 kDa. L: load, FT: flow 
through, numbers refer to fractions collected.  
Full length MSP-1 separates again into the two halves on denaturing SDS-gels resulting in two bands at 
~140 kDa and ~90 kDa. Suitable elutions were pooled and dialysed against PBS for storage or a second 
purification step if needed.  
 
Here, the elution with 75 mM NaCl was the purest and required no further purification. However, some 
preparations contained more contaminants of lower molecular weight that can be eliminated by size 
exclusion chromatography. This technique is also known as gel filtration and is one of the mildest and 
simplest chromatography methods. Proteins are separated based on their hydrodynamic radius with larger 
molecules eluting earlier than smaller molecules. There is no binding to the matrix and buffer composition 
does not directly affect the resolution. To simplify the process, all size exclusion chromatographies were 
performed with PBS because it is a versatile buffer for storage and following experiments. PvMSP-1 
preparations from ion exchange purifications were concentrated to a maximum concentration of 
1.2 mg/mL. The solution was filled into a 6 mL sample loop via direct injection and loaded onto a 
Superdex 200 prep grade 26/600 column, which consists of a composite matrix of cross-linked agarose 
and dextran. The run was performed with a constant flow rate of 1.4 mL/min. Fractions were collected 
according to the OD280 curve and analysed on SDS gel.  
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Figure 23. Size exclusion chromatography can separate PvMSP-1 from smaller contaminants. A) Selected elutions 
from the Q-sepharose purification were concentrated and loaded onto a Superdex 200 prep grade column. The UV 
spectrum shows two significant peaks. Numbers indicate collected fractions, which were further analysed by 
SDS-PAGE. B) Analysis on SDS gel reveals that PvMSP-1 can be found in the first peak, whereas other proteins of lower 
molecular weight can be found in the second peak. The Pv8330 half runs at ~140 kDa and the Pv3842 half at ~90 kDa. 
L: load. 
Typically, the UV spectrum showed two peaks (Figure 23). According to SDS-PAGE, PvMSP-1 elutes in 
the first peak and other contaminating proteins elute in the second peak. While this technique works well 
to separate PvMSP-1 from considerably smaller degradation products or E. coli proteins, contaminating 
proteins too close to the hydrodynamic radius of PvMSP-1 cannot be removed. Protein samples are diluted 
during size exclusion chromatography, so PvMSP-1 containing fractions were concentrated to ~1 mg/mL 
before storage. 
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3.4.2. Optimised PvMSP-1 purification using Mono S/Mono Q columns 
The previously described purification procedure for P. vivax MSP-1 was suitable to produce protein 
preparations of high purity. However, the rather laborious protocol resulted in a low yield, making it 
both time- and material-consuming to obtain sufficient material for further analysis. The cause of the low 
yield is not found in low expression levels, but in protein precipitation during refolding and dialysis, and 
also during the chromatography steps as PvMSP-1 cannot be completely recovered from the column. 
Therefore, a new approach was developed together with our collaboration partners Dr. Dirk Görlich and 
Jürgen Schünemann from the Max Plank Institute in Göttingen.  
 
Figure 24. New approach for the production of P. vivax MSP-1. Inclusion bodies of both halves are solubilised in 8 
M urea and further purified using Mono Q or Mono S columns. These matrixes are strong ion exchangers and offer a 
high resolution. After these individual purification steps, both halves are mixed in a ratio of 1:1. The buffer is replaced 
with refolding buffer using a desalting column and the solution is incubated overnight at 4°C. Next, the buffer is 
exchanged with PBS or any other buffer required for downstream experiments. Size exclusion chromatography (SEC) 
can be performed if further purification is required.  
The major difference between the new and the previously established protocol is the purification of 
solubilised inclusion bodies individually before reconstitution of the heterodimer (Figure 24). The goal is 
to use highly pure inclusion bodies so no degradation products or contaminants are present during the 
refolding step. Apart from creating optimal conditions for refolding, this technique would also make any 
further purification steps after the renaturation obsolete. This is especially beneficial as most protein had 
precipitated or bound too strongly to the chromatography resins after the refolding step in the previous 
protocol. 
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In comparison to the Q-sepharose fast flow matrix, Mono Q and Mono S columns provide an even higher 
resolution. These chromatography resins consist of monodispersed 10 µm porous beads substituted with 
quaternary ammonium (Q) or methyl sulfonate (S) groups, making them strong ion exchangers.  
As a preparation for purification, inclusion bodies were solubilised in 8 M urea instead of 6 M guanidine 
hydrochloride as the latter would behave similarly to NaCl at the pH values used for ion exchange 
chromatography, resulting in reduced binding or premature elution of the protein.  
 
 
Figure 25. Preparation of inclusion bodies for purification with Mono Q or Mono S columns. In contrast to previous 
cell rupture procedures, inclusion bodies were solubilised using 8 M urea instead of guanidine hydrochloride. PfPv83/30 
runs at ~130 kDa, while Pv38/42 can be seen at ~90 kDa. - : noninduced culture, + : induced culture, BL: bacterial lysate, 
SN: supernatant containing soluble proteins, IB: inclusion bodies. 
As before, the halves PfPv83/30 and Pv38/42 were expressed separately and accumulated in inclusion 
bodies. These were solubilised in 8 M urea, 20 mM NaPO4, 5 mM DTT, pH 6.5 for cation exchange 
chromatography using a Mono S column (Figure 25). Although both proteins display similar expression 
levels, the solubilised inclusion bodies of Pv83/30 contained less contaminating proteins than those of 
Pv38/42. The isoelectric points of the individual halves are 6.5 and 6.6 for Pv38/42 and PfPv83/30, 
respectively. In theory, both proteins should have only minimal to no net charge at the used standard 
buffer for cation exchange with Mono S. Nevertheless, Pv38/42 did bind to the column while the main 
contaminant did not. 25 mL of solubilised inclusion bodies were loaded onto a Mono S 10/10 column 
and eluted using a salt gradient with a final concentration of 500 mM NaCl. Fractions were collected 
automatically using the ÄKTA system at increased OD280 values. Similar to observations with PvMSP-1 
and the Q-sepharose resin, Pv38/42 starts to elute at >60 mM NaCl. Fortunately, most contaminating 
proteins did not bind to the Mono S column and the majority of those that had bound eluted at a higher 
salt concentration (Figure 26).  
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Figure 26. Purification of Pv38/42 inclusion bodies using a Mono S column. A) OD280 and conductivity spectrum 
as recorded during the chromatography run. 25 mL of inclusion bodies were loaded. Bound proteins were eluted using 
a NaCl gradient with a maximum concentration of 500 mM (%B). Significant peaks were observed after 138 and 144 mL 
matching samples 4-8 on the SDS gel. B) The SDS gel of collected fractions shows a good separation of Pv38/42 (runs 
at ~90 kDa) and other proteins. The main contaminant did not bind to the Mono S column and is found in the flow 
through. The majority of Pv38/42 elutes in samples 3-8. L: load, FT: flow through, numbers refer to collected fractions. 
Cation exchange using Mono S did not work for PfPv83/30 as the protein did not bind the column. An 
alternative with identical resolution is using the anion exchanger Mono Q. The inclusion bodies were 
solubilised in 8 M urea, 20 mM Tris, 5 mM DTT, pH 8. As the pH value is higher than PfPv83/30’s 
isoelectric point, the protein’s net charge should be negative allowing it to bind to the positively charged 
Mono Q resin. 25 mL of solubilised inclusion bodies were loaded onto a Mono Q 10/10 column followed 
by a gradient elution with 500 mM NaCl. All proteins bound to the resin, so the binding alone had no 
purification effect as seen for Pv38/42. However, the majority of contaminating proteins eluted at different 
salt concentrations than PfPv83/30 and could be removed by strict fractionization (Figure 27). Fractions 
4–9 contain mostly PfPv83/30 and were used to reconstitute the P. vivax MSP-1 heterodimer.  
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Figure 27. Purification of PfPv83/30 inclusion bodies using Mono Q columns. A) OD280 and conductivity were 
monitored during the purification. 25 mL of Inclusion bodies in 8 M urea buffer were loaded onto the column. Elution 
was performed using a salt gradient from 0 – 500 mM NaCl. The OD280 spectrum shows several peaks, with the highest 
peak occurring at 72 mL. B) Collected fractions were analysed on an SDS gel. Almost all proteins bound to the column. 
According to the OD280 curve and the SDS gel analysis, PfPv83/30 started to elute from the column at a NaCl 
concentration of 170 mM (see peak at 72 mL and samples 4-8 on the SDS gel). Most contaminating proteins eluted at 
other salt concentrations. PfPv83/30 runs at 120 kDa. L: load, FT: flow through, numbers refer to collected fractions.   
Both purified inclusion bodies had a concentration of 1.2 mg/mL and were mixed in a ratio of 1:1 for 
refolding. At this point, the mixed halves added up to a volume of 94 mL, which exceeded the capacity 
of the pulse renaturation technique. Instead, the urea buffer was directly replaced with renaturation buffer 
(1 M arginine, 100 mM Tris, 1 mM EDTA, 10 mM GSH and 1 mM GSSG, pH 8.5) using a HiPrep 26/10 
desalting column. The solution had a concentration of 1.1 mg/mL and was incubated at 4°C overnight. 
Precipitated protein was removed via centrifugation.  
 
A sample of the refolded protein was analysed on a Superdex 200 Increase 10/300 column to check if 
both halves elute together. This column is generally used for analytical purposes and provides a much 
higher resolution than the preparative size exclusion columns. 300 µL of refolded protein were injected 
onto the column and analysed at a constant flow rate. Samples were collected in 500 µL fractions and 
loaded on an SDS-gel. As seen in Figure 28, both halves elute together despite minor differences in their 
individual concentrations. This suggests that not all halves have bound to their respective partner, but the 
main proportion is expected to have reconstituted the P. vivax MSP-1 heterodimer. 
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Figure 28. Test for PvMSP-1 heterodimer formation using size exclusion chromatography. The refolded protein 
was analysed using a Superdex 200 Increase 10/300 column which offers a high resolution. The aim of this test is to see 
if the two halves elute together or separately. If the two halves had not bound to each other, PfPv83/30 would elute 
earlier than Pv38/42. While there are some minor differences when comparing the PfPv83/30 and Pv38/42 bands within 
each sample, no half completely runs without the other, suggesting that the main proportion is present as a heterodimer. 
L: load.  
This PvMSP-1 preparation was lyophilised in arginine buffer without any additional buffer exchange 
because tests with lower arginine concentrations or PBS did not show an improved lyophilisation 
behaviour. Following experiments also require different buffers, so storing the protein in the refolding 
buffer offers a higher flexibility. The lyophilised PvMSP-1 is stored at -80°C. 
 
The final yield using this protocol was 90 mg of P. vivax MSP-1 from 31 g E. coli wet paste. This 
corresponds to 2.9 mg per 1 g wet paste. In comparison, the previous approach yielded only 1 mg from 
6 g wet paste, thus 0.17 mg per 1 g wet paste. The wet paste values always refer to the sum of both halves 
and not each half individually. 
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3.4.3. Purification of P. vivax MSP-1 processing subunits  
Purification tags offer the possibility of a quick and simple protein enrichment using affinity 
chromatography. All P. vivax MSP-1 processing fragments were expressed with an N-terminal 6x His-tag, 
which is one of the most common isolation tags and allows binding of recombinant proteins to 
nickel-charged affinity resins. Pv30 and Pv38 were produced as soluble proteins whereas Pv83 and Pv42 
were insoluble and required refolding prior to purification (Figure 29).  
 
 
 
Figure 29. Recombinant proteins representing the P. vivax processing fragments differ in their solubility. Cells 
were lysed by sonication and soluble and insoluble proteins were separated by centrifugation. Insoluble proteins were 
solubilised in 6 M guanidine hydrochloride. The proteins of lower molecular weight, namely Pv30 and Pv38 are found as 
soluble and insoluble proteins (see B and C), whereas those of higher molecular weight, Pv42 and Pv83, accumulate in 
inclusion bodies (A and D). Pv83 runs at 83 kDa, Pv30 at ~55 kDa, Pv38 at 50 kDa and Pv42 at 41 kDa. Discrepancies 
to the theoretical molecular weight can be explained by high proline content found in these proteins. SN: supernatant 
containing soluble proteins, IB: inclusion bodies.Pv30 and Pv38 were purified from the first supernatant 
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obtained after cell rupture. A total concentration of 10 mM imidazole was added to the bacterial lysate 
to reduce unspecific binding to the affinity resin Ni-NTA. This material consists of nitrilotriacetic acid 
(NTA), a chelating ligand, coupled to a cross-linked agarose resin and is precharged with nickel. 1 mL of 
Ni-NTA slurry was used per 4 mL of bacterial lysate using the batch method. This means that Ni-NTA 
and lysate or buffers were incubated in a falcon tube and separated by centrifugation instead of using a 
column for gravity flow chromatography. The Ni-NTA and lysate were mixed in a 50 mL falcon tube, 
rolled for one hour to bind the recombinant protein to the matrix followed by centrifugation. 
Unspecifically bound proteins were removed using a wash buffer (50 mM NaH2PO4, 300 mM NaCl, pH 
8) with 20 mM imidazole. Finally, His-tagged proteins were eluted with 250 mM imidazole. All steps 
were performed at 4°C to limit protein degradation.  
Pv42 could be purified following the same protocol after the protein had been refolded using the “pulse 
renaturation” technique as described previously. Samples of each purification step were analysed on SDS 
gel (Figure 30). Attempts to purify Pv42 in a denatured state using Ni-NTA were unsuccessful ( data not 
shown).  
 
 
Figure 30. Three out of four P. vivax MSP-1 processing fragments were successfully purified using Ni-NTA. The 
6xHis-tagged PvMSP-1 fragments Pv30, Pv38 and Pv42 bound to the Ni-NTA matrix. However, most of Pv30 remained 
in the flow through, which can be caused by exceeding the binding capacity of the applied Ni-NTA. This effect can also 
be observed for Pv38 and Pv42 to a lesser extent. The Ni-NTA matrix was washed with 20 mM imidazole to remove 
loosely bound proteins and impurities. Finally, proteins of interest were eluted using 250 mM imidazole. L: load, FT: flow 
through, W: wash, E: eluate. 
Three out of four PvMSP-1 processing fragments were successfully enriched using Ni-NTA. However, not 
all of the His-tagged proteins bound to the Ni-NTA and were found in the flow through, as can be seen 
in Figure 30. This could mean that the binding capacity of Ni-NTA was exceeded in these cases. 
Unfortunately, some contaminants remain in all eluates, likely caused by histidine rich proteins found in 
the lysate or degradation products. The high concentration of imidazole was removed by dialysis against 
PBS before storing the proteins at -80°C.  
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The final yield of Pv30 and Pv38 was 0.75 mg per gram E. coli wet paste, although this value could be 
increased by additional purification using the second bacterial lysate and refolding the protein that 
accumulated in inclusion bodies as these proteins were expressed as both soluble and insoluble proteins 
(Figure 29). The final yield of Pv42 after refolding the protein and enrichment by Ni-NTA affinity 
chromatography was 1.6 mg per gram E. coli wet paste.  
 
Pv83 was the most challenging to purify of all P. vivax MSP-1 processing fragments. Similar to Pv42, 
Pv83 was refolded in 500 mM arginine buffer with 5 mM DTT, pH 8.5 following the previously described 
“pulse renaturation” technique. The majority of the refolded protein did not bind to the Ni-NTA and 
was found in the flow through despite using generous amounts of Ni-NTA resin. The remaining Pv83 
that had bound to the Ni-NTA eluted equally during the washing and elution steps and the final eluate 
was also highly contaminated with other proteins of lower molecular weight (data not shown). While 
these contaminants could represent degradation products, obtaining a purer preparation was desirable. 
Additional washing steps with lauroyl-sarcosine did not lead to the improved purity, so instead of 
pursuing the affinity chromatography approach further, a combination of ion exchange chromatography 
and size exclusion chromatography was tested for Pv83.  
 
Refolded Pv83 was dialysed against buffer D.1 (18.9 mM Na2HPO4, 1.1 mM NaH2PO4, 20 mM NaCl, 
pH 8.5) to prepare the protein for ion exchange chromatography. The isoelectric point of Pv83 is 7.3, 
meaning a buffer with a pH of 8.5 changes the net charge of Pv83 so that it becomes negatively charged 
and can bind to a positively charged medium, such as Q-sepharose. A low amount of NaCl was added to 
the buffer to reduce unspecific binding to the matrix. Ion Exchange chromatography was performed using 
the ÄKTA system with a low flow rate (0.5 mL/min) during the binding step. Afterwards, the column was 
washed with different NaCl concentrations starting from 50 mM to 1 M NaCl to elute the protein. 
Fractions were collected when a peak was observed in the UV spectrum and samples were analysed on 
SDS gel (Figure 31). Most of Pv83 bound to the column. The little amount visible in the flow through can 
be further reduced by using more Q-sepharose matrix. The elution with 75 mM NaCl is the purest elution 
in this purification. Using 100–150 mM NaCl elutes remaining Pv83 but also other proteins of 40 kDa 
from the column. The 1 M NaCl elution removes most still bound proteins from the column but is usually 
not included in further purification steps as it contains a lot of contaminants besides Pv83.  
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Figure 31. Purification of Pv83 using ion exchange chromatography. A) Purification of refolded Pv83 using 
Q-sepharose and a NaCl gradient to elute the protein from the matrix. Conductivity and OD280 were monitored during 
the purification. Numbers indicate collected fractions, which were analysed via SDS-PAGE. B) Most of the protein bound 
to the Q-sepharose resin as only a little amount can be seen in the flow through sample. But not all of Pv83 could be 
eluted with up to 150 mM NaCl (samples 1-4) as the final wash with 1 M NaCl (sample 5) still contains Pv83. The 
calculated molecular weight for Pv83 is 83 kDa. L: load, FT: flow through.  
The collected fractions ranging from 75 mM to 150 mM NaCl were pooled and purified further using 
size exclusion chromatography with a Superdex 200 column (total column volume = 320 mL). The protein 
solution was concentrated from 0.1 mg/mL to 1.3 mg/mL in a total volume of 6 mL before directly 
injecting it into a sample loop. The entire run was performed using PBS and a flow rate of 1.4 mL/min. 
The 280 nm UV spectrum was observed during the run and revealed two separate peaks. Fractions were 
collected and analysed on SDS gel (Figure 32). The first sample contains the majority of Pv83 and only 
low amounts of contaminants. Most of the proteins around 40 kDa were found in the second sample and 
were therefore successfully separated from Pv83. The final yield of Pv83 was 3 mg per gram E. coli wet 
paste. 
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Figure 32. Additional size exclusion chromatography to purify Pv83. Left: Selected elutions from the ion exchange 
chromatography were pooled, concentrated and loaded onto a Superdex 200 column to remove contaminants of lower 
molecular weight by size exclusion. PBS was used for equilibration and performing the run. The 280 nm spectrum shows 
one small peak at around 100 mL and two bigger peaks ranging from 150 to 250 mL. Samples were collected from the 
two main peaks and analysed on SDS gel. Right: SDS-PAGE analysis of collected samples. Pv83 was mainly found in 
the first sample, referring to the first peak in the UV spectrum. The main portion of contaminants was in the second 
sample and could be separated from Pv83. L: load. 
 
 
3.5. Purification of P. berghei MSP-1 
The production of recombinant P. berghei MSP-1 followed the same protocol as previously explained for 
P. vivax MSP-1 (Figure 20) and includes protein refolding prior to ion exchange and size exclusion 
chromatography purifications. After expression of both halves, bacterial cultures were lysed as described 
in 3.4. Again, both halves accumulated in inclusion bodies and were solubilised in 6 M guanidine 
hydrochloride buffer with dithiothreitol (DTT), pH 8 (Figure 33). The theoretical molecular weights of 
the two halves are 118 kDa (Pb83/30) and 79 kDa (Pb38/42). However, Pb83/30 contains 75 prolines, 
which corresponds to 7% of its amino acids and influences its running behaviour on SDS gels in a similar 
manner as observed for P. vivax MSP-1 proteins.   
Another difficulty of Pb83/30 purification becomes visible in SDS gels as seen in Figure 19 and Figure 33 
as the samples do not only contain one strong band matching the calculated molecular weight or a protein 
of apparent higher molecular weight. Instead, the induced samples contain bands running at 
approximately 140 kDa, 120 kDa and 90 kDa, which were not found in the noninduced sample. This 
observation leads to the assumption that Pb83/30 is prone to degradation during protein expression.  
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Figure 33. Cell rupture of cultures expressing Pb83/30 and Pb38/42. E. coli cells were lysed by sonication. Soluble 
and insoluble proteins were separated by centrifugation. After washing the bacterial pellet twice with lysis buffer, 
inclusion bodies were solubilised using 6 M guanidine hydrochloride. Both halves of P. berghei MSP-1 are expressed 
as insoluble proteins. The inclusion bodies of Pb83/30 contain various bands that could represent full length Pb83/30 or 
degradation products. Samples were analysed in dilutions of 1:10 and 1:20 or 1:20 and 1:50. The molecular weights 
were calculated as 118 kDa (Pb83/30) and 79 kDa (Pb38/42). SN: supernatant containing soluble proteins, IB: inclusion 
bodies. 
The protein concentrations were estimated by SDS-PAGE and Biuret assay measurements, but the high 
amount of degraded protein makes it difficult to determine the exact concentration of intact Pb83/30 for 
refolding with Pb38/42. Refolding of P. berghei MSP-1 was performed using 500 mM arginine, 50 mM 
NaH2PO4, 1 mM EDTA, 10 mM reduced glutathione and 1 mM oxidised glutathione, pH 8 according to 
the pulse renaturation method. A ratio of 1:1 was aimed for to reconstitute the PbMSP-1 heterodimer, 
however due to the high amount of presumable degradation products, it cannot be excluded that some 
Pb38/42 bound to partially degraded Pb83/30. Attempts to enrich intact Pb83/30 using the N-terminal 
His-tag and Ni-NTA did not improve the purity of the inclusion bodies as the contaminants had bound 
to the column as well and eluted at the same imidazole concentration. 
  
The theoretical isoelectric point of PbMSP-1 is 5.8, so dialysis against D.1 buffer (18.9 mM Na2HPO4, 
1.1 mM NaH2PO4, 50 mM NaCl, pH 8) should result in a negatively charged protein that can be purified 
using anion exchange chromatography. Additionally, arginine from the refolding step was removed and 
precipitated protein was separated from the soluble protein by centrifugation.  
The protein was loaded onto a self-packed Q-sepharose ÄKTA column using a 150 mL sample loop and 
a flow rate of 0.8 mL/min. Elution was performed using a salt gradient from 50 mM to 300 mM NaCl to 
achieve a better separation compared to stepwise elution. PbMSP-1 started to elute at a salt concentration 
of 160 mM. Finally, the column was washed with 1 M NaCl to remove any remaining bound proteins. 
Samples were analysed on SDS-gel to select suitable PbMSP-1 containing fractions for further purification 
(Figure 34). The load contains the four bands described as Pb83/30 and presumable degradation products 
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thereof. However, eluted fractions seem to contain only one band matching Pb83/30 at approximately 
140 kDa and the Pb38/42 band at 80 kDa in addition to contaminating proteins visible at lower molecular 
weights (labelled 3-8 in Figure 34).  
 
 
 
 
Figure 34. P. berghei MSP-1 purification using Q-sepharose. A) This spectrum including OD280 and conductivity 
was recorded during ion exchange chromatography and reveals one pronounced peak after increasing the NaCl 
concentration. B) According to the SDS gel, all of the loaded protein bound to the Q-sepharose resin. Increasing the 
NaCl concentration gradually eluted PbMSP-1 with contaminating proteins of approximately 50 kDa. However, only one 
band matching Pb83/30 can be found in the eluates, meaning other degradation products still present in the load were 
eliminated. Pb83/30 runs at 140 kDa, Pb3842 at 80 kDa. L: load, FT: flow through, numbers refer to collected fractions.  
Fractions 3 to 8 were pooled and concentrated to 1.4 mg/mL for size exclusion chromatography. The aim 
of this purification step was the removal of contaminating proteins found at approximately 50 kDa and 
below (Figure 34). 6 mL of concentrated protein solution were loaded on a Superdex 200 prep grade 
26/600 column and separated at a constant flow rate of 2 mL/min using PBS. Fractions were collected 
according to the OD280 curve and analysed by SDS-PAGE. The OD280 curve shows three distinct peaks. 
The first peak does not seem to contain the protein of interest in meaningful concentrations as no bands 
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are visible in the SDS-gel. Bands matching the expectations for recombinant P. berghei MSP-1 are seen in 
sample 5 and 6 and also very weakly in sample 4. The highest peak in the UV spectrum was observed 
later and probably contains proteins of smaller hydrodynamic radius and lower molecular weight.  
Fractions 5 and 6 were concentrated to a final concentration of ~1 mg/mL and stored at -80°C. The final 
yield of P. berghei MSP-1 using this approach was 0.25 mg per gram E. coli wet paste.  
 
 
Figure 35. Gel filtration of P. berghei MSP-1 could remove most contaminants. Eluates from the ion exchange 
chromatography were concentrated and loaded onto the size exclusion column. A) The OD280 spectrum includes three 
peaks. Several samples were collected mostly for the first two peaks and one for the third peak. B) Bands matching the 
expected molecular weight for P. berghei MSP-1 were found in sample 5 and 6. The load contains numerous 
contaminants, which are apparently not present in the fractions 5 and 6. However, running a protein solution over a size 
exclusion column always results in dilution of the sample. Hence, proteins whose bands were already weak in the load 
sample might simply not be detected by Coomassie staining in later samples anymore. The main contaminating proteins 
around 35-50 kDa were prominent in the load sample and cannot be seen in sample 5 and 6, suggesting successful 
removal of these contaminants. Pb83/30 runs at 140 kDa and Pb38/42 at 80 kDa. L: load, numbers refer to collected 
fractions. 
 
3.6. Generation of a MSP-1 hybrid protein 
Generally, refolding the MSP-1 heterodimer using two halves works well when both halves are derived 
from the same Plasmodium species. As halves of P. falciparum MSP-1 and P. vivax MSP-1 were available, 
it was also interesting to attempt creating a hybrid MSP-1 protein. If successful, this could be used as a 
vaccine to induce immune reactions against both parasite species instead of using both full length MSP-1 
proteins in one formulation.  
Here, solubilised inclusion bodies of PfPv83/30 and Pf38/42 were refolded in the same buffer as used for 
P. vivax MSP-1 (1 M arginine, 100 mM Tris, 1 mM EDTA, 10 mM reduced glutathione, 1 mM oxidised 
glutathione, pH 8.5) using the pulse renaturation method. After removing precipitated protein, the buffer 
was replaced with D.1 buffer using a HiPrep 26/10 desalting column. The benefit of this column is the 
efficient and controllable removal of arginine, which would hinder binding to the Q-sepharose resin.  
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50 mL of protein solution were purified using the anion exchange approach and a salt gradient for elution 
with stringent fractionation (Figure 36). The spectrum shows various peaks, suggesting a heterogenous 
mixture. Analysis via SDS-PAGE showed that first, PfPv83/30 elutes alone (samples 1-4). Then, there are 
samples which contain both halves, but also an excess of Pf38/42 (samples 6-9). The latter were pooled 
and further purified by gel filtration.  
 
 
 
 
 
Figure 36. Potential hybrid protein enrichment via ion exchange chromatography. A) The hybrid protein was 
refolded using the PfPv83/30 half and the Pf38/42 half, followed by ion exchange chromatography. The OD280 curve 
rose as soon as the salt concentration was increased, suggesting only weak binding of some proteins. B) The SDS gel 
shows that a portion of PfPv83/30 elutes early, whereas Pf38/42 and the presumable hybrid complex elute at higher 
NaCl concentrations. In general, all collected samples contain only few contaminating proteins of lower molecular 
weight. Numbers refer to collected fractions. 
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In theory, size exclusion chromatography should be able to separate a potential hybrid complex and the 
excess of both individual halves if the resolution of the used column is high enough. The pooled fractions 
were concentrated to a volume of 5 mL and loaded onto a Superdex 200 prep grade 26/600 column using 
a constant flow rate of 3 mL/min and PBS as running buffer. The absorbance spectrum shows one peak 
with a plateau after 200 mL (Figure 37). The SDS-PAGE analysis revealed two bands representing both 
halves in equal intensity in the first 3 samples. Afterwards, more Pf38/42 is present than PfPv83/30 
(sample 4). The retention volume of the first samples matches the values for other full length MSP-1 
complexes, suggesting that these fractions might indeed contain a hybrid complex. However, additional 
analytical techniques were required to test proper complex formation.  
 
      
Figure 37. Separation of excess halves and the potential hybrid protein using SEC. A) After ion exchange 
chromatography, suitable fractions were pooled and purified by gel filtration to remove protein halves that are not part 
of the MSP-1 heterodimer. The OD280 curve reveals one peak with a plateau after 200 mL. B) The first fraction collected 
during the purification was not analysed on SDS gel due to its low protein concentration. Samples 2 and 3, which eluted 
at a similar retention volume than other MSP-1 complexes, seem to contain PfPv83/30 and Pf38/42 in the same amount. 
Sample 5-7 include a more pronounced band of Pf38/42 and were therefore discarded. L: load, numbers refer to 
collected fractions. 
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3.7. Structural characterisation of Plasmodium MSP-1 
3.7.1. Molecular weight determination of PvMSP-1 
A combination of sedimentation velocity and size exclusion chromatography was used to determine if the 
previously described production protocol resulted in correctly assembled MSP-1 heterodimers. 
This method of molecular weight calculation requires two experimentally determined variables, the 
Svedberg coefficient and the hydrodynamic radius. The Svedberg coefficient can be determined using a 
sedimentation velocity run, an analytical ultracentrifugation method that measures the rate at which 
molecules move in response to centrifugal force. This sedimentation rate is influenced by the mass and 
shape of the molecules. The hydrodynamic radius can be defined by analytical size exclusion using 
proteins with a known hydrodynamic radius as reference.  
Sedimentation velocity runs were performed in collaboration with Dr. Norbert Mücke, from the DKFZ 
in Heidelberg. This process was first established using MSP-1D (GMP material). Lyophilised MSP-1D 
was solved in PBS and additionally dialysed against PBS to remove arginine that had been added during 
the lyophilisation process. The analytical ultracentrifugation was performed at 20°C and 42,000 rpm. 
Comparison of OD230 measurements at 3,000 rpm and 42,000 rpm revealed the presence of protein 
aggregates in the sample (Figure 38).  
 
 
Figure 38. Analytical ultracentrifugation run of MSP-1D. The OD230 signal dropped when the speed was increased 
from 3,000 rpm to 42,000 rpm, suggesting that the sample contains protein aggregates. R is referring to the radius from 
the centre of the rotor to the sample; A in OD is the measured absorbance at 230 nm.  
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Figure 39. Plot of the sedimentation coefficient distribution against the Svedberg coefficient for MSP-1D. Three 
species were detected, with the species 1 (purple) representing 10% of the sample, species 3 (turquoise) represents 
~15% of the sample and the main proportion being species 2 (green). The determined Svedberg coefficient is 7.36 S.  
The plot of the measured sedimentation coefficient distribution against the Svedberg coefficient includes 
three species (Figure 39). One of them has a Svedberg coefficient of 3.9 S and contributes to 10% of the 
protein sample (purple peak). Another 15% of the sample contain another species with a sedimentation 
coefficient of 11.10 (turquoise). The green peak represents the majority of the sample. This species has a 
Svedberg coefficient of 7.36 S and was subsequently used for the molecular weight calculation. 
The same method was used to analyse P. vivax MSP-1 (Figure 40). However, the sample was less 
homogenous as the previously analysed GMP material of MSP-1D. As with the previous run, three species 
were identified, but the proportions of species one was remarkably increased. Still, the majority of the 
PvMSP-1 sample consisted of a species with a Svedberg coefficient similar to the one of MSP-1D. As no 
major contaminations were found in the SDS gel, species one could represent free MSP-1 halves that have 
not bound their respective partner to form the heterodimer. 
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Figure 40. Analytical ultracentrifugation of P. vivax MSP-1 revealed a less homogenous protein preparation. Three 
species were detected, with the first and second contributing to the majority of the protein sample, whereas species 3 
was detected in lower amounts. The main peak (green) corresponds to a similar Svedberg coefficient than determined 
for MSP-1D while species one could represent unbound MSP-1 halves.  
The hydrodynamic radius was determined using an analytical Superdex 200 Increase 10/300 GL column 
and the High Molecular Weight Calibration Kit. The proteins of the kit and the MSP-1 samples were 
analysed in separate runs. The recorded spectra were overlaid with the Unicorn software (Figure 41). 
Comparison of the peaks from the calibration kit run and the recombinant proteins led to a hydrodynamic 
radius of 6.17 nm and 6.5 nm for MSP-1D and PvMSP-1, respectively. 
 
 
Figure 41. Analytical size exclusion chromatography to determine the hydrodynamic radius of MSP-1 by 
comparison with the High Molecular Weight calibration kit. The proteins were analysed in PBS and an analytical 
Superdex 200 Increase column. MSP-1D is represented by the green curve, P. vivax MSP-1 by the blue one. The 
hydrodynamic radiuses of MSP-1D and PvMSP-1 were determined as 6.17 nm and 6.5 nm, respectively. 
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The molecular weight calculation based on the Svedberg coefficient and hydrodynamic radius are shown 
in Figure 42. The hydrodynamic radius is first used to define the diffusion constant (D) before calculating 
the molecular weight by dividing the Svedberg coefficient by the diffusion constant. In case of MSP-1D, 
the result was 189 kDa, which matches the values found in literature. For PvMSP-1, the same Svedberg 
coefficient was used as no significant difference was observed in the sedimentation velocity run for species 
2 and no purer sample was available for additional measurements at the time. The result was a molecular 
weight of 199 kDa, which also corresponds to published values. 
 
 
Figure 42. Molecular weight calculation based on hydrodynamic radius and Svedberg coefficient. The diffusion 
coefficient (D) is calculated by inserting the hydrodynamic radius as determined by analytical size exclusion 
chromatography into the Stokes-Einstein relation. The Svedberg coefficient is divided by the diffusion constant to 
calculate the molecular weight. This technique led to a molecular weight of 189 kDa for MSP-1D and 199 kDa for 
PvMSP-1. 
3.7.2. Construction of phylogenetic tree and sequence identity 
MSP-1 can be found in all Plasmodium species and some similarities but also differences already became 
apparent when the production process for recombinant MSP-1 proteins was adjusted in our laboratory. 
Bioinformatical analysis can complement data obtained from biophysical and biochemical assays to attain 
structural information. Here, a combination of multiple sequence alignment, protein blast and 
phylogenetic tree generation was used to highlight common characteristics of MSP-1.  
Amino acid sequences of MSP-1 from Plasmodium falciparum, P. vivax, P. berghei and P. knowlesi were 
aligned using the CLUSTAL OMEGA multiple sequence alignment online tool (version 1.2.4). All 
sequences include an N-terminal signal peptide and a C-terminal GPI anchor signal sequence. Both of 
these were not present in the recombinant proteins used for subsequent experiments. The complete 
alignment can be found in the appendix (6.1). All six aligned sequences were used to create a phylogenetic 
tree by inferring evolutionary history using the neighbour-joining method (Saitou and Nei, 1987). The 
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evolutionary distances were computed using the Poisson correction method (Zuckerkandl and Pauling, 
1965) and are in the units of the number of amino acid substitutions per site. The method applied for the 
creation of this phylogenetic tree included partial deletion, which means all positions with less than 95% 
site coverage were excluded. The final dataset includes 1528 positions. The robustness of this phylogenetic 
tree was tested using the Bootstrap method with 500 replicates and showed a high reliability. 
The created phylogenetic tree suggests an evolutionary split between the Plasmodium species infecting 
humans and P. berghei, the only parasite species not infecting humans included in this analysis (Figure 
43). P. knowlesi MSP-1 shows a higher similarity with both P. vivax strains than with P. falciparum.  
 
 
Figure 43. Evolutionary analysis based on MSP-1. The phylogenetic tree was created using the amino acid sequence 
of MSP-1 and the MEGA7 software (Kumar, Stecher and Tamura, 2016). Evolutionary history was modelled using the 
neighbour-joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch length = 1.77042031 is shown. 
The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) 
are shown next to the branches (Felsenstein, 1985). The tree is drawn to scale, with branch lengths in the same units as 
those of the evolutionary distances used to infer the phylogenetic tree. The Poisson correction model was used to 
calculate evolutionary distances (Zuckerkandl and Pauling, 1965), which are in the units of the number of amino acid 
substitutions per site. The analysis involved 6 amino acid sequences. All positions with less than 95% site coverage 
were eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at any 
position. There were a total of 1528 positions in the final dataset.  
Another indicator of molecular evolution is sequence identity. The same amino acid sequences as used for 
the phylogenetic tree were compared to each other by Protein Blast (NCBI protein blast, version 2.8.0, 
(Altschul et al., 1997)). The computed sequence identities range from 36% to 84% (Table 16). The highest 
similarity was found between MSP-1 from P. vivax Salvador I and P. vivax Belem. MSP-1 from the two 
Plasmodium falciparum strains 3D7 and FCB-1 only show a sequence identity of approximately 40% 
when compared with P. vivax MSP-1. The amino acid sequence of P. knowlesi MSP-1 is closer to P. vivax 
than P. falciparum MSP-1 with ~63% vs. ~40% sequence identity. A comparison of P. berghei MSP-1 
with other Plasmodium strains revealed a sequence identity value of ~36% for all of them.  
 P. vivax Belem
 P. vivax Sal1
 P. knowlesi
 P. falciparum FCB1
 P. falciparum 3D7
 P. berghei ANKA
100
100
100
0 .10
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Table 16. Sequence identities of MSP-1 from several Plasmodium strains according to Protein Blast by NCBI. The 
full amino acid sequences were analysed including the GPI anchor signal sequence and signal peptide. PvSal: P. vivax 
Salvador I, PvBelem: P. vivax Belem, PbANKA: P. berghei ANKA, Pf3D7: P. falciparum 3D7, PfFCB-1: P.  falciparum 
FCB-1, Pk: P. knowlesi.  
 PvSal1 PvBelem PbANKA Pf3D7 PfFCB-1 Pk 
PvSal1  84% 36% 39% 40% 62% 
PvBelem 84%  36% 38% 40% 64% 
PbANKA 36% 36%  36% 34% 38% 
Pf3D7 39% 38% 36%  59% 40% 
PfFCB-1 40% 40% 34% 59%  39% 
Pk 62% 64% 38% 40% 39%  
 
3.7.3. Processing by subtisilin-like protease 1 
The proteolytic processing of MSP-1 by the subtilisin-like protease 1 (SUB1) is crucial for egress and 
invasion of red blood cells. It is assumed that all Plasmodium parasites express MSP-1 as a precursor, 
which is cleaved by a protease into four fragments. The amino acid sequences from six Plasmodium strains 
were analysed using the P. falciparum SUB1 model (de Monerri et al., 2011) and the PoPs online tool 
(Boyd et al., 2005). All analysed MSP-1 sequences contain at least three predicted cleavage sites. The exact 
locations of these motifs are not the same for all MSP-1 proteins, leading to fragments of varying length.  
The alignment in Figure 44 includes the predicted cleavage sites with the highest scores. Other suggested 
sequences were regarded as alternative cleavage sites.  
 
 
Figure 44. Predicted SUB1 cleavage sites in different MSP-1 proteins. MSP-1 amino acid sequences of several 
Plasmodium strains were analysed using the PfSUB1 model and the PoPs online tool (Boyd et al., 2005; de Monerri et 
al., 2011). Predicted cleavage sites with the highest score were aligned and highlighted.  
Recombinant proteins based on P. vivax Salvador I, P. knowlesi and P. berghei ANKA MSP-1 were 
incubated with PfSUB-1 to test if the proteolytic processing is indeed conserved. Samples were taken after 
30 min, 1 hour, 3 hours, 6 hours and 24 hours and analysed by SDS-PAGE (Figure 45). In all cases, the 
two bands representing full length MSP-1 are gone in the overnight sample and only bands representing 
proteins of lower molecular weight remain. Bands presumably representing processing fragments are 
labelled in relation to their P. falciparum counterpart, irrespective of their actual molecular weight. In 
case of P. knowlesi, the calculated molecular weights of the predicted MSP-1 fragments are 79 kDa, 
43 kDa, 40 kDa and 45 kDa for Pk83, Pk30, Pk38 and Pk42, respectively. For P. berghei values of 82 kDa 
(Pb83), 35 kDa (Pb30), 57 kDa (Pb38) and 23 kDa (Pb42) were calculated. 
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Figure 45. PfSUB1 assay with different MSP-1 proteins derived from P. vivax, P. knowlesi and P. berghei.  
A) Recombinant proteins were incubated with PfSUB1. Samples were taken at the start of the assay, after 30 min, 1 
hour, 3 hours, 6 hours and 24 hours. The two bands representing full length MSP-1 disappear over time and cannot be 
found in the overnight sample anymore. Instead, bands of lower molecular weight appear, presumably representing the 
processing fragments (indicated with arrows). B) P. knowlesi MSP-1 processing fragments have a molecular weight of 
79 kDa (Pk83), 43 kDa (Pk30), 40 kDa (Pk38) and 45 kDa (Pk42). Pk30 contains 43 prolines, leading to an altered running 
behaviour on SDS gels as observed for some P. vivax fragments. C) Processing of P. berghei MSP-1 should result in 
proteins of 82 kDa (Pb83), 35 kDa (Pb30), 57 kDa (Pb38) and 23 kDa (Pb42).  
 
 
 
 
 
A           B 
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3.7.4. Secondary structure prediction  
Most biophysical assays can only be used to obtain overall structural information and do not allow the 
identification of specific structures or lack thereof at precise locations. Bioinformatical tools can partially 
fill that gap and deliver location specific predictions based on a protein or nucleotide sequence. The JPred4 
software (Drozdetskiy et al., 2015) uses a combination of the Jnet algorithm (Cuff and Barton, 2000) and 
the LUPAS method to predict beta-sheets, alpha-helical and coil regions based on amino acid sequences 
(Lupas, 1997). The protein sequences of MSP-1 from P. falciparum 3D7, P. vivax Salvador I, P. berghei 
ANKA and P. knowlesi were analysed using default settings. On average, approximately 40% of the 
protein sequences were classified as alpha-helical and only a low percentage of 4-5% matched the criteria 
for a beta-sheet. Surprisingly, all proteins include large areas of unpredicted and therefore unstructured 
regions. Figure 46 shows an overview of MSP-1 with known conserved, dimorphic and oligomorphic 
regions of MSP-1D in white, grey and black, respectively. Cleavage sites used for proteolytic processing 
of the precursor protein are indicated with arrows and their position is given below. Unstructured regions 
were defined as stretches of >40 amino acids with no predicted secondary structure and are shown in the 
scheme in green. Notably, these unstructured regions can be found in similar positions in all Plasmodium 
species included in this comparison. The p30 processing fragment contains two, sometimes even three 
unstructured regions. In case of P. knowlesi, these regions are separated only by short coil regions. The 
precise position of these unstructured regions are given in Table 17.  
 
 
Figure 46. Scheme of MSP-1 with predicted unstructured regions. The secondary structure of MSP-1 was computed 
using JPred4, a software that recognises alpha-helical, beta-sheet and coiled structures. The top part shows a previously 
published overview of MSP-1D with conserved, dimorphic and oligomorphic regions in white, grey and black (Kauth et 
al., 2006). Arrows indicate cleavage sites used for proteolytic processing of the precursor protein, resulting in four 
fragments p83, p30, p38 and p42. Unpredicted regions are shown in green. SP: signal peptide, blue: 
glycosylphosphatidylinositol signal sequence (also labelled GPI). 
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Table 17. Exact position of unstructured regions within MSP-1 according to the secondary structure prediction. 
Plasmodium strain unstructured region no. position in the amino acid sequence 
P. falciparum 3D7 1 53  -138 
 2 713 – 791 
 3 904 – 994 
 4 1247 – 1287 
P. vivax Salvador I 1 207 – 287 
 2 716 – 821 
 3 944 – 982 
 4 1255 – 1316 
P. berghei 1 277 – 376 
 2 680 – 833 
 3 942 – 1121 
 4 1340 – 1392 
P. knowlesi 1 204 – 258 
 2 691 – 857 
 3 873 – 931 
 4 946 – 1042 
 5 1320 - 1403 
 
3.7.5. Circular dichroism (CD) spectroscopy 
Circular dichroism (CD) spectroscopy is a frequently used tool to check whether recombinant proteins 
are folded correctly. This method is based on circular dichroism, which is the difference in absorption of 
left- and right-handed circularly polarised light, meaning it can be used to study chirally active molecules, 
such as proteins and macromolecules. These measurements usually result in a characteristic spectrum, 
representing the secondary structure that is most common in the molecule. An a-helix causes negative 
bands at 208 and 222 nm and a positive band at 193 nm, while an antiparallel b-sheet can be recognized 
by negative bands at 218 nm and positive bands at 195 nm, making these two structures easy to 
distinguish.  
Here, recombinant MSP-1 proteins were dialysed against 10 mM NaH2PO4 buffer (pH 7) to remove any 
absorbing salts or arginine from the lyophilisation process. Measurements were performed using a protein 
concentration of ~0.3 mg/mL over a wavelength range of 190 to 250 nm. Changes in these spectra were 
monitored while performing thermal denaturation by increasing the temperature from 10°C to 85°C.  
The CD spectrum of MSP-1D represents a mostly alpha-helical secondary structure with negative bands 
at 208 nm and 222 nm and a positive band at 193 nm (Figure 47). The peak heights decrease at higher 
temperatures, as the protein begins to unfold. However, even at 85°C MSP-1D is not completely unfolded.  
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Figure 47. CD spectra of MSP-1D at different temperatures. The spectrum matches the typical CD spectrum for 
alpha-helical proteins with two negative bands at 208 and 222 nm and a positive band at 193 nm. The intensity of this 
spectrum decreases with rising temperatures, but even at very high temperatures, such as 85°C, the protein is not 
completely unfolded. 
The melting temperature of MSP-1D was determined by measuring the CD signal at 222 nm during 
thermal denaturation. Scans were performed in 0.1°C intervals while the temperature was increased from 
10°C to 85°C. The measured CD signal was plotted against the temperature and the melting temperature 
was calculated by applying a nonlinear fit in Prism (Figure 48). For MSP-1D, the melting temperature 
was determined as 45.6°C ± 0.09 with an R2 value of 0.99. 
 
 
 
Figure 48. Fitted data from thermal denaturation of MSP-1D monitored by CD spectroscopy. Scans were 
performed at 222 nm in 0.1°C intervals while the temperature increased from 10°C to 85°C. The melting point was 
determined as 45.6°C ± 0.09 by using a nonlinear fit in Prism. 
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Recombinant MSP-1 proteins derived from P. vivax, P. knowlesi, P. falciparum FCB-1 and a hybrid 
protein consisting of one 3D7 half and one FCB-1 half (hybrid D/F) were prepared and measured the 
same way as MSP-1D. All CD spectra show the typical shape of a mostly alpha-helical secondary structure 
(Figure 49). Different peak heights are caused by slight variations in protein concentration but also by 
different extinction coefficients of the MSP-1 proteins. Individual melting temperatures are shown in 
Table 18. The average melting temperature is 44°C. CD spectroscopy results for each measured protein 
can be found in the appendix (6.2). 
 
 
 
Figure 49. CD spectra of all measured MSP-1 proteins. The CD measurements were performed individually for each 
recombinant MSP-1 protein at 20°C in phosphate buffer. Differences in relative peak heights are caused by slight 
variations in protein concentration. All CD spectra correspond to the typical spectrum of an alpha-helical protein.   
 
 
Table 18. Melting temperatures of MSP-1 determined by CD spectroscopy. 
Recombinant MSP-1 based on melting temperature (in °C) Standard error 
3D7 (MSP-1D) 45.6 0.09 
- processed MSP-1D 44.7 0.05 
FCB-1 44.0 0.1 
vivax 42.5 0.15 
knowlesi 44.9 0.07 
hybrid 3D7/FCB-1 42.9 0.1 
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All recombinant proteins used in this study were assembled from two halves. However, MSP-1 only occurs 
as a precursor protein or as a non-covalently associated complex composed of four fragments. To allow 
a comparison between such a complex and the other recombinant proteins, MSP-1D was incubated with 
PfSUB1 overnight and subsequently measured by CD spectroscopy. Successful proteolytic processing was 
confirmed by SDS-PAGE. The salts present in the SUB1 cleavage buffer would interfere with CD 
spectroscopy, so the buffer was exchanged with 10 mM NaH2PO4 buffer (pH 7) using a PD10 desalting 
column. The CD spectrum measured at low temperatures matches the one for unprocessed MSP-1D 
(Figure 50). However, the processed protein seems to be completely unfolded at temperatures higher than 
42°C. The melting point was calculated as 44.7 °C.  
 
 
 
Figure 50. CD spectra of MSP-1D after processing with PfSUB1. A) MSP-1D was incubated with PfSUB1 overnight. 
Successful proteolytic processing was confirmed by SDS-PAGE. B) After a buffer exchange to remove light-absorbing 
salts, CD measurements were performed as previously described. The recorded CD spectrum shows the positive band 
at 193 nm and two negative bands at 208 and 222 nm, which is characteristic for an alpha-helical structure. The CD 
spectra measured at 50°C or higher are flatter without any significant peaks, suggesting that the protein is mostly 
unfolded at these temperatures. The melting temperature was determined as 44.7°C by repeated CD signal 
measurements at 222 nm during thermal denaturation. 
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3.7.6. Crosslinking of MSP-1 
Interactions within the MSP-1 complex were analysed by cross-linking combined with mass spectrometry 
analysis. Initial experiments were performed using the cross-linker BS3, which is a water-soluble 
homobifunctional N-hydroxysuccinimide ester (NHS) with a defined spacer arm. These esters form stable 
amide bonds with primary amino groups (-NH2), which are present in the side chain of lysine residues 
and at the N-terminus of each polypeptide. The water-insoluble cross-linker disuccinimidyl sulfoxide 
(DSSO) follows the same principle, but can be cleaved in the gas phase during tandem mass spectrometry 
by collision-induced dissociation (Kao et al., 2011). This cleavage facilitates data acquisition and analysis 
as the fragmentation patterns are unique to specific cross-linking types, allowing the identification of 
interlinks, intralinks or dead ends. The spacer arms of BS3 and DSSO are 11.4 and 10.3 Angström, 
respectively (Figure 51). 
 
 
      
 
Figure 51. Structure of the cross-linkers BS3  and DSSO. A) The chemical structure of BS3 contains amine-reactive 
N-hydroxysuccinimide (NHS) esters at each side of a spacer of 11.4 Angström. The reactive groups (highlighted in grey) 
form stable bonds with primary amino groups present in side chains of lysine residues. B) DSSO includes of two 
symmetric collision-induced dissociation (CID)-cleavable sites that facilitate identification of crosslinked peptides based 
on a distinct fragmentation profile. The spacer length of DSSO is 10.3 Angström.  
Cross-linking reactions with BS3 were performed using MSP-1D and MSP-1F and analysed at the mass 
spectrometry core facility in the ZMBH. Both P. falciparum derived MSP-1 proteins included a mixture 
of cross-links within processing fragments but also between them (Figure 52). Such interactions between 
processing fragments were found for p83 with p30, p38 and p42. P30 interacted only with p83 in these 
experiments, p38 only with p42 and p30, while p42 interacted with p38 and p83. Interestingly, no 
interactions involving the p19 portion of MSP-1 were found. All shown cross-links were manually checked 
in addition to software-based analysis of valid interactions.  
 
 
 
 
 
 
 
 
BS3 DSSO 
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Figure 52. Interactions within P. falciparum MSP-1 proteins analysed by cross-linking with BS3. Recombinant 
MSP-1D and MSP-1F were incubated with a 2.5 fold molar excess of BS3 for 30 minutes. The cross-linking reaction was 
stopped with quenching buffer and samples were digested with trypsin before mass spectrometry analysis. According 
to this data, p83 interacts with all processing fragments of MSP-1. P30 interacts with p83 only, p38 binds to p83 and 
p42. The C-terminal p42 binds to p38 and p83 but not to p30. No interactions involving the very C-terminal end which 
comprises the p19 fragment were found in any samples. 
Due to technical difficulties with the BS3 cross-linker, DSSO was used as an alternative. This cross-linker 
has the additional advantage that analysis is more straightforward, especially when intermolecular 
interactions are analysed. The experiments shown here only look for interactions within MSP-1, but the 
same cross-linker can be used for further studies in the future. DSSO was used at a 20-fold molar excess, 
leading to more cross-links being detected compared to BS3. P. falciparum MSP-1D, P. vivax and 
P. knowlesi MSP-1 were analysed under the same conditions. The results are similar to the ones detected 
using BS3 but there are also some differences. In the MSP-1D sample, p83 does not interact with p30, but 
with p38 and p42 (Figure 53). In general, p30 shows only a low amount of interactions with other 
processing fragments in this analysis. The P. vivax and P. knowlesi MSP-1 proteins shows a similar 
interaction pattern among their processing fragments, but here p83 interacts with all other processing 
fragments, including p30. However, in all three samples p30 does not interact with p42. P38 appears to 
bind to all other processing fragments and the C-terminal p42 interacts with p38 and p83 in all analysed 
MSP-1 heterodimers. In agreement with previous findings using BS3 cross-linked samples, no interactions 
involving the p19 region were detected. 
MSP-1D 
MSP-1F 
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Figure 53. Detected interactions using the MS-cleavable cross-linker DSSO. All shown links have reached a score 
of >80. The cross-linker was added to the recombinant proteins at a 20-fold molar excess. In all three proteins the p83 
processing fragment interacts with p42 and p38, while an additional interaction with p30 was found in P. vivax and 
P. knowlesi MSP-1. P38 interacts with all other processing fragments, whereas p30 seems to only bind to p83 and p38. 
Interestingly, no interactions were found for the very C-terminal part of MSP-1.  
In addition to strain-specific MSP-1 proteins, recombinant proteins created from halves of two different 
Plasmodium strains or species were cross-linked and analysed (Figure 54). One hybrid protein was 
assembled using the N-terminal 83/30 half of MSP-1F and the C-terminal 38/42 half of MSP-1D. While 
interactions between both fragments were detected after cross-linking with DSSO, the majority of 
interactions occur within the N-terminal fragment itself. This might be explained by an excess of the 83/30 
half in the sample, leading to more detected cross-links within that fragment only. However, the 
interaction pattern is similar to previously tested MSP-1 proteins and includes interactions between p83 
and p42, as well as between p30, p83 and p38. An interaction between p30 and p42 was not detected, 
which is identical to the findings for MSP-1D, P. vivax and P. knowlesi MSP-1.  
Cross-linking and mass spectrometry analysis of the presumable hybrid protein consisting of P. vivax 
83/30 and P. falciparum 38/42 revealed a very low number of interactions and all of them were limited 
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to interactions within the two halves. As no links between the two fragments were found, despite including 
results with a very low score of ~20, it has to be assumed that the creation of a hybrid protein derived 
from two different species was unsuccessful.  
 
 
Figure 54. Cross-linking of presumable hybrid proteins created from two halves of different Plasmodium strains 
or species. The hybrid protein created using the 83/30 half of MSP-F and the 38/42 half of MSP-1D shows a similar 
interaction pattern than the other recombinant MSP-1 proteins. However, most interactions were detected within the 
N-terminal fragment, suggesting that there might be an excess of 83/30 in the sample. Successful generation of a hybrid 
protein can be assumed as cross-links between both halves were found. Unfortunately, this was not the case for the 
second protein. Here, the creation of a hybrid protein based on one half of P. vivax MSP-1 and one half of P. falciparum 
was attempted. In this case also cross-links of a score as low as 20 are shown. The lack of interactions between both 
fragments indicate that the assembly of a hybrid protein consisting of MSP-1 halves from two different Plasmodium 
species is not possible with the applied protocol. 
 
3.8. Recombinant PvMSP-1 is recognised by naturally infected donors 
The most crucial criterium for a vaccine based on a recombinant protein is achieving the identical or at 
least highly similar structure compared to the native protein. Sera from volunteers living in a 
malaria-endemic region in Brazil were used to measure the interaction between recombinant PvMSP-1 
and naturally acquired antibodies. Two types of samples were available from each volunteer. The T1 
sample, which was taken at the beginning of a cohort study in an agricultural settlement (Bastos et al., 
2007) and the T2 sample, which was collected during an acute infection with P. vivax.  
A 96 well plate was coated with 100 nM PvMSP-1 or one of its processing fragments in coating buffer. 
After washing with TBST, the plate was incubated with blocking buffer, followed by another washing 
step with TBST before sera from the Brazilian cohort were added. Predilutions of the sera were determined 
with an initial test using only 5 sera with the most volume. PvMSP-1, Pv83 and Pv42 are apparently the 
most immunogenic proteins as test sera could be prediluted at a ratio of 1:100. ELISAs using Pv30 and 
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Pv38 required a lower predilution of 1:25. All sera were prediluted in blocking buffer and incubated on 
the plate for 2 hours at room temperature. Successful binding was detected using anti-human IgG coupled 
with alkaline phosphatase and 4-Nitrophenyl phosphate disodium salt hexahydrate as substrate. All sera 
were tested in duplicates, but a quantitative analysis was not possible because of insufficient sera volumes.  
N-terminal Pv83, C-terminal Pv42 and the full length PvMSP-1 were well recognised by naturally acquired 
antibodies. Analysis of Pv30 or Pv38 resulted in a lower signal with all sera. Statistical significance 
between T1 and T2 samples was calculated using the Wilcoxon signed-rank test. In theory, an ongoing 
P. vivax infection should boost the immune response. However, the increased signal between T1 and T2 
samples was only significant for Pv83 and Pv30. In some cases the signal measured for the T2 sample was 
even lower than the one for the T1 sample (Figure 55). 
 
 
 
Figure 55. Recombinant PvMSP-1 and its processing fragments are recognised by naturally acquired antibodies. 
96 well plates were coated with 100 nM of protein and incubated with sera from Brazilian donors collected at the 
beginning of a cohort study (T1 sample) and when they suffered from an acute P. vivax infection (T2 sample). PvMSP-1 
and its processing fragments Pv83 and Pv42 showed the highest recognition and sera could be used at a predilution of 
1:100. Less naturally acquired antibodies recognised Pv30 or Pv38 and sera had to be used at a lower predilution of 
1:25. Statistical significance between T1 and T2 samples was calculated with the Wilcoxon signed-rank test. An 
expected boost effect was not observed for many samples and the absorbance increase between the T1 and T2 samples 
was only significant for Pv83 and Pv30.  
 Pv
MS
P-
1(T
1)
Pv
MS
P-
1 (
T2
)
0
1
2
3
4
ab
so
rb
an
ce
 4
05
 n
m
P = 0.1475
1:100
Pv
83
 (T
1)
Pv
83
 (T
2)
Pv
42
 (T
1)
Pv
42
 (T
2)
Pv
30
 (T
1) 
Pv
30
 (T
2)
Pv
38
 (T
1)
Pv
38
 (T
2)
0
1
2
3
ab
so
rb
an
ce
 4
05
 n
m
1:100 1:25
P = 0.0098 P = 0.1230 P = 0.0029 P = 0.523
Discussion 
 93 
4. Discussion 
The merozoite surface protein 1 is one of the most researched proteins on the surface of Plasmodium 
parasites. However, most studies use only fragments of the full length MSP-1 protein, such as the 
C-terminal p42 or p19 fragments. While the information gathered from such experiments can be useful 
and has created the base for most immunological studies regarding this protein, using the full length 
protein has several advantages. (i) The overall structure of a protein of this size will most likely differ 
from those of the individual fragments, (ii) binding interactions and binding sites could only be revealed 
when the entire protein sequence is present and (iii) crucial immunogenic epitopes might be found in full 
length MSP-1 protein only. A key prerequisite of all structural and immunological studies is a supply of 
sufficient amounts of MSP-1. The development of recombinant MSP-1 as a vaccine is a main objective in 
our laboratory and a production protocol for P. falciparum MSP-1 was successfully developed and 
patented in 2011 (Bujard et al., 2011).  
However, another Plasmodium parasite, P. vivax has received more attention over the years as reports of 
severe malaria have accumulated and the numbers of P. vivax infections have increased in areas where 
P. falciparum infections have been reduced. But research efforts focusing on P. vivax face more difficulties 
than P. falciparum studies as a long-term cell culture system is missing and freshly isolated or thawed 
parasites have to be used for experiments, which are not readily available all around the world.  
 
The aim of this project was to establish a protein production process for P. vivax and P. berghei MSP-1, 
which can be used as reliable sources for structural and immunological assays. The comparison of 
structural information obtained from recombinant MSP-1 proteins of several Plasmodium species could 
provide insights into the protein’s function and deliver information about which elements could be 
exploited by a vaccine. Recombinant P. berghei MSP-1 can be used for vaccination studies in mice to 
analyse if immunisation with MSP-1 has a beneficial influence on experimental cerebral malaria 
development in mice. While immunological studies using P. vivax MSP-1 (PvMSP-1) are challenging to 
execute in our laboratory, a robust protein production protocol puts us into the position to collaborate 
with other research groups that have access to cohorts in P. vivax endemic areas.  
 
4.1. Production of recombinant P. vivax MSP-1 
The development of a malaria vaccine is the primary goal in our laboratory. As a consequence, the 
production process developed in this thesis had to fulfil several requirements in addition to providing 
enough material for experiments. The protocol has to be planned with the option to upscale the process 
for mass production, which eliminates a number of expression systems, such as mammalian cell lines. 
E. coli was chosen as a suitable expression host as this system is cost-effective, commonly used and can 
be adapted to an upscaled format. The lack of posttranslational modifications in E. coli can be a problem 
for the production of other pharmaceutical or therapeutic proteins, which is why other expression systems 
such as mammalian or insect cells are chosen for the manufacture of some protein based products. This 
Discussion 
 94 
shortcoming of the E. coli system is an advantage for MSP-1 expression as it was shown to be not 
glycosylated despite the presence of potential glycosylation sites (Berhe et al., 2000). Using other 
expression systems could result in glycosylation of MSP-1 and therefore potentially compromise epitopes 
that would otherwise lead to immune responses, rendering the expression host unsuitable for vaccine 
production.  
One risk of the E. coli host is the potential presence of endotoxins in the final product. These 
lipopolysaccharides are pyrogenic components of the cell membrane, which are released during cell lysis 
of gram-negative bacteria and can cause severe reactions in humans, such as fever, leukopenia, 
leucocytosis, induction of thrombosis and septic shock (Sandle, 2016). While less important for functional 
or structural assays in the laboratory, this can become crucial if the production process is upscaled for the 
manufacture of a human vaccine. The amount of endotoxins was quantified for the P. falciparum 
protocol, which is highly similar to the P. vivax production process, using the Limulus amebocyte lysate 
(LAL) testing method. This assay is based on the reaction of lipopolysaccharides with a clottable protein 
isolated from amoebocyte cells from the blood of Limulus polyphemus. The purified P. falciparum MSP-1 
protein contained below 50 endotoxin units (EU) per mg protein. The typical vaccine formulation used 
in ongoing clinical trials includes only 150 µg of MSP-1 per dose, resulting in an estimated endotoxin 
level of 7.5 EU/dose. For comparison, the commercially available vaccines against typhus and cholera 
contain 100,000 EU/mL and 1,000,000 EU/mL, with an average volume of 0.5 mL per dose (Brito and 
Singh, 2011). As the purification principle of P. vivax MSP-1 is very similar to P. falciparum MSP-1, 
comparable endotoxin levels are expected although they were not quantified during this project. 
 
The P. vivax MSP-1 sequence chosen for protein expression is based on the Salvador I strain, which is the 
best analysed P. vivax strain with its genome being sequenced in 2008 (Carlton, Adams, et al., 2008). 
Many molecular cloning approaches in Plasmodium face the problem of AT-richness. In comparison to 
P. falciparum, whose genome has an AT composition of 80% (Gardner et al., 2002), the genome of 
P. vivax is already less AT-rich (58%)(Carlton, Adams, et al., 2008). However, the AT percentage of the 
P. vivax MSP-1 gene could be further reduced from 57% to 46%, a reduction by 11%, by optimising a 
synthetic gene for human codon usage. This adaptation also has the advantage that the synthetic gene can 
be used for integration into adenoviruses if a protein-based vaccine is not successful. Additional 
modifications of the original MSP-1 sequence include the removal of the signal peptide and GPI anchor 
signal sequence as those are not required for the production of a soluble non-membrane bound protein. 
Expression of the full length MSP-1 protein as one recombinant protein was problematic as it is very 
prone to degradation. A tandem purification using a GST-tag at the 5’ end and a His-tag at the 3’ end 
resulted in a low yield and was subsequently abandoned as a protein expression technique (Kauth, 2006). 
Splitting the protein into two halves and assembling MSP-1 from two individually expressed proteins was 
a more successful alternative. Accordingly, the coding sequence of PvMSP-1 was analysed using a model 
for the subtilisin-like protease-1 (SUB1) (de Monerri et al., 2011) and the Prediction of Protease specificity 
online tool (Boyd et al., 2005) to determine the cleavage sites of each MSP-1 processing fragment. Splitting 
the protein at a naturally occurring cleavage site was considered superior to cutting the sequence into two 
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halves of equal length. As MSP-1 is proteolytically processed at the site separating the 83/30 and the 38/42 
fragments, two recombinant proteins who are separated at this site have a higher probability of folding 
into the same conformation as the native protein. In that regard, assembling the MSP-1 protein from four 
processing fragments might result in an even higher structural similarity to the native protein than creating 
a heterodimer, but such a protocol would be even more difficult to combine with GMP guidelines. The 
sequence analysis revealed several cleavage sites, but only those with the highest score values were 
considered as potential cleavage sites in P. vivax MSP-1. In addition to defining the two halves of 
PvMSP-1, this analysis was also used to identify the four processing fragments which are created during 
SUB1 processing before egress. Nonetheless, it should be remembered that the chosen cleavage sites might 
not represent all possible MSP-1 fragments as alternative cleavage sites, which were found for 
P. falciparum (Das et al., 2015) most likely also exist in the P. vivax MSP-1 sequence.  
 
All recombinant MSP-1 halves and the individual processing fragments could be expressed under standard 
conditions (LB medium, 37°C) using pZE expression plasmids and the E. coli strain W3110-Z1. This 
system offers a tight regulation and no recombinant protein expression was detected before addition of 
IPTG. The His-tagged processing fragments and the Pv38/42 half showed very high expression levels after 
induction. The N-terminal Pv83/30 protein was not significantly expressed without the addition of an 
N-terminal 6xHis-tag or the replacement of the first 22 amino acids with the already optimised sequence 
from another P. falciparum 83/30 expression plasmid. The reasons for these difficulties were analysed in 
more detail when the expression plasmids for P. falciparum MSP-1 were created and suggested that the 
ribosomal binding site is not accessible in the unaltered sequence. The mRNA structure of Pv83/30 was 
analysed using the mFold web server and revealed some unfavourable structures, such as partially closed 
or hairpin structures, that could hinder binding of the ribosome during translation. Another contributing 
factor is the instability of the 83/30 fragment, which is prone to degradation by proteases. Susceptibility 
to proteases can be enhanced by flexible regions or destabilising amino acids at the N-terminus, a 
phenomenon known as the N-end rule (Varshavsky, 1997). But the 83/30 sequence of all MSP-1 proteins 
used in this study have either glutamic acid or valine at their N-terminal position, which are stabilising 
amino acids in E. coli. As these recombinant protein expression issues were overcome by adding an N-
terminal 6xHis-tag or changing 66 base pairs in the N-terminal coding sequence, access to the ribosomal 
binding site seems to have a stronger negative impact on protein expression than degradation.  
 
The majority of recombinant proteins based on MSP-1 accumulate in inclusion bodies, which consist of 
unfolded or partially folded proteins. The only exception are the Pv30 and Pv38 processing fragments, 
which are present as soluble and insoluble proteins and were purified using the bacterial lysate. The Pv83 
and Pv42 processing fragments and both halves of PvMSP-1, comprised of Pv83/30 and Pv38/42 are 
expressed in insoluble form. This result is not surprising given the large molecular weight of these proteins 
and the presence of intramolecular disulphide bonds at the C-terminus of MSP-1. E. coli has a reducing 
milieu in the cytosol that can be problematic for the expression of soluble proteins with disulphide bonds. 
However, this outcome was beneficial for the reconstitution of the full length MSP-1 protein as both 
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halves can be refolded together from solubilised inclusion bodies. Another advantage of the accumulation 
in inclusion bodies is the low amount of E. coli host proteins found in inclusion bodies and the protection 
from endogenous proteolytic enzymes of the host cell. This can be particularly beneficial for the Pv83/30 
half as all recombinant MSP-1 proteins produced in our laboratory showed a decreased stability for this 
half in particular.  
Reconstitution of full length MSP-1 was achieved by using the “pulse renaturation” technique during 
which solubilised inclusion bodies are quickly diluted into the refolding buffer. This method has the 
advantage that only a low amount of folding intermediates are present during each “pulse” and correctly 
folded proteins are removed from the equilibrium and are not available for aggregation when the next 
load of solubilised inclusion bodies is added. An alternative approach is refolding by dialysis, which results 
in a slow removal of denaturing agents, allowing the formation of folding intermediates. These can be 
beneficial for the refolding process but some proteins also tend to aggregate more when dialysis is used 
as a refolding method. The key components of the refolding buffer include arginine, a glutathione redox 
system and a pH of 8.5. The exact mechanisms how arginine contributes to protein refolding is not 
known. One theory states that the guanidinium group of arginine interacts with tryptophan in the protein 
to suppress aggregation. This might be a contributing factor for P. vivax MSP-1, which includes 
tryptophan at three positions, but P. falciparum MSP-1 lacks this amino acid entirely. Another proposed 
mechanism is the interaction of arginine with amino acid side chains and peptide bonds, which is a more 
generally applicable idea (Arakawa et al., 2007). The mildly reducing conditions in the refolding buffer 
paired with a ratio of reduced glutathione to oxidised glutathione of 10 mM to 1 mM aid in protein 
refolding and disulphide bonds formation by repeatedly breaking energetically unfavourable 
conformations until the native conformation is reached. The latter are of particular importance for the 
C-terminal half of MSP-1. For optimal reconstitution of MSP-1 with the correct stoichiometry an equal 
amount of 83/30 and 38/42 were added. Initial attempts to refold P. vivax MSP-1 with the standard 
arginine concentration of 500 mM were not successful and resulted in both halves running separately on 
an SDS gel when initial purification attempts were tested (data not shown). Increasing the arginine 
concentration to 1 M could reduce these issues although not all MSP-1 halves successfully bound to each 
other and excess proteins had to be removed during the purification process.  
Whereas the usage of isolation tags was legitimate for the enrichment of recombinant proteins meant for 
laboratory experiments only, the production protocol for full length PvMSP-1 had to be transferable for 
human vaccine manufacturing. Regulatory agencies do not allow the usage of any purification tags, such 
as 6xHis-tags, due to their immunogenic potential in humans. So in contrast to the MSP-1 processing 
fragments, no isolation tags were allowed for the expression of both PvMSP-1 halves. The pZE23 
expression plasmids can be used for such protein expression demands, however, as mentioned above, 
Pv83/30 could not be expressed unless the N-terminal sequence was altered. The addition of an 
N-terminal His-tag was fine for initial structural experiments, but the replacement of the first 22 amino 
acids is a preferable alternative for vaccine applications. The overall sequence identity of these 22 amino 
acids of P. falciparum MSP-1 and P. vivax is 65% and includes 6 direct matches. The coding sequence 
for P. falciparum 83/30 was previously optimised to overcome similar protein expression difficulties and 
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while the same optimisation process can theoretically be done for the original P. vivax sequence, it was 
considered too time-consuming for this project.  
 
The P. vivax MSP-1 processing fragments were expressed with an N-terminal His-tag and showed very 
high expression levels using the pZE13 expression plasmids (Figure 17). All induced samples contain a 
very pronounced band representing the protein of interest and some weaker bands of lower molecular 
weight that could result from protein degradation. Pv30 and Pv38 were purified from the bacterial lysate 
as soluble proteins and required no further refolding. Pv42 was expressed in insoluble form, which is most 
likely due to the six disulphide bonds not being formed in the reducing conditions found in the cytosol 
during protein expression. In theory, Ni-NTA can also be used to purify unfolded His-tagged proteins. In 
case of Pv42 this was unsuccessful. The causes for this were not further analysed as refolding the protein 
allowed protein enrichment in the same manner as for Pv30 and Pv38. Pv42 was refolded using the 
standard refolding buffer with 500 mM arginine, a glutathione redox system and a pH of 8.0. The final 
eluates of the Ni-NTA purifications contain mostly the desired protein, but also low amounts of 
contaminating proteins of both higher and lower molecular weight. These proteins could be degradation 
products, which still have an intact N-terminal His-tag, or histidine-rich E. coli proteins. The final yield 
of Pv42 was 1.6 mg/g E. coli wet paste, whereas Pv30 and Pv38 were obtained at a lower yield of 
0.75 mg/g E. coli wet paste. An explanation for this is that both Pv30 and Pv38 were expressed as soluble 
and insoluble proteins in almost equal amounts, whereas Pv42 was almost exclusively in inclusion bodies. 
As refolding of recombinant proteins requires additional steps and Pv30 and Pv38 were only required in 
low amounts for this project, the inclusion bodies containing these proteins were discarded and not 
considered for the final yield calculations.  
Pv83 was expressed as an insoluble protein as well, but as there are no disulphide bonds in this protein, 
the glutathione redox system was replaced with 5 mM DTT to reduce the formation of intermolecular 
disulphide bonds between the 3 cysteines found in Pv83. In contrast to Pv42, Pv83 could not be purified 
by His-tag affinity chromatography despite the presence of the His-tag as proven by Western Blot. Possible 
reasons could be based on the three-dimensional structure of the refolded protein. If the N-terminal 
His-tag is in the protein core, it is not accessible for binding to the affinity resin. Instead, Pv83 was purified 
in a similar manner as the full length protein by combining two chromatography techniques that do not 
rely on the presence of purification tags. First, Pv83 was enriched by anion exchange chromatography 
before contaminants of lower molecular weight were removed by size exclusion chromatography. Pv83 
began to elute from the Q-sepharose column at a salt concentration of 75 mM, a concentration that is 
commonly used to wash the column and remove any unwanted contaminants. However, most of Pv83 
remained bound to the column and could only be removed at a NaCl concentration of 1 M. This large 
range of binding strength and required salt concentration to elute the protein indicated that anion 
exchange chromatography is accompanied with a high loss of Pv83 protein. The final yield after additional 
size exclusion chromatography was 3 mg per gram E. coli wet paste.  
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The purification of P. vivax MSP-1 after refolding using both halves faced similar challenges than the 
purification of Pv83 alone. Protein enrichment without relying on affinity tags limits the possible 
purification procedures and required the combination of anion exchange chromatography and size 
exclusion chromatography with multiple buffer exchange steps in between. Technical progress since the 
development of the patent for P. falciparum MSP-1 production allowed the replacement of some 
labour-intensive steps, such as using desalting columns for buffer exchange instead of overnight dialysis. 
Nevertheless, some disadvantages of the original protocol remained after adaption to P. vivax MSP-1. 
(i) All recombinant MSP-1 proteins produced in our laboratory can only be handled at a maximum 
concentration of 1.2 mg/mL without precipitation. This is not a problem for final storage of the protein, 
but it complicates chromatography runs as the volume limits for columns and sample loops are reached 
quicker than when a protein solution of higher concentration can be used. Also, protein concentration 
steps in between can result in protein loss if the maximum concentration is exceeded by accident. (ii) On 
the one hand, MSP-1 binds very strongly to the Q-sepharose matrix used for anion chromatography, but 
also begins to elute at low NaCl concentrations. This hinders efficient washing steps to remove 
contaminating proteins that might still be present after the refolding step. Additionally, protein is lost 
during this purification step since a large proportion of it binds very strongly to the column and cannot 
be eluted unless 1 M of NaCl is applied. This eluate, often termed “final wash” is highly contaminated 
with other proteins and including it into a following size exclusion chromatography would forfeit the 
purpose of the anion exchange chromatography step. (iii) Despite the efforts to add both P. vivax MSP-1 
halves in equal amounts, not all of them formed a heterodimer and excess PfPv83/30 and Pv38/42 have 
to be removed during purification steps. In theory, both halves should have the same negative net charge 
at a buffer at pH 8 since their pIs are close with 6.6 and 6.5 for PfPv83/30 and Pv38/42, respectively. 
However, both halves display a distinct binding affinity to Q-sepharose with the C-terminal Pv38/42 half 
binding stronger to the matrix as PfPv83/30, enabling the separation of full length PvMSP-1 from excess 
PfPv83/30 during anion exchange chromatography, as the latter remains in the flow through. Remaining 
unbound halves and smaller degradation products that were co-eluted with PvMSP-1 can be removed 
during size exclusion chromatography. Such contaminating proteins of around 40 kDa were observed for 
both PvMSP-1 and Pv83, suggesting that these are either degradation products derived from the 
N-terminal portion of the protein or host proteins that are co-enriched by ion exchange chromatography. 
While the purification protocol resulted in protein preparations with only a small amount of remaining 
contaminants, the final yield of this laborious technique was rather low with 0.17 mg per g wet paste. 
 
During this project I could successfully demonstrate the efficiency of an alternative purification process 
for full length PvMSP-1. In this approach, the individually expressed halves are purified in their denatured 
state using strong ion exchange resins before refolding the protein. This not only allows working with 
higher concentrations during protein purification, it also significantly reduces protein precipitation that 
occurs after the refolding step in the previously described protocol. Additionally, all dialysis steps are 
replaced by a less time-consuming buffer exchange using desalting columns. The different binding 
properties of the PfPv83/30 and the Pv38/42 could also be observed in this approach. Denatured Pv38/42 
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could be purified using a Mono S column, whereas PfPv83/30 did not bind to this cation exchanger and 
required the anion exchanger Mono Q instead. A major contaminant in the solubilised inclusion bodies 
of Pv38/42 did not bind to the Mono S resin, suggesting that this contaminant is not a degradation 
product, as these would have a similar net charge and hence similar binding behaviour. Applying different 
NaCl concentrations efficiently removed most contaminating proteins during the purification of 
PfPv83/30. The purified PvMSP-1 halves were refolded by direct buffer exchange into refolding buffer 
while not exceeding a maximum concentration of 1.2 mg/mL for this final step. Complex formation was 
tested by size exclusion chromatography and showed no significant separation of the two halves, 
indicating successful reconstitution of MSP-1.  
The advantages of this approach are (i) a higher yield of 2.9 mg per g wet paste, (ii) a faster purification 
process and (iii) a reduction of MSP-1 complexes containing contaminating proteins or incomplete halves 
as the individual halves undergo rigorous purification before refolding. This alternative protocol uses 
more expensive chromatography materials, but time-saving qualities and higher yield could contribute to 
a more cost-effective manufacturing process if PvMSP-1 production were upscaled for vaccine production 
under GMP conditions. In that case, size exclusion chromatography should be added as mandatory step 
after refolding to remove low amounts of unbound MSP-1 halves. 
 
4.2. Production of P. berghei MSP-1 
The production of recombinant P. berghei MSP-1 (PbMSP-1) and the challenges associated with its 
expression and purification are very similar to other MSP-1 proteins. As with P. vivax MSP-1, the base 
for cloning the expression plasmids was a synthetic gene. The AT content of the original coding sequence 
could be reduced from 75% to 45% by optimising the codon usage for mice. PbMSP-1 is not intended 
for human use but the codon optimised gene can be inserted into adenoviral vectors for usage in 
vaccination studies in mice.  
Initially, only the pZE23 expression plasmids without a His-tag were used for recombinant protein 
expression in the E. coli host W3110Z1. The Pb38/42 half was expressed after addition of IPTG, but the 
Pb83/30 half demonstrated expression problems as observed for P. vivax 83/30. Instead of replacing the 
coding sequence with the nucleotide sequence of another Plasmodium species, an N-terminal His-tag 
followed by a factor Xa cleavage site was added to enable protein expression and include the option to 
remove the His-tag by enzymatic cleavage. As PbMSP-1 will not be used as a human vaccine, regulatory 
restrictions regarding isolation tags do not apply to this protein.  
Another difficulty regarding Pb83/30 is its instability. All SDS gels of induced E. coli cultures expressing 
this protein show bands at 140 kDa, 120 kDa and 90 kDa that are not found in the noninduced sample. 
This suggests that P. berghei 83/30 is even more prone to degradation or premature termination during 
translation as P. vivax MSP-1. This severely limits the obtainable yield and complicates reconstitution of 
the MSP-1 heterodimer. Not only is it more difficult to precisely determine the concentration of intact 
Pb83/30 that has to be added during the pulse renaturation, the chance of Pb38/42 binding to degradation 
products is much higher. Interestingly, degradation of Pb83/30 seems to begin at the C-terminal end as 
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the attempt to enrich intact Pb83/30 using Ni-NTA enriched the degradation products as well (data not 
shown). Refolding of PbMSP-1 was performed using the same technique as for P. vivax MSP-1, although 
an arginine concentration of 500 mM instead of 1 M was sufficient. Interestingly, anion exchange 
chromatography seemingly eliminated the presumable Pb83/30 degradation products and the final eluate 
after size exclusion chromatography contained only two bands matching the Pb83/30 and Pb38/42 halves 
(Figure 35). This effect could be caused by an unequal charge distribution or the degradation products 
lacking an interaction site, which is involved in binding to Pb38/42, resulting in them themselves not being 
able to bind to the anion exchanger. However, freezing and thawing purified PbMSP-1 apparently caused 
further degradation as the previously eliminated proteins of 120 and 90 kDa can be seen again in a later 
assay (Figure 45). Because of the instability of the Pb83/30 half, P. berghei MSP-1 was excluded from 
most experiments which had the purpose to elucidate the structure of MSP-1. The full length protein 
might still be suitable for immunisation studies in mice, but such experiments were not performed during 
this project due to the lack of a suitable adjuvant. The final yield of PbMSP-1 using this protocol was 
0.25 mg per gram E. coli wet paste, which is similar to other yields obtained with this protocol. The 
alternative production process as described for P. vivax MSP-1 was not tested with other MSP-1 proteins 
but could be beneficial for P. berghei MSP-1 in regard to final yield but also in purity as degraded Pb83/30 
halves could potentially be removed before assembling the full length protein. However, the instability 
problem of Pb83/30 as observed after freezing and thawing most likely remains. 
 
4.3. Creation of a hybrid protein consisting of P. falciparum and P. vivax MSP-1 halves  
Malaria endemic areas are often known for either having mostly P. falciparum or P. vivax infections 
despite both parasite species being found in the same area. The ideal vaccine against malaria induces 
cross-reactive immune responses targeting both of these parasite species. The sequence identity of the full 
length MSP-1 protein of P. falciparum and P. vivax is 39%, with the N-terminal 83/30 half sharing a 
sequence identity of 36% and the C-terminal 38/42 half achieving a value of 44% due to the highly 
conserved sequence of p19. The availability of MSP-1 halves from both of these species led to the idea to 
create an MSP-1 heterodimer consisting of one P. falciparum and one P. vivax half. For this experiment, 
the N-terminal 83/30 half of P. vivax was refolded with the C-terminal 38/42 half of P. falciparum 
followed by purification via ion exchange chromatography and size exclusion chromatography. Anion 
exchange chromatography could eliminate excess 83/30 that did not bind to the resin, but free Pf38/42, 
and the potential hybrid MSP-1 complex eluted at the same salt concentrations. Size exclusion 
chromatography can be used to separate individual proteins or in this case unbound MSP-1 halves from 
a complex or from each other if the used column offers sufficient resolution. The preparative column used 
here could not provide the resolution required for separating excess halves and the potential complex into 
two distinct peaks in the UV spectrum. According to the SDS gel, the final eluate contains both halves in 
equal concentrations (see sample 3 and 4 in Figure 37). However, unbound 83/30 fragment elutes first 
from a size exclusion chromatography column due to its higher hydrodynamic radius compared to the 
38/42 processing fragment. If the resolution of the used column is not high enough, both proteins could 
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have eluted separately and the beginning elution of 38/42 overlapped with the elution of 83/30, resulting 
in samples containing both halves in an unbound state. Hence, size exclusion chromatography was 
unsuitable to test whether the two halves had bound together and additional cross-linking experiments 
were performed (Figure 54). In these experiments, no interactions between the two processing fragments 
were found, indicating that the binding affinity between the P. falciparum and P. vivax MSP-1 halves is 
too low to form a hybrid complex. 
 
4.4. Structural characterisation 
4.4.1. Molecular weight determination 
Heterologous expression of P. vivax MSP-1 and its processing fragments was successful as described 
above. But especially the PfPv83/30, Pv30 and Pv38 protein migrate in SDS gels as if they had a higher 
molecular weight than calculated. P. vivax MSP-1 consists of 1751 amino acids and contains 73 prolines 
(4.2%), which are known as “helix breakers”. The cyclic side group of this amino acid restricts the 
structural flexibility and introduces kinks into the polypeptide backbone. As a consequence, the 
electrophoretic mobility of proteins consisting of many prolines is decreased (Hames, 1998). The most 
noticeable shift can be seen for Pv30. This MSP-1 fragment has an expected molecular weight of 31 kDa, 
but according to the SDS gel it is closer to the 60 kDa marker. As this is double the expected molecular 
weight, dimerization of Pv30 might also be a possible explanation. However, this is unlikely as such a 
dimer should have been disrupted by DTT in the sample buffer or guanidine hydrochloride, which is used 
to solubilise inclusion bodies (Figure 29). The Pv30 processing fragment consists of 287 amino acids and 
23 of those are prolines (8%), which are probably the cause for the decreased mobility in SDS gels. The 
P. falciparum MSP-1 protein as found in the 3D7 strain consists of 1720 amino acids and includes 
67 prolines. But these prolines are equally distributed throughout the protein and the percentage of proline 
is in the range of 3.8 to 4.3% in each of the processing fragments. This difference probably explains why 
P. falciparum MSP-1 based recombinant proteins do not show such an altered migration behaviour in 
SDS gels. 
As SDS-PAGE was obviously not a reliable method to determine the precise molecular weight of P. vivax 
MSP-1, a combination of size exclusion chromatography and sedimentation velocity analysis was used to 
calculate the molecular weight and check if the recombinant protein meets the expectations. The GMP 
product MSP-1D was used as a positive control for this method. Some companies sell molecular weight 
marker kits to analyse the molecular weight via size exclusion chromatography alone. However, results 
can vary a lot since the running behaviour during gel filtration is influenced by the hydrodynamic radius 
of the molecule and not the molecular weight directly. For P. vivax MSP-1, the result from the size 
exclusion chromatography alone would suggest a molecular weight of 400 kDa, indicating the formation 
of a heterotetramer instead of a heterodimer. Alternative ways to determine the molecular weight include 
analytical ultracentrifugation. A sedimentation equilibrium analysis can measure the molecular weight 
directly, but requires a lot of material. Combining size exclusion chromatography to determine the 
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hydrodynamic radius and a sedimentation velocity run to define the Svedberg coefficient was a more 
feasible approach.   
The Svedberg coefficient is defined as the ratio of a particle’s sedimentation velocity in response to 
centrifugal force and it is influenced by the molecular mass and geometrical shape of the molecule. The 
purity of MSP-1D was demonstrated in several individual tests as preparation for the clinical trial, which 
justified using it as a comparison for PvMSP-1. The sedimentation velocity run revealed three distinct 
populations in the PvMSP-1 sample of similar forms than those observed for MSP-1D. The first 
population most likely contains excess Pv38/42, which was not successfully removed during the protein 
purification following the original protocol. The second and main population contains the MSP-1 
complex in heterodimeric form and the third population probably consists of aggregated protein. All 
samples were centrifuged before analysis to remove aggregates, but residual or newly aggregated protein 
can still be detected during the sedimentation velocity run. However, the Svedberg coefficient for P. vivax 
MSP-1 is very close to the value for MSP-1, indicating correct complex formation.  
The molecular weight of P. vivax MSP-1 of 199 kDa was calculated using the determined values for the 
hydrodynamic radius (6.5 nm) and a Svedberg coefficient of 7.36 S. According to literature, PvMSP-1 has 
a molecular weight of 200 kDa. A value of 199 kDa for the recombinant protein matches this value since 
the GPI anchor signal sequence and signal peptide were removed. In addition to precisely determining the 
molecular weight, this analysis also shows that the recombinant P. vivax MSP-1 produced in this thesis 
forms a heterodimer and not a heterotetramer.  
 
4.4.2. Bioinformatic analysis 
Finding similarities between different Plasmodium species and strains was considered useful to evaluate 
whether the P. falciparum protein alone could be sufficient to induce cross-reactive immune responses or 
if it would be advisable to formulate a vaccine including MSP-1 from P. vivax or P. knowlesi as well. 
Three bioinformatic tools were combined to analyse MSP-1 sequences and to gather information 
biophysical and biochemical experiments could not provide at the time. A multiple sequence alignment 
combined with the predicted and successfully tested SUB1 processing sites highlighted the different lengths 
of MSP-1 processing fragments as described above. A protein blast using MSP-1 sequences of 
P. falciparum, P. vivax, P. knowlesi  and P. berghei and the generation of a phylogenetic tree based on 
MSP-1 alone revealed how similar some Plasmodium species are to each other. The phylogenetic tree was 
created using the neighbour-joining method and the Poisson method to calculate evolutionary distances 
(Zuckerkandl and Pauling, 1965; Saitou and Nei, 1987). The generated phylogenetic tree is in agreement 
with previously reviewed evolutionary data based on partial mitochondrial genomes (Carlton, Escalante, 
et al., 2008). P. knowlesi MSP-1 shows a higher similarity with P. vivax MSP-1 than with P. falciparum 
MSP-1, which can be seen as an indication that P. knowlesi and P. vivax MSP-1 have a higher chance of 
inducing cross-reactive antibodies than P. vivax and P. falciparum. This data also indicates an early split 
between parasite species infecting humans or monkeys and rodents. However, the overall sequence 
identity of P. berghei MSP-1 and the other Plasmodium species included in this analysis is between 
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34-38%, which is almost identical to the values estimated for P. vivax and P. falciparum (38-40%). 
P. vivax and P. knowlesi share a higher sequence similarity of 62-64%, meaning the chance of these two 
MSP-1 proteins sharing immunogenic epitopes is higher. Interestingly,  the two P. falciparum strains 3D7 
and FCB-1 also only share a sequence identity of 59%, whereas both P. vivax strains Belem and Salvador  I 
reached a value of 84%. Effective immune responses against multiple Plasmodium strains or species have 
to target epitopes found in more than one strain and chances of achieving this are higher if more than one 
MSP-1 protein is included in the vaccine. To elucidate this possible strategy, hybrid proteins consisting of 
P. falciparum and P. vivax as well as both P. falciparum strains were produced as recombinant proteins 
and were included in some structural studies in this project. Nevertheless, the sequence identity gives no 
information about structural epitopes and should never be considered as the only indicator of 
cross-reactive potential. 
 
4.4.3. Processing by SUB1 
The maturation of MSP-1 by SUB1 mediated cleavage is thought to induce conformational changes within 
the MSP-1 molecule leading to the exposure of interaction sites that are required to bind to other proteins. 
One example is the increased binding affinity of processed MSP-1 to spectrin, an interaction that leads to 
the disruption of the red blood cell membrane and egress of merozoites (Das et al., 2015). A sequence 
alignment and analysis of MSP-1 sequences from P. falciparum, P. vivax, P. knowlesi and P. berghei using 
the Prediction of Protease Specificity online tool (Boyd et al., 2005) and the published SUB1 model (de 
Monerri et al., 2011) revealed cleavage motifs in all of the analysed sequences. The exact position of these 
motifs within the amino acid sequence is not conserved though, resulting in processing fragments of 
varying length. This variation is the most striking between P. falciparum and P. berghei. The p30 fragment 
of P. berghei consists of 350 amino acids and is almost double as long as the one of P. falciparum MSP-1, 
which comprises 189 amino acids. Instead, the p42 fragment of P. falciparum is the longer one with 373 
amino acids compared to 185 amino acids of the P. berghei p42 protein. As a result of these varying 
lengths, some interaction sites responsible for MSP-1 complex formation or interaction with binding 
partners might be part of different processing fragments in each Plasmodium species. P. vivax and 
P. falciparum show less variation, but P. knowlesi also has an increased length of the p30 processing 
fragment (368 amino acids) without a simultaneously shortened p42 processing fragment. 
 
The recombinant MSP-1 proteins derived from P. vivax, P. knowlesi and P. berghei were incubated with 
recombinant P. falciparum SUB1 to test if the proteolytic processing is not only theoretically conserved 
and if the cleavage motifs are universal enough to be recognised by the P. falciparum protease. Samples 
were taken at specific time points to follow the processing in time. After 24 hours, all recombinant MSP-1 
proteins were cleaved into four fragments as shown in Figure 45. Obviously, this experiment does not 
represent the timeline of proteolytic processing in the parasite as the quantities of MSP-1 protein and 
PfSUB1 were not adjusted to the amount in the parasite. In case of P. knowlesi and P. vivax MSP-1, the 
C-terminal 38/42 half seems to be processed quicker than the 83/30 half, suggesting an increased 
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accessibility of the cleavage motif in that fragment. The P. berghei MSP-1 sample shows significant 
degradation of the 83/30 fragment after freezing and thawing the purified protein, making a similar 
observation difficult in this assay. However, the P. falciparum SUB1 protease was able to cleave all tested 
MSP-1 proteins, indicating a high conservatism of these motifs and the process itself.  
 
4.4.4. Secondary structure prediction and CD spectroscopy 
Whenever recombinant proteins are used for functional characterisation, the structural integrity has to be 
tested. Bioinformatic tools can predict the secondary structure and sometimes even model the 
three-dimensional structure if certain criteria, like commonly found motifs and a high level of structured 
regions, are met. The amino acid sequence of MSP-1 from the Plasmodium species P. falciparum, P. vivax, 
P. knowlesi and P. berghei were analysed using the JPred software, which predicts alpha-helical 
structures, beta-sheets and coil regions. 40% of the protein sequence were alpha-helical, but surprisingly, 
all analysed sequences contain large stretches of unpredicted sequences with at least 40 amino acids in 
length. Such disordered regions are characterised by low sequence complexity, low proportions of bulky 
hydrophobic amino acids (phenylalanine, tyrosine and tryptophan) and high proportions of charged and 
hydrophilic amino acids (arginine, histidine, lysine, aspartic acid and glutamic acid) (Wright and Dyson, 
2015). About a third of the amino acid composition of MSP-1 from all analysed Plasmodium species 
consists of charged and hydrophilic amino acids. Lysine is the most common charged and hydrophilic 
amino acid in MSP-1 and usually comprises about 10% of all amino acids found in the protein sequence.  
The locations of these presumable unstructured regions are similar albeit not identical when different 
Plasmodium species are compared. For instance, one unstructured region is found in the N-terminal p83 
region, two and, in case of P. knowlesi, even three of these regions are in the p30 fragment and another 
one occurs in p38 in all species. This pattern suggests a non-coincidental occurrence. The presence of 
unstructured domains challenges the central dogma of biology that function is closely linked to the 
three-dimensional structure of a protein. But these unstructured regions possess an enhanced flexibility 
and could form loops that include interaction sites for other proteins. For MSP-1 these sequences might 
function as docking sites for MSP-6, MSP-7 and MSPDBL-1 and MSPDBL-2. These proteins were 
previously shown to form a complex with MSP-1 (Kauth et al., 2006; Lin et al., 2014), but the precise 
interaction sites remain unknown. 
Protruding flexible loops could also harbour cleavage sites for proteases as these are typically found on 
the surface and have to be sterically accessible. The SUB1 cleavage site separating p83 and p30 and the 
one separating p30 and p38 overlaps with unpredicted domains in P. berghei MSP-1 and the SUB1 
cleavage motif causing the split between p30 and p38 in P. falciparum MSP-1 is also found in such an 
unstructured region. However, other cleavage sites are found in structured regions, suggesting that in 
general, these sites do not have to be exposed in form of an unstructured loop for productive proteolytic 
processing.  
The disordered domains could also change their conformation upon binding to an interaction partner. 
This mechanism is observed for some intrinsically disordered proteins involved in cell cycle control and 
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some disordered regions have been linked to biological functions, such as transcriptional activation 
domains (Wright and Dyson, 1999). Such an intrinsic plasticity could enable MSP-1 to recognise several 
biological targets without sacrificing specificity and be the base for the formation of various MSP-1 
complexes with different interaction partners as previously proposed (Lin et al., 2016). Induced folding 
events can also be a control mechanism that ensures the incorporation of individual components of a 
multiprotein complex in the correct order (Wright and Dyson, 1999). 
The amount of unstructured regions found in MSP-1 complicates the construction of a reliable 
three-dimensional model and could also pose problems for crystallography and cryo-electron microscopy. 
Unstructured or only partially structured proteins have an increased susceptibility to protease degradation 
(Wright and Dyson, 2015), which might be a contributing factor for the decreased stability of the 
N-terminal 83/30 MSP-1 half, as this part of the protein contains more and longer stretches of disordered 
regions. 
 
Circular dichroism (CD) spectroscopy is a commonly used biophysical method to analyse the secondary 
structure of a protein. In this project recombinant MSP-1 proteins were analysed by thermal denaturation, 
which includes recording a CD spectrum in certain intervals while the temperature increases from 10°C 
to 85°C. All tested MSP-1 proteins display the CD spectrum typical for a mostly alpha-helical secondary 
structure and melting temperatures range from 42.5 to 45.6°C with an average of 44°C. Interestingly, a 
hybrid protein consisting of the P. falciparum strains 3D7 and FCB-1 achieved a similar stability profile 
with a melting temperature of 42.9°C. This observed alpha-helical structure corresponds to the 
predictions made by the JPred software. However, this method cannot provide residue-specific 
information so no further analysis in regard to disordered domains is possible with CD spectroscopy. 
Recombinant MSP-1 proteins that were not processed by SUB1 were still partially folded at 85°C. 
MSP-1D, which was incubated with SUB1 and processed into four fragments was less stable and was 
mostly unfolded at temperatures >42°C. This suggests that the heterodimeric composition of recombinant 
MSP-1 stabilises the protein in addition to the disulphide bonds in the EGF-like domains at the 
C-terminus. Accordingly, heterologous production of MSP-1 based on two halves instead of four 
fragments is beneficial for stability and possibly also storage of the final product.  
In addition to CD spectroscopy, correct conformation of recombinant P. vivax MSP-1 was tested with 
sera from study participants in Brazil who were infected with P. vivax parasites. These sera were used in 
ELISA experiments to test if naturally acquired antibodies recognise the recombinant P. vivax MSP-1 
protein and its processing fragments. In this assay, previous observations made for P. falciparum 
processing fragments (Epp, 2003; Woehlbier et al., 2006) were confirmed for P. vivax: While all 
recombinant PvMSP-1 proteins were recognised, Pv30 and Pv38 are apparently less immunogenic as the 
sera had to be used at a higher concentration in ELISA experiments than when Pv83, Pv42 and the full 
length protein were tested. The available sera corresponded to two different time points. T1 was collected 
at the beginning of the study, T2 during an ongoing P. vivax infection. However, the T1 sample does not 
correspond to a naïve patient. Still, the T2 sample was expected to show an increased reaction to P. vivax 
MSP-1 proteins, but this was not the case in all samples. Some study participants had good antibody 
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responses at baseline with a decline during the infection. One possible explanation for this is that this 
subgroup has defective B cell responses, for example due to atypical B cells, during acute-phase infections. 
The absence of the expected boosting response might also be due to antigenic diversity if the recombinant 
antigen does not match the variant expressed by the infecting parasites. However, this effect would be 
more pronounced with the most polymorphic domains of PvMSP-1 and less evident for the whole antigen, 
which includes both conserved and polymorphous domains. Nevertheless, all recombinant P. vivax 
proteins were recognised by naturally acquired antibodies, indicating that the heterologous production 
process established in this thesis can be used to manufacture PvMSP-1 in its natural conformation. 
 
4.4.5. Cross-linking 
Cross-linking paired with mass spectrometry can provide peptide-specific information about intra- and 
intermolecular interactions. Binding interactions within the P. falciparum MSP-1 heterodimer were 
previously analysed by co-expression, co-renaturation or incubation of separately refolded processing 
fragments followed by affinity chromatography to determine which MSP-1 processing fragments are 
binding to each other. In these experiments, p30 was the only processing fragment which interacted with 
all other fragments. While this seems surprising at first since p30 is dimorphic in P. falciparum MSP-1 
and a protein forming the core of a complex is usually expected to be highly conserved, a closer look at 
the sequence reveals a middle grade of conservatism of block 9, which comprises 2/3 of p30 (Tanabe et 
al., 1987). P83 was shown to exclusively interact with p30 in these experiments and p38 and p42 interact 
with each other in addition to binding to p30. A close proximity of p38 and p42 was already suggested 
by another study, which identified a monoclonal antibody recognising a structural epitope formed by 
these two processing fragments (Lyon et al., 1987). These co-purification experiments can only provide a 
limited amount of information regarding interactions and binding of the processing fragments needs to 
be strong enough to allow co-purification using an isolation tag that is only present in one of the proteins. 
Hence, weak interactions were most likely missed and interactions which mask isolation tags could lead 
to a false-negative result. Cross-linking combined with mass spectrometry is a more precise and sensitive 
method to further elucidate and localise interactions among the MSP-1 processing fragments. Due to 
technical difficulties, the initially used BS3 cross-linker was substituted with DSSO, which is a cleavable 
cross-linker and facilitates data analysis due to its specific fractionation pattern. Most striking was the 
detection of an interaction between p83 and p42 in all MSP-1 heterodimers as this interaction was not 
found in previous experiments. Another change involved the p30 fragment, which seems to interact only 
with p83 and p38 but not with p42. Previous experiments already showed that p30 has a weaker affinity 
to p42 than p42 to p38 and p30 to p83 (Kauth et al., 2003). As the cross-linking experiments performed 
in this study used the full length MSP-1 protein, interactions of lower affinity might not be detected when 
binding sites of higher affinity are available. If these indications are taken into account, the MSP-1 model 
would change from the previously proposed asymmetric shape (Kauth et al., 2003) and form a more 
globular molecule (Figure 56).  
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Figure 56. Old and new model of MSP-1. Left: The previously published model with p30 forming the core of the MSP-1 
complex and p83 only binding to p30. This model was based on affinity chromatography-based experiments and 
suggested a more elongated, asymmetric form of the protein complex. Right: According to the cross-linking data, the 
MSP-1 model was changed to include the interactions of p83 with other processing fragments and p30 only binding to 
p83 and p38.  
The discrepancies between previous data and the cross-linking results might also be explained by the low 
sensitivity of the co-purification technique. Especially the p83 fragment of P. falciparum was difficult to 
use in the previous experiments as this protein was highly instable during co-expression in E. coli. As an 
alternative approach, p83 and a fusion protein of p38/42 were refolded separately before incubating them 
and continuing with the affinity chromatography step (Kauth et al., 2003), which could lead to different 
structural conformations as when both proteins are refolded together. The crosslinking experiments 
performed here use the MSP-1 heterodimer reconstituted from two halves, which can also result in some 
variation compared to experiments using a complex assembled from all four processing fragments.  
One major advantage of this cross-linking technique is the sequence specific information that allows the 
localisation of found interactions. The previously mentioned unstructured regions within MSP-1 could be 
involved in interactions within the MSP-1 protein or with other binding partners, such as MSP-6, MSP-7, 
MSP-3 or MSPDBL1 and MSPDBL2. A closer look at the found cross-links revealed that most interactions 
within the MSP-1 protein do not occur between unstructured regions, suggesting that these unstructured 
domains could be reserved for other interactions, while the structured regions are responsible for 
interactions within the protein and potentially stabilise its three-dimensional structure. The p30 
processing fragment contains most unstructured regions in all analysed MSP-1 proteins and according to 
previous experiments binds to MSP-7 (Kauth et al., 2006). However, further cross-linking experiments 
using suggested binding partners for MSP-1 are required to test this hypothesis. The usage of DSSO as a 
cross-linker will be beneficial for such studies as the fractionation pattern allows an easier distinction 
between interactions found within MSP-1 and MSP-1 and another protein.  
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4.5. Outlook 
The availability of recombinant full length P. vivax MSP-1 facilitates further immunological research on 
P. vivax, as long as access to P. vivax parasites or cohorts in P. vivax endemic areas is possible. In that 
sense, a collaboration with Dr. Sócrates Herrera, who has access to such cohorts in Columbia and offered 
to perform immunological assays, is planned.  
A long-term cell culture of P. vivax parasites is still not available, but some laboratories have made 
remarkable progress in short-term cultures and functional assays using P. vivax parasites. One of these 
assays is an ex vivo invasion inhibition assay (Russell et al., 2011; Cho et al., 2015) which could be used 
to test P. vivax MSP-1 antibodies for their invasion-blocking potential. Briefly, enriched cord blood 
reticulocytes are mixed with matured trypsin-treated P. vivax schizonts, which were isolated and 
concentrated from clinical isolates. Target reticulocytes are labelled with carboxyfluorescein succinimidyl 
ester (CFSE) to distinguish newly invaded reticulocytes from those of the initial inoculum. After 24 hours 
of incubation, the numbers of invaded reticulocytes are quantified by flow cytometry (Figure 57). 
Polyclonal antibodies against PvMSP-1 and its processing fragments were already generated in rabbits 
(data not shown) and IgGs were purified, ready to be used in this or similar assays.  
 
 
Figure 57. Scheme of the ex vivo invasion assay using P. vivax. P. vivax infected reticulocytes are enriched from 
clinical isolates and mixed with CFSE labelled target cells. After 24 hours of incubation, invaded CFSE+ reticulocytes are 
quantified by flow cytometry. Antibodies could be tested for their invasion-blocking potential by adding them when the 
inoculum and target cells are mixed. The graphic above is based on the scheme published by Cho et al., 2015. 
The cross-linking data presented here already includes new insights compared to previous 
immunoaffinity-based experiments, but only looked at interactions within the MSP-1 protein so far. The 
next logical step is to generate complexes of MSP-1 and its known binding partners MSP-6, MSP-7, 
MSPDBL-1 and MSPDBL-2, and cross-link them with DSSO. The advantage of this cross-linker compared 
to BS3 is the distinct fragmentation pattern for inter- and intramolecular cross-links (Kao et al., 2011), 
which allows to easily identify interactions between MSP-1 and a binding partner. The peptide-specific 
information could be used to further optimise the MSP-1 model and localise the exact interaction sites. 
This information could be used to design drugs or vaccines that inhibit MSP-1 complex formation with 
MSP-6 or MSPDBL proteins and prevent MSP-1 complex-mediated attachment of the parasite to red 
blood cells. 
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The best way to obtain structural information about MSP-1 would be to obtain a three-dimensional 
structure. Attempts to crystallise MSP-1 have failed in our laboratory, most likely because of the presence 
of unstructured regions in the protein and the associated flexibility. Cryo-electron microscopy (Cryo-EM) 
is another promising technology to obtain three-dimensional structures and a collaboration with Dr. 
Kudryashev at the Max Planck Institute in Frankfurt is currently ongoing. Current efforts concentrate on 
MSP-1D as this protein is available as a GMP product, offering the highest purity. Nonetheless, using the 
protein on its own was less successful and preliminary data revealed a preferential orientation, which 
makes the rendering of a three-dimensional structure difficult. Recent efforts include the formation of a 
complex of MSP1-D and a Fab fragment of the monoclonal antibody 5.2, which binds to a conformational 
epitope in one of the EGF-like domains at the C-terminus. For one, this further increases the size of the 
molecule and also facilitates analysing the data as previously published structural information of the p19 
fragment (Pizarro et al., 2003) can be used as a starting point. However, the large stretches of unstructured 
regions could limit the resolution of the cryo-EM structure. Another approach would be to express MSP-1 
with the GPI anchor signal sequence and signal peptide in a mammalian cell line to study membrane-
bound MSP-1.  
Overall, this study provides new structural information about MSP-1 from various Plasmodium species 
and the established protein production processes can be used to obtain sufficient amounts of P. vivax 
MSP-1 for further functional and immunological studies.  
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6. Appendix 
6.1. Multiple sequence alignment 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
        signal peptide 
falciparum_FCB-1      MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGT 60 
falciparum_3D7        MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEEEITT 60 
berghei_ANKA          MKVIGLLFSFVFFAIKCKSETIEVYNDIIQKLEKLESLSVEGLELFQKSQVIINASPP-- 58 
knowlesi              MKALLFLFSLIFFVTKCQCET-EDYKQLLVKLDKLEGLVVDGYELFHKNKISLDNIDAVQ 59 
vivax_Sal1            MKALLFLFSFIFFVTKCQCET-ESYKQLVAKLDKLEALVVDGYELFHKKKLGENDIKVET 59 
vivax_Belem           MKALLFLFSFIFFVTKCQCET-ESYKQLVAKLDKLEALVVDGYELFHKKKLGENDIKVDA 59 
                      ** : :* *::**  : :. * * *:::: **: **   : * .**:*.::  :       
 
falciparum_FCB-1      AVTTSTPGSKG-SVASGGSGGSVASGGSVASGGSVASGGSVASGGSG------------- 106 
falciparum_3D7        KGASAQSGASAQSGASAQSGASAQSGASAQSGASAQSGTSGPSGPSGTSPSSRSNTLPRS 120 
berghei_ANKA          ---S-------------------------------------------------------- 59 
knowlesi              ------------------------------------------------------------ 59 
vivax_Sal1            NASA-------------------------------------------------------- 63 
vivax_Belem           N--A-------------------------------------------------------- 61 
                                                                                   
 
falciparum_FCB-1      -NSRRTNPSDNSSDSDAKSYADLKHRVRNYLLTIKELKYPQLFDLTNHMLTLCDNIHGFK 165 
falciparum_3D7        NTSSGASPPADASDSDAKSYADLKHRVRNYLFTIKELKYPELFDLTNHMLTLCDNIHGFK 180 
berghei_ANKA          ------------ETINPFSDNTFAPKLQGFITKFEELGFTEQTELVNLIKTLVPNKYGLK 107 
knowlesi              -------------NIDGNNVNALAYKIRDIVGKYLELQIPGHGNLLHMIRELALDANGLK 106 
vivax_Sal1            ------------NNNNNNQVSVLTSKIRNFLSKFLELQIPGHTDLLHLIRELAVEPNGIK 111 
vivax_Belem           ------------NNNNNNQVSVLTSKIRNFVGKFLELQIPGHTDLLHLIRELAFEPNGIK 109 
                                     :  .   :  :::. : .  **      :* : :  *  :  *:* 
 
falciparum_FCB-1      YLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYR 225 
falciparum_3D7        YLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYR 240 
berghei_ANKA          YLIESKEEFNGLMHAINFYYDVFRDKLNDMCANNYCEIPEHLKISEEETEMLKKVILGYR 167 
knowlesi              YLVENYEEFNQLMHVINFNYDLLRAKLNDMCAHEYCKIPEHLKISAKELDMLKKVVLGYR 166 
vivax_Sal1            YLVESYEEFNQLMHVINFHYDLLRAKLHDMCAHDYCKIPEHLKISDKELDMLKKVVLGYR 171 
vivax_Belem           YLVESYEEFNQLMHVINFHYDLLRAKLHDMCAHDYCKIPEHLKISDKELDMLKKVVLGYR 169 
                      **::. **:* *:: :** :*::* **:*:**::**:** :***  :* ::***:::*** 
 
falciparum_FCB-1      KPLDNIKDNVGKMEDYIKKNKKTIENINELIEESKKTIDKNK------------------ 267 
falciparum_3D7        KPLDNIKDNVGKMEDYIKKNKTTIANINELIEGSKKTIDQNK------------------ 282 
berghei_ANKA          KPIENIQDDIEKLEIYITKNKETVTALNTLIAEETKKITPENEAD--------------- 212 
knowlesi              KPLDNIKDDIGKMEAFINKNKETINNINQLITAENAKIVGHPINGVNVTGASSDAVA--- 223 
vivax_Sal1            KPLDNIKDDIGKLETFITKNKITIKNISDLIIAENKKRSGHPTTTTNGAGTQPANGSIAA 231 
vivax_Belem           KPLDNIKDDIGKLETFITKNKETISNINKLISDENAKRGGQSTNTTNGTGAQNNAAQ--- 226 
                      **::**:*:: *:* :*.*** *:  :. **  .. .   .                    
 
falciparum_FCB-1      ---------------------------------------------------NATKEEEKK 276 
falciparum_3D7        ---------------------------------------------------NADNEEGKK 291 
berghei_ANKA          ---------------------------------------------CNDNTCDESKYSKKK 227 
knowlesi              -----------------NTGTPVAA----AAGAAAAAVPGAIASPSPVESSTPENYDQKK 262 
vivax_Sal1            ASSETTQISGSSNSGSSSTGSSNSGSSSTGSSGTGSTGTGQSPPAAADASSTNANYEAKK 291 
vivax_Belem           -----------GSTGNTETGTRSSASSNTLSGGDGTTVVGTSSPAPAAPSSTNEDYDEKK 275 
                                                                            . . ** 
 
falciparum_FCB-1      KLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKELLDKINEIKNPPPANSGNT 336 
falciparum_3D7        KLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKKLLDKINEIKNPPPANSGNT 351 
berghei_ANKA          IIYQAMYNVIFYKKQLAEIQKVIETLEKRVSALKKNDVIKPLLQQIEDIKAAPVTTEGQI 287 
knowlesi              VIFQAIYNFIFYTNQLEEAQKLMQVLEKRVKLLKEHKSIKALLEQIATEKNNLTTNNA-- 320 
vivax_Sal1            IIYQAVYNTIFYTNQLQEAQKLIAVLEKRVKVLKEHKDIKVLLEQVAKEKEKLPSDYP-- 349 
vivax_Belem           KIYQAMYNGIFYTSQLEEAQKLIEVLEKRVKVLKEHKGIKALLEQVEAEKKKLPKDNT-- 333 
                       ::** *:  :*..** * :::: .****:. **::. ** **:::   *           
 
falciparum_FCB-1      ------------------------------------------------------------ 336 
falciparum_3D7        ------------------------------------------------------------ 351 
berghei_ANKA          TTSGQSSTEPASTGTPSSGEVSTGTSTGGASAGVTNTGAATTGTTGTGAATTGTTGAEAV 347 
knowlesi              ------------------------------------------------------------ 320 
vivax_Sal1            ------------------------------------------------------------ 349 
vivax_Belem           ------------------------------------------------------------ 333 
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falciparum_FCB-1      --------------------------PNTLLDKNKKIEEHEKEIKEIAKTIKFNIDSLFT 370 
falciparum_3D7        --------------------------PNTLLDKNKKIEEHEEKIKEIAKTIKFNIDSLFT 385 
berghei_ANKA          TTGNTGAEAATTGNTNTEVTQVQTVPTLTPEEKKKKMDGLYAQIKEIAKTIKFNLDGIFV 407 
knowlesi              --------------------TTGGATTI-PEEVQKKIADLEKQIVAIAKTVNFDMDGLFT 359 
vivax_Sal1            --------------------NTTNLTNV-HKEAESKIAELEKKIEAIAKTVNFDLDGLFT 388 
vivax_Belem           --------------------TNTPLTDEQQKAAQKKIADLESQIVANAKTVNFDLDGLFT 373 
                                                       :.*:     :*   ***::*::*.:*. 
 
falciparum_FCB-1      DPLELEYYLREKNKNIDIS------AKVETKE---STEPNEYPNGVTYPLSYNDINNAL- 420 
falciparum_3D7        DPLELEYYLREKNKKVDVT------PKSQDPTKSVQIPKVPYPNGIVYPLPLTDIHNSLA 439 
berghei_ANKA          NPIELEYFKKEKKKESCNLSTSS--CKKNKTSETIIPLNVRYPNGIGYPLPENDVYNKIA 465 
knowlesi              NVEELEYYLREKAKMAGTLIGPESSQSTGTPGKAVPTLKETYPYGITYALPERTIYELIE 419 
vivax_Sal1            DAEELEYYLREKAKMAGTLIIPESTKSAGTPGKTVPTLKETYPHGISYALAENSIYELIE 448 
vivax_Belem           DAEELEYYLREKAKMAGTLIIPESTKSAGTPGKTVPTLKETYPHGISYALAENSIYELIE 433 
                      :  ****: :** *            .              ** *: * *    : : :  
 
falciparum_FCB-1      --NELNSFGDLINPFDYTKEPSKNIYTDNERKKFINEIKEKIKIEKKKIESDKKSYEDRS 478 
falciparum_3D7        ADNDKNSYGDLMNPHTKEKINEKIITDNKERKIFINNIKKKIDLEEKNINHTKEQNKKLL 499 
berghei_ANKA          NNAAETTYGDLTNPDNTPI-TEDLATNEQARKNLIKAIKKKIEAEEKNLESLKTNYDNKL 524 
knowlesi              KFGSEESFGDLQNPDNGRQPNKGIIINETKRKTLVDKIMSKIKLEEEKLPKLKKEYDEKM 479 
vivax_Sal1            KIGSDETFGDLQNPDDGKQPKKGILINETKRKELLEKIMNKIKIEEDKLPNLKKEYEEKY 508 
vivax_Belem           KIGSDETFGDLQNPDDGKQPKKGILINETKRKELLEKIMNKIKIEEDKLPNLKKEYEEKY 493 
                            ::*** **       .     :  ** ::. * .**. *:.::   * . ..   
 
falciparum_FCB-1      KSLNDITKEYEKLLNEIYDSKFNNNIDLTNFEKMMGKRYSYKVEKLTHHNTFASYENSKH 538 
falciparum_3D7        EDYEKSKKDYEELLEKFYEMKFNNNFNKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVY 559 
berghei_ANKA          ASFNQQKAPFKEAAKLFYESKFGNKLTSDIFEKFKTQRTEYMNKKTELEN--CLYGNTKQ 582 
knowlesi              EQYKQKVQDFLPTLKYFYEGKLDNTLVGSKFDEFKNKREAYMKEKEELEK--CTYEQSIN 537 
vivax_Sal1            KVYEAKVNEFKPAFNHFYEARLDNTLVENKFDDFKKKREAYMEEKKKLES--CSYEQNSN 566 
vivax_Belem           KVYEAKVNEFKPAFNHFYEARLDNTLVENKFDEFKTKREAYMEEKKKLES--CSYEQNTN 551 
                         :     :    : :*: ::.*.:    .:.:   *  *  :*   ..  .   :.   
 
falciparum_FCB-1      NLEKLTKALKYMEDYSLRNIVVEKELKYYKNLISKIENEIETLVENIKKDEEQLFEKKIT 598 
falciparum_3D7        NVQKLKKALSYLEDYSLRKGISEKDFNHYYTLKTGLEADIKKLTEEIKSSENKILEKNFK 619 
berghei_ANKA          LISKLNKQLNYLQDYSLRKDIISDEIEYFSNKKKGLQYNINRLAEAVQAKQNILVA---- 638 
knowlesi              LINKLKKQLTYLVDYTLKKDVTEDEINYFSDLEWKLKNEIYELAKEVRKNENKLIM---- 593 
vivax_Sal1            LINKLKKQLTYLEDYVLRKDIADDEIKHFSFMEWKLKSEIYDLAQEIRKNENKLTI---- 622 
vivax_Belem           LINKLKKQLTYLEDYVLRKDIADDEIKHFSFMEWKLKSEIYDLAQEIRKNENKLTV---- 607 
                       :.**.* *.*: ** *:: : ..:::::      :: :*  *.: :: .:: :       
 
falciparum_FCB-1      KDENKPDEKILEVSDIVKVQVQKVLLMNKIDELKKTQLILKNVELKHNIHVPNSYKQENK 658 
falciparum_3D7        G-LTHSANGSLEVSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNK 678 
berghei_ANKA          -------SKDVPLSTLVELQIQKSLLTKQIEQLNKTELSLRKAQLKDKVYVPKSYGNGGK 691 
knowlesi              -------ENKFDFSGVLELQIHKVLMIKKIGALKNVQNLLKNAKLKDKLYIPKVYKTGQK 646 
vivax_Sal1            -------ENKFDFSGVVELQVQKVLIIKKIEALKNVQNLLKNAKVKDDLYIPKVYKTSEK 675 
vivax_Belem           -------ENKFDFSGVVELQVQKVLIIKKIEALKNVQNLLKNAKVKDDLYVPKVYKTGEK 660 
                             .  . .* ::::*::* *: ::*  *.: :  *::.::*..:::*: *    * 
 
          83/30 
falciparum_FCB-1      QEPYYLIVLKKEIDKLKVFMPKVESLINEEKKNIKT-------EGQSDN--SEPSTEGEI 709 
falciparum_3D7        PEPYYLIVLKKEVDKLKEFIPKVKDMLKKEQAVLSS-------ITQPLVAASETTEDGGH 731 
berghei_ANKA          PEPYYLIAVKREVDRLAQFIPKIENMIAKEKEKTEQVPV---VT-----GESEETSSVST 743 
knowlesi              PEPYYLIVLKKEIDKLKDFIPKIETMIATEKAKAPTEP--VKVRAQSLRGASETAPSEPP 704 
vivax_Sal1            PEPYYLMVLKREIDKLKDFIPKIESMIATEKNKPTVAAADIVAKGQSLRGASETGTTGNT 735 
vivax_Belem           PEPYYLMVLKREIDKLKDFIPKIESMIATEKAKPAASA--PVTSGQLLRGSSEAATEVTT 718 
                       *****:.:*:*:*:*  *:**:: ::  *:                    **        
 
falciparum_FCB-1      ---------TGQATTKPGQQ-----------------------AGSAL--EG-DSVQAQA 734 
falciparum_3D7        ---------STHTLSQSGET-----------------------EVTEETEETEETVGHTT 759 
berghei_ANKA          EV-------SVQASSQSGTSSTVPAAGATSPT------------VTPVTEEAQ-SSQNAP 783 
knowlesi              TATESGSTTSASTAVQQPTQQAAQAAQAASPVTVTQPTETVTQTPAPATETAGEAAQETS 764 
vivax_Sal1            --------VNAQTAVVQPQHQVVNA------VTV-QPGTTGHQA------QGGEAETQTN 774 
vivax_Belem           --------NAV-TSEVQQQQQQ-------------------QQQ------QQQQQQQQQQ 744 
                                  :                                                
 
falciparum_FCB-1      QEQKQ---------------------------------------AQP---------PVPV 746 
falciparum_3D7        TVTIT---------------------------------------LPP---------TQPS 771 
berghei_ANKA          PTTAATP---------------------------ATTPEAA------------TTAATPA 804 
knowlesi              PVSPTAPAVVSEAGTEGGEGTTEVVAQPEAASGETQTPTPGAVDASPAAPVPAGTPGTTD 824 
vivax_Sal1            --SVQA---------------AQVQQTPAGAGGQVAS----------------TQTISQA 801 
vivax_Belem           --QQQQ---------------SQVVPAPAGDAQQVIS----------------TQPTSQS 771 
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falciparum_FCB-1      PVPEAKA--------QVPTPPAPVNNKTENVSKLDYLEKLYEFLNTSYICHKYILVSHST 798 
falciparum_3D7        PPKEVKV--------VENSIEHKSNDNSQALTKTVYLKKLDEFLTKSYICHKYILVSNSS 823 
berghei_ANKA          TTPEA----ATTSTTTSTTTSTTTSTTTPVMTKLYYLEKLQKFLVFSYSCHKYLLLQNST 860 
knowlesi              AAPEASVPAPAGSALPATTAPAAAAPAAPAMSKLEYLEKLLEFLKSSYACHKHIFLTNST 884 
vivax_Sal1            PAPTQASPEPAPA--APPSTPAAAVAPAPTMSKLEYLEKLLDFLKSAYACHKHIFVTNST 859 
vivax_Belem           AAPG------VSA--TPAPTPAAAAAPAPAMSKLEYLEKLLDFLKSAYACHKHIFVTNST 823 
                                                 :  ::*  **:** .**  :* ***:::: :*: 
 
falciparum_FCB-1      MNEKILKQYKITKEEESK--LSSCDPLDLLFNIQNNIPVMYSMFDSLNNSLSQLFMEIYE 856 
falciparum_3D7        MDQKLLEVYNLTPEEENE--LKSCDPLDLLFNIQNNIPAMYSLYDSMNNDLQHLFFELYQ 881 
berghei_ANKA          INKDALSKYALTTEEDKIRTLKRCSELDILLAIQNNMPTMYSLYESIVDGLQNIYAELYE 920 
knowlesi              MNPELLKQYALTTDEEKKIKESACDELDLLFNVQNNLPSMYSIYDTMINDLQNLYIELYQ 944 
vivax_Sal1            MKKELLDQYKLNADEQNKINETKCDELDLLFNVQNNLPAMYSIYDSMSNELQNLYIELYQ 919 
vivax_Belem           MDKKLLKEYELNADEKTKINQNKCDELDLLFNVQNNLPAMYSIYDSMSNELQNLYIELYQ 883 
                      :. . *. * :. :*..    . *. **:*: :***:* ***::::: : *.::: *:*: 
 
falciparum_FCB-1      KEMVCNLYKLKDNDK-IKNLLEEAKKVSTSVKTLSSSSMQP-----------LSL----- 899 
falciparum_3D7        KEMIYYLHKLKEENH-IKKLLEEQKQITGTSSTSSPGNTTV-----------NTA----- 924 
berghei_ANKA          KEMMYHIYKLKDENPSIKSILVKAGVIDPEP--VASPPTPPTPPTPPTPPTPPTLPTTPT 978 
knowlesi              KEMVYNIYKNKDTDTKIKAFLETLKSNAASVTPAVVPAAAP--VVTPAPAEPVV---TPA 999 
vivax_Sal1            KEMVYNIYKNKDTDKKIKAFLETLKSKAAAPAQSAA---------------------KP- 957 
vivax_Belem           KEMVYNIYKNKDTDKKIKAFLETSNNKAAAPAQSAA---------------------KP- 921 
                      ***:  ::* *: :  ** :*                                        
 
falciparum_FCB-1      --T--------------------PQ----------------DKPEV-SA--------NDD 912 
falciparum_3D7        --QSATHSNSQNQQSNA--SSTNTQN----------GVAVSSGPAVVEE--------SHD 962 
berghei_ANKA          PVTPAAPS-EQTTTPEAATAASNPGASASETPASNPGASASSTPSTPAAASNPGASASST 1037 
knowlesi              P-----AP-GQA-APAAAPTTTNPST--------TPSGT---------------TTNAVS 1029 
vivax_Sal1            -------S-GQA-GTTP-VTTT------------APVTT--------------------- 974 
vivax_Belem           -------S-GQA-GTTP-VTTT------------APVTT--------------------- 938 
                                                                                   
          30/38 
falciparum_FCB-1      TSHSTNLNNSL-------------------------KLFENILSLGKNKNIYQ-ELIGQK 946 
falciparum_3D7        PLTVLSISNDL-------------------------KGIVSLLNLGNKTKVPNPLTISTT 997 
berghei_ANKA          PSTASNPSAPASSTVQPTQVQPAAPAAPAAVPAQPANSNGSITTRAE---SEEDIPADDF 1094 
knowlesi              PTTAVTPGAQDT-TQ-------------TTTQDTTVTEEGGVTVQAS---SEEEPETNIV 1072 
vivax_Sal1            --TTVTPSPQTS-VV-------------TSTP-PTPQAEENRRVGGN---SEEKPEADTA 1014 
vivax_Belem           --TTVTPSPQTS-VV-------------TSTP-PTPQAEENQRVGGN---SEEKPEADTA 978 
                           . .                                .    ..     :    .   
 
falciparum_FCB-1      SSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFD 1006 
falciparum_3D7        EMEKFYENILKNNDTYFNDDIKQFVKSNSKVITGLTE-TQKNALNDEIKKLKDTLQLSFD 1056 
berghei_ANKA          ELDNLYKSYLQRIDG-NNTEFINFIKSKKELIKALTP-EKVNQLYLEIAHLKELSEHYYD 1152 
knowlesi              NVEKIYEKHLSQMDK-YNDYFIKFLESQKEKITSMTE-EQANALGAEIEALKKKVQVSLD 1130 
vivax_Sal1            QVEKFYEKHLSQIDK-YNDYFQKFLESQKDEITKMDE-TKWKALGAEIEELKKKLQVSLD 1072 
vivax_Belem           QVEKFYEKHLSQIDK-YNDYFKKFLESKKEEIIKMDD-TKWNALGKEIEELKKKLQVSLD 1036 
                      . :::*:. *.  *   *  : :*::*: . *  :    : : *  :*  **.  :   * 
 
falciparum_FCB-1      LYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKK 1066 
falciparum_3D7        LYNKYKLKLDRLFNKKKELGQDKMQIKKLTLLKEQLESKLNSLNNPHNVLQNFSVFFNKK 1116 
berghei_ANKA          RYYKYKLKLERLYEKHEQIQVSNRQIRELSILKARLLKRKQNINGIFYILSGYVNFFNKR 1212 
knowlesi              HYGKYKLKLERFLEKKNKISNSKEHIKKLTSLKNKLERKLNFLNNPTSVLKNYIIFFNKK 1190 
vivax_Sal1            HYGKYKLKLERLLKKKNKISNSKDQIKKLTSLKNKLERRQNLLNNPTSVLKNYTAFFNKK 1132 
vivax_Belem           HYGKYKLKLERFLKKKNKISNSKDQIKKLTSLKNKLERRQNLLNNPTSVLKNYTAFFNKK 1096 
                       * ******:*: .*:: :   : :*::*: ** :*  : : :*.   :*..:  ****: 
 
falciparum_FCB-1      KEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLS 1126 
falciparum_3D7        KEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLS 1176 
berghei_ANKA          READKQYVDNALKNNDMLLKYYKARIKYFTSEAVPLKTLTKASLDRETNYLKIEKFRAYS 1272 
knowlesi              KEAEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESLQKEDNYLNLEKFRVLS 1250 
vivax_Sal1            RETEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESMQKEDNYLNLEKFRVLS 1192 
vivax_Belem           RETEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESMQKEDNYLNLEKFRVLS 1156 
                      :*::   .:*:*:*..:***:**.  **: .*  *****:: *:: * ** .:*:*:. * 
 
falciparum_FCB-1      KLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYK 1186 
falciparum_3D7        KIDGKLNDNLHLGKKKLSFLSSGLHHLITELKEVIKNKNYTGNSPSENNKKVNEALKSYE 1236 
berghei_ANKA          RLELRFKKNINLGKEKISYVSGGLYHVFEEFKELLKNKNYTGKTNPDTVPEVTNAFEQYK 1332 
knowlesi              RMEGRLGNNINLEKENISYLSSGLHHVFTELKEIIKNKKYTGNDHAKNTTAVKEALQAYE 1310 
vivax_Sal1            RLEGRLGKNIELEKENISYLSSGLHHVLTELKEIIKNKKYSGNDHTKNIAAVKEALQAYQ 1252 
vivax_Belem           RLEGRLGKNIELEKENISYLSSGLLHVLTELKEIINDKKYSGKDHAKNIAEVKKALQAYQ 1216 
                      ::: :: .*:.* *:::*::*.** *:: *:**::::*:*:*:   ..   *.:*:: *: 
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falciparum_FCB-1      KFLPEGTDVATVV-----SE--------------------------------SGSDTLEQ 1209 
falciparum_3D7        NFLPEAKVTTVVT-----PP--QPDVTPSP-----------------LSVRVSGSSGSTK 1272 
berghei_ANKA          ELLPKGVTASASPAAATTPT-SADAATQRATP---------------ESRSGSGSG---- 1372 
knowlesi              ELLPKVATQTASL-----PPVAPPAVVPPVVPEAEAEAEAEAEAEPATSTQPATADTAAP 1365 
vivax_Sal1            ELIPKVTTQEGASTTAATLPVTVPSAVPGGLPGAGVPGAA--------------AGLTPP 1298 
vivax_Belem           ELIPKVTSQESTSVA-----VTVPGAVVPGVPTAAAAGSGASGAVPPAAAAGSGASGAVP 1271 
                      :::*:                                                 :.     
 
falciparum_FCB-1      S-QPK---------------------KPASTHVGAESNTITTSQNVDDEVDDVIIVPIFG 1247 
falciparum_3D7        E-ETQ---------------------IPTSGSLLTELQQVVQLQNYDEEDDSLVVLPIFG 1310 
berghei_ANKA          --------------------SGSVV--SSTPEEVA---------RSGSGEN----AVVSG 1397 
knowlesi              TQTPAAPTQTPAEPATATATTGETAAAPAAPAPVEVQNAEVKAQEYGEDYDKVITLPLFG 1425 
vivax_Sal1            ---PP---AGSVPATGPGAAA-----------GSTEENVAAKAQDYAEDYDKVIALPLFG 1341 
vivax_Belem           ---PA---GGPSPPATGGVVP--------GVVESAEAQTKAQAQDYAEDYDKVIALPLFG 1317 
                                                                     .  :      : * 
 
        38/42 
falciparum_FCB-1      ESEEDY--DDLGQVVTGEAVTPSVIDNILSKIENEYEVLYLKPLAGVYRSLKKQLENNVM 1305 
falciparum_3D7        ESEDND--EYLDQVVTGEAISV-TMDNILSGFENEYDVIYLKPLAGVYRSLKKQIEKNIF 1367 
berghei_ANKA          SSVDDNDDDDIDQIASGQSENA-QEKNILEAFKNESEYLYARSLGITYKSLKKHMIREFS 1456 
knowlesi              NDEDDVEDQEEKQIITGEAENA-QPENIVPEGINEYEVVYIKPLAGMYKSIKKQLENHVA 1484 
vivax_Sal1            NNDDDG---EEDQVTTGEAESE-APEILVPAGISDYDVVYLKPLAGMYKTIKKQLENHVN 1397 
vivax_Belem           NNDDDG---EEDQVTTGEAESE-APEILVPAGISDYDVVYLKPLAGMYKTIKKQLENHVN 1373 
                      .. ::       *: :*:: .    . ::    .: : :* : *.  *:::**:: ...  
 
falciparum_FCB-1      TFNVNVKDILNSRFNKRENFKNVLESDLIPYKDLTSSNYVVKDPYKFLNKEKRDKFLSSY 1365 
falciparum_3D7        TFNLNLNDILNSRLKKRKYFLDVLESDLMQFKHISSNEYIIEDSFKLLNSEQKNTLLKSY 1427 
berghei_ANKA          TIKEDMTTGLNNKLQKRNDFLEVLNHELDLFKDLSTNKYVIRNPYQLLDNDKKDKQIVNL 1516 
knowlesi              AFNTNITDMLDSRLKKRNYFLDVLDSELNPFKYSSSGEYIIKDPYKLLDLEQKKKLLGSY 1544 
vivax_Sal1            AFNTNITDMLDSRLKKRNYFLEVLNSDLNPFKYSSSGEYIIKDPYKLLDLEKKKKLIGSY 1457 
vivax_Belem           AFNTNITDMLDSRLKKRNYFLEVLNSDLNPFKYSPSGEYIIKDPYKLLDLEKKKKLLGSY 1433 
                      ::: ::.  *:.:::**: * :**: :*  :*   :.:*::.: :::*: :::.. : .  
 
falciparum_FCB-1      NYIKDSIDTDINFANDVLGYYKILSEKYKSDLDSIKKYIND------------------- 1406 
falciparum_3D7        KYIKESVENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEKEKFPSSPP--------- 1478 
berghei_ANKA          KYAAKGVNEDIETTADGIKFFNKMIELYKIQLAAVKEQIDAIEAATT------------- 1563 
knowlesi              QYIGASVDKDLITAKDGMEYYNKMGELYKQHLEAVNAQIKEIEASVPGEQ---------- 1594 
vivax_Sal1            KYIGASIDMDLATANDGVTYYNKMGELYKTHLDGVKTEIKKVEDDIKKQDEELKKLGNVN 1517 
vivax_Belem           KYIGASIDKDLATANDGVTYYNKMGELYKTHLTAVNEEVKKVEADIKAEDDKIKKIGSDS 1493 
                      :*   .:: *:  : : : ::: :   ** .* .::  :.                     
 
falciparum_FCB-1      -----------KQGENEKYLPFLNNIETLYKTVNDKIDLFVIHLEAKVLNYTYEKSNVEV 1455 
falciparum_3D7        -TTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHV 1537 
berghei_ANKA          -----------DKDEKKKYVPIFEDLKGLYETILGQSEEYIEVLQNRLDSYKNEKTEFEI 1612 
knowlesi              ------SQLNAQKEELKKYLPFLNSIQKEYESLVNMAHTYKENLKKFINNCQIEKKETEI 1648 
vivax_Sal1            SQDSKKNEFIAKKAELEKYLPFLNSLQKEYESLVSKVNTYTDNLKKVINNCQLEKKEAEI 1577 
vivax_Belem           TKTTEKTQSMAKKAELEKYLPFLNSLQKEYESLVSKVNTYTDNLKKVINNCQLEKKEAEI 1553 
                                 .: : .*::*:: .::  *:.: .  . :   *:  : .   ** : .: 
 
falciparum_FCB-1      KIKELNYLKTIQDKLADFKKNNNFVGIADLSTDYNHNNLLTKFLSTGMVFENLAKTVLSN 1515 
falciparum_3D7        KITKLSDLKAIDDKIDLFKNPYDFEAIKKLINDDTKKDMLGKLLSTGLV-QNFPNTIISK 1596 
berghei_ANKA          LTKNLETYIKIDEKLENFVENAEN-------NKHIASIALNNLNKSGLVGEGESKKILAK 1665 
knowlesi              IVKKLEDYTKIDENLEIYKKSKKE-------SDVRSSGLLEKLKNSKLINEEESKKVLSQ 1701 
vivax_Sal1            TVKKLQDYNKMDEKLEEYKKSEKK-------NEVKSSGLLEKLMKSKLIKENESKEILSQ 1630 
vivax_Belem           TVKKLQDYNKMDEKLEEYKKSEKK-------NEVKSSGLLEKLMKSKLIKENESKEILSQ 1606 
                        .:*.    :::::  : :  .        ..   .  * :: .: :: :   : :::: 
 
falciparum_FCB-1      LLDGNLQGMLNIS-QHQCVKK-QCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT 1573 
falciparum_3D7        LIEGKFQDMLNIS-QHQCVKK-QCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT 1654 
berghei_ANKA          MLNMDSMDLLGIDPKHVCINTRDIPANAGCFRYDNGNEEWRCLLGYKKNNNTCIEDSNPT 1725 
knowlesi              LLNVQT-QMLNMSSAHKCIDT-NVPENAACYRYLDGTEEWRCLLGFKEVGGKCVPAS-IT 1758 
vivax_Sal1            LLNVQT-QLLTMSSEHTCIDT-NVPDNAACYRYLDGTEEWRCLLTFKEEGGKCVPASNVT 1688 
vivax_Belem           LLNVQT-QLLTMSSEHTCIDT-NVPDNAACYRYLDGTEEWRCLLTFKEEGGKCVPASNVT 1664 
                      ::: .   :* :.  * *:.. : * *:.*:*: :  ** :*** :*: ...*:     * 
 
          GPI anchor signal sequence 
falciparum_FCB-1      CNENNGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILML 1633 
falciparum_3D7        CNENNGGCDADATCTEEDSGSSRKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILML 1714 
berghei_ANKA          CGNNNGGCDPTAGCQTAENRENSKKIICTCKEPTPNAYYDGVFCSSSSFMGLSILLIITL 1785 
knowlesi              CEENNGGCAPEAECTMD----DKKEVECKCTKEGSEPLFEGVFCSSSSFLSLSFLLLILI 1814 
vivax_Sal1            CKDNNGGCAPEAECKMT----DSNKIVCKCTKEGSEPLFEGVFCSSSSFLSLSFLLLMLL 1744 
vivax_Belem           CKDNNGGCAPEAECKMT----DSNKIVCKCTKEGSEPLFEGVFCSSSSFLSLSFLLLMLL 1720 
                      * :*****   * *       . ::: * *.:      ::*:*****.*:.:*:**:: : 
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falciparum_FCB-1      ILYSFI*- 1639 
falciparum_3D7        ILYSFI*- 1720 
berghei_ANKA          IVFNIF*- 1791 
knowlesi              FFLSMEL* 1821 
vivax_Sal1            FLLCMEL- 1751 
vivax_Belem           FLLCMEL* 1727 
                      :.  :    
 
6.2. CD spectra of recombinant MSP-1 proteins 
 
 
 
                       
Figure 58. CD spectra and melting curve of P. vivax MSP-1. A) CD spectra were recorded at temperatures ranging 
from 10°C to 85°C. The individual CD spectra match the typical spectrum for a mostly alpha-helical protein. As seen with 
MSP-1D, PvMSP-1 remains partially folded even at very high temperatures. B) The calculated melting temperature based 
on CD222 values is 42.45°C.  
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Figure 59. CD spectra and melting curve of MSP-1F. A) The CD spectra recorded at temperatures ranging from 10°C 
to 85°C all correspond to an alpha-helical structure. B) The melting temperature of 43.96°C was calculated using a linear 
fit in Prism. 
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Figure 60. CD spectra and melting curve of P. knowlesi MSP-1. A) The obtained CD spectra of P. knowlesi MSP-1 
also correspond to a protein with a mostly alpha-helical secondary structure. B) The melting temperature of 44.89°C was 
determined using a nonlinear fit in Prism using the 222 nm data from the thermal denaturation.  
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Figure 61. CD spectra and melting curve of a hybrid MSP-1 protein consisting of MSP-1D 38/42 and MSP-1F 83/30. 
A) The hybrid protein based on two P. falciparum strains displays an alpha-helical structure is still partially folded at very 
high temperatures. B) The melting temperature is similar to the ones determined for MSP-D and MSP-F. The calculated 
value based on thermal denaturation data is 42.92°C.  
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Figure 62. Melting curve of MSP-1D after proteolytic processing by PfSUB1. MSP-D was proteolytically processed 
by PfSUB1 overnight before performing thermal denaturation. The CD222 data was plotted against temperature and the 
melting temperature was determined using a nonlinear fit in Prism. The result of this fit is a melting temperature of 
44.67°C, which is one degree lower than the calculated melting temperature for the unprocessed protein.  
A 
